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Summary 
Demyelination occurs in several CNS diseases.  If demyelinated axons are not remyelinated 
they become vulnerable to irreversible degeneration.  There is, therefore, a clinical need for 
therapies that enhance remyelination. This can be achieved by 1) pharmacologically targeting 
endogenous oligodendrocyte progenitor cells (OPCs) responsible for remyelination or 2) 
transplantation of myelinogenic cells (including OPCs).  The first approach is appropriate for 
diseases with no defect in the myelinating cells, such as multiple sclerosis (MS), while the 
second approach is suitable for genetic disorders of myelination such as Pelizaeus Merzbacher 
disease (PMD).  Translation into the clinic has or will shortly begin for both approaches.  
However, there are no current outcome measures providing direct evidence of OPCs 
differentiation to assess the efficacy of a remyelination therapy.    
This thesis presents data which it is hoped will form the foundation of a novel outcome 
measure for such therapies. 
It demonstrates that, by using a novel MRI gene reporter system; OATP, and controlling its 
expression under a Myelin Basic Protein promoter, OPCs can take up gadolinium based 
contrast, and be detected using T1 weighted MRI imaging in vitro and ex vivo.  Using a 
constitutively active promoter, transplanted cells can be detected by an in vivo model of 
remyelination. 
It is hoped that this data will form the foundation for the development of an outcome 
measure for assessing the efficacy of new, pro-remyelination therapies, and provide a non-
invasive, longitudinal, and translational imaging technique for use in drug discovery, or even 
personalised medicine. 
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Summary 
Demyelination occurs in several CNS diseases.  If demyelinated axons are not remyelinated 
they become vulnerable to irreversible degeneration.  There is, therefore, a clinical need for 
therapies that enhance remyelination. This can be achieved by 1) pharmacologically targeting 
endogenous oligodendrocyte progenitor cells (OPCs) responsible for remyelination or 2) 
transplantation of myelinogenic cells (including OPCs).  The first approach is appropriate for 
diseases with no defect in the myelinating cells, such as multiple sclerosis (MS), while the 
second approach is suitable for genetic disorders of myelination such as Pelizaeus Merzbacher 
disease (PMD).  Translation into the clinic has or will shortly begin for both approaches. 
However, there are no current outcome measures providing direct evidence of OPCs 
differentiation to assess the efficacy of a remyelination therapy.    
This thesis presents data which it is hoped will form the foundation of a novel outcome 
measure for such therapies. 
It demonstrates that, by using a novel MRI gene reporter system; OATP, and controlling its 
expression under a Myelin Basic Protein promoter, OPCs can take up gadolinium based 
contrast, and be detected using T1 weighted MRI imaging in vitro and ex vivo.  Using a 
constitutively active promoter, transplanted cells can be detected by an in vivo model of 
remyelination. 
It is hoped that this data will form the foundation for the development of an outcome 
measure for assessing the efficacy of new, pro-remyelination therapies, and provide a non-
invasive, longitudinal, and translational imaging technique for use in drug discovery, or even 
personalised medicine. 
1 
1. Introduction
In multicellular bilaterally symmetrical organisms such as mammals, fish, birds, and reptiles, 
coordination of body movements and functions is organised, regulated and elicited by the 
central nervous system (CNS).  Jelly fish, for example, which are radially symmetrical 
multicellular organisms, do not have a CNS, instead they have a neural net located across their 
epidermis which coordinates movements, and to a more limited extent, homeostasis.  The role, 
structure and functions of the CNS are distinct from those of the peripheral nervous system 
(PNS), and despite its highly conserved structure throughout all vertebrate life, it shows 
significant specialisation and variation across species.  A diagrammatic representation of the 
structure of the CNS is shown in Figure 1. 
Figure 1: The components of the Central Nervous System. 
The CNS is divided in to the White and Grey Matter, this distinction is based on the location of 
cell bodies of neurons which are found in Grey, but not White Matter.  White Matter is 
characterised by the presence of myelinated axons.  Myelin is formed by Oligodendrocytes. 
The Oligodendrocyte precursor is found in both White and Grey Matter, as is the Astrocyte 
and the tissue resident immune cell of the CNS; the microglia. Not to scale. 
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The CNS is one of the most complex systems in the body, and despite centuries of 
investigations, a full understanding of its functions still eludes us, and may well continue to do 
so.  We have, however, made great progress since the nineteenth century, when only the 
neuron, alone of the cells of the CNS, was known.  It was Virchow, in 1846, who first described 
the cells between neurons; naming them neuroglia, he drew on the Latin term for glue in this 
moniker, thinking these cells a form of connective tissue.  The current delineation of this 
neuroglia in to its constituent cells types; astrocytes, oligodendrocytes, and microglia, was 
established variously by, inter alia, the work of Ramon y Cajal, and his student Del Rio Hortega. 
 
Whilst the precise functions of these cell types and their progenitors is still a matter of 
significant investigation, our current understanding suggests that there is significant 
communication and interplay between the four cell types. 
 
It has been clear for centuries that neurons are largely responsible for the conduction of action 
potentials within both the peripheral and the central nervous system.  These action potentials 
form the foundation of homeostatic coordination throughout the body and are the basis for 
cognition, memory, and movement.  In the CNS, the major anatomical distinction is made 
between regions of grey matter and regions of white matter.  This is based the localisation of 
the neuron cell bodies and their axons respectively.  Beyond this broad distinction of white and 
grey matter there are differences between grey matter regions in their function and in the 
nature of these neurons.  The grey matter in the brain stem, the phylogenetically oldest part 
of the brain, also known as the paleo cortex, are known as nuclei, these nuclei have distinct 
properties and functions when compared to the neurons found in the phylogenetically 
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youngest part of the brain; the cerebral, or neo cortex.  The differences in these neuronal 
populations is expansive and complex and will not be further addressed here. 
 
Astrocytes are the most abundant cell type in the mammalian brain, they have a range of 
functions within the CNS including synaptic regulation (Chung et al. 2013), they play a crucial 
role in forming and maintaining the blood brain barrier (Sofroniew and Vinters 2009), in 
providing trophic and metabolic support (Allaman, Bélanger, and Magistretti 2011) to neurons, 
and in neurotransmitter metabolism (Hamilton and Attwell 2010).  They derive from the 
neuroepithelia, and are morphologically divided in to two main types in the adult mammalian 
brain; fibrous and protoplasmic, and are found in the white and grey matter respectively 
(Rowitch and Kriegstein 2010). 
 
Oligodendrocytes form the myelin sheath, they arise from a population of stem like cells 
(Crawford et al. 2014) which are initially responsible for the developmental myelination of the 
CNS, but remain resident within the tissue and activate in instances of injury, differentiating in 
to the mature oligodendrocyte in a process known as remyelination.   
 
The function of the oligodendrocyte is, at its simplest, to provide trophic support to the neuron 
and to facilitate salutatory conduction (Jeffery et al. 1999; Baumann and Pham-Dinh 2001; 
Nave 2010), however work by many groups over the years since the cell was first identified has 
demonstrated a far wider variety of functions (McKenzie et al. 2014; Young et al. 2013; Cassoli 
et al. 2015). 
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Microglia are of mesodermal, specifically haematopoetic, origins and are the tissue resident 
monocytes of the CNS, they make up around 10% of the cells of the CNS (Kreutzberg 1996).  
They are, perhaps, somewhat mis-named, as they are neither small, nor truly glia, like other 
innate immune cells they play a regulatory role in tissue homeostasis.  They cross in to the CNS 
prior to closure of the blood brain barrier (BBB)(Ginhoux 2013) during embryological 
development.  Once within the CNS they play a regulatory role in synaptic plasticity, and a 
phagocytic role, clearing debris and infectious agents.  Upon encountering a stimulus indicative 
of injury or infection they become activated, this state of activation is characterised by a 
distinct profile of cytokine production, morphology and behaviour (McMurran et al. 2016). 
 
1.1 Oligodendrocyte lineage cells 
  
The oligodendrocyte was first identified by Rio del Hortega (Pérez-Cerdá, Sánchez-Gómez, and 
Matute 2015), but it was not until the 1980s when Raff and colleagues identified its precursor 
naming it the O-2A.  They were later renamed Oligodendrocyte Precursor Cell, and later still 
have been re termed Oligodendrocyte Progenitor Cell (OPC).  The distinction being that the 
progenitor cell is now thought not to be restricted to the oligodendrocyte lineage alone, and 
in fact to have a multipotent, stem like quality (Crawford, Chambers, and Franklin 2013). 
 
OPCs arise in several discrete waves from the embryological neuroepithelium migrating 
throughout the CNS (Cai et al. 2005; Fogarty 2005; Vallstedt, Klos, and Ericson 2005).  They 
account for approximately 5% of the cells of the CNS in the adult. 
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The OPC is characterised by the expression of various defined markers as outlined in Figure 2. 
The cell surface proteoglycan Nerve-Glial antigen 2 (NG2), also known as CSPG4, Platelet 
Derived Growth Factor Receptor Alpha (PDGFRa), and A2B5 are the most reliable and 
commonly used markers.  However, it is not clear that these markers necessarily identify 
exactly the same population of cells.  The transcription factor Olig 2 is expressed by the OPC 
and throughout differentiation through the lineage to the oligodendrocyte (Fancy, Zhao, and 
Franklin 2004).  There is a significant degree of heterogeneity within the population of adult 
OPCs, this may represent inherent differences in the cells themselves, or it may represent 
populations of OPCs at different points along the continuum of differentiation from progenitor 
cell to myelinating oligodendrocyte. 
 
Despite their potential to make a variety of different cell types, there is indirect evidence that, 
in vivo, the oligodendrocyte progenitor cell is the major source of remyelinating 
oligodendrocytes.  It has been shown that, following demyelination, OPCs repopulate the 
lesion prior to remyelination (Sim et al. 2002; Fancy, Zhao, and Franklin 2004; Aguirre et al. 
2007).  Transplanted OPCs readily differentiate in to myelinating oligodendrocytes in regions 
of demyelination (Groves et al. 1993), and their differentiation from OPC in to oligodendrocyte 
has been demonstrated by a variety of different cell tracing experiments (Fancy, Zhao, and 
Franklin 2004; Gensert and Goldman 1997), including genetic fate mapping using OPC specific 
promoters which demonstrate more directly OPC derived oligodendrogliogenesis (Tripathi et 
al. 2011; Zawadzka et al. 2010; Nakatani et al. 2013).   
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Figure 2: Oligodendrocyte Progenitor Cell Markers expressed in the neonate and adult brain. 
Overlap of OPC (NG2, PDGFRA, and A2B5) and oligodendrocyte lineage cell marker expression 
(Olig2 and Sox10) in neonatal (top) and adult (bottom) OPCs based on published in vivo lineage 
tracing experiments (Clarke et al., 2012; Kang, Fukaya, Yang, Rothstein, & Bergles, 2010; 
Karram et al., 2008; Ligon et al., 2006; Riverset al., 2008; Stallcup & Beasley, 1987). A2B5 data 
was generated from immunostainings of OPCs isolated with the A2B5 antibody (unpublished 
data from Franklin Lab). The overlap of OPC marker expression changes during development: 
adult OPCs show a higher overlap of the OPC marker proteins when compared to neonatal 
OPCs. Figure from Foerster, Hill, Franklin 2019. 
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1.2 Myelin and Myelin Proteins 
Myelin is the insulating membrane which ensheathes the axons of the central and peripheral 
nervous system (Franklin et al. 2012).  It is highly conserved throughout vertebrate species.  In 
the central nervous system myelin is formed by oligodendrocytes; arboreal cells which wrap 
axons in specialised projections of their plasma membrane, one oligodendrocyte my wrap up 
to 60 internodes forming only one internode on any one axon (Chong et al. 2012). 
 
Myelin is composed of proteins and fats; Figure4.  It is produced in the central nervous system 
by oligodendrocytes, and in the peripheral nervous system by Schwann Cells. Table 1 outlines 
the composition of central myelin. 
 
 
 
 
 
 
 
Table 1: The composition of the myelin membrane in vertebrates highlighting the distribution 
of proteins and fats and their major subtypes.  Adapted from Deber and Reynolds Clinical 
Biochemistry 1991 
 
 
 
 
 
Substance % of total Total 
Proteins 
MBP 22.5 
30% PLP 30.0 LH-20 components 17.5 
Others 30.0 
Lipids 
Cholesterol 27.7 
70% 
Cerebroside 22.7 
Cerebroside Sulfate 3.8 
Sphingomyelin 7.9 
Gangliosides <1.0 
Others 36.9 
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Figure 3: Composition and structure of the Central Myelin Sheath.  
Schematic representation of the main components of the myelin sheath in the CNS.  Compact 
Myelin is formed by the appositional wrapping of the oligodendrocyte plasma membrane 
projections A. The ‘Inner Membrane’ represents the cytoplasmic side of the plasma membrane, 
making MBP an ‘intracellular’ component, and the ‘Outer Membrane’ is the extra cellular side of 
the plasma membrane, making the PLP component a transmembrane protein B. The plasma 
membrane comprises specialised components to form the classical phospholipid bilayer with the 
spiral structure augmented by myelin proteins such as MBP and PLP C. (Aggarwal, Yurlova, and 
Simons 2011); (Deber and Reynolds 1991); (Laule et al. 2007) 
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The presence of myelin is highly conserved in vertebrates with myelin first arising in the 
gnathastome fish (Zalc, Goujet, and Colman 2017).  Evidence from the fossil record 
demonstrates the oculomotor nerve of some paleozoic fish maintains a similar diameter to 
that of their ancestors, but is increased in length.  The inferred corollary of this is that in order 
to maintain conduction along an increased length at a fixed diameter, conduction speed must 
have been augmented by the addition of the myelin sheath (Gans and Northcutt 1983). 
 
In the vertebrate, oligodendrocytes develop form the neuroepithelium in the ventral portion 
of the spinal cord, the same region from which motor neurons arise and is mediated by sonic 
hedgehog signalling, but temporally separated (Warf, Fok-Seang, and Miller 1991).  Although 
some invertebrate species do demonstrate some glial derived axonal wrapping, (Hartline and 
Colman 2007) it is only the vertebrate which exhibits myelin as a fully specialised component 
of the nervous system. 
 
The fossil record has an understandable paucity of evidence regarding the nature of 
myelinating cell types; however, examination of extant species is more illuminatory in this 
regard.  It is not unreasonable, given their existence in all modern vertebrates, to assume that 
the nervous systems of extinct species bore similarities in composition to those of their 
evolutionary progeny, and that they might, therefore have exhibited similar patterns of 
heterogeneity.  Evidence examined by Tomassy and colleagues suggests that the greatest 
degree of heterogeneity in the myelinating orchestra exists in the upper layers of the cerebral 
cortex in mice (Tomassy and Fossati, 2017).  In the chicken spinal cord molecular heterogeneity 
of oligodendrocytes has been identified based on the expression of the cell surface peptide T4-
O, with T4-O high cells appearing to myelinate earlier in development and targeting larger 
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diameter fibres (Anderson et al. 1999).  In addition, lower orders of vertebrate such as the 
rattle snake have been shown to have less myelin basic protein post translational modification 
in comparison to bovine MBP (Zhang et al. 2012), suggesting that more complex myelin is 
required for higher levels of function. 
 
The developmental heterogeneity of OPC origin (Dorsal vs Ventral) has been identified in the 
chick in a similar fashion to that seen in the mouse: Sox10 positive, PDGFRa positive OPCs 
appear ventrally around E6 and then populate the whole cord (Ono et al. 1995).  In the 
forebrain chick OPCs originate in the ventral telencephalon, going on to populate both the 
ventral and dorsal forebrain (Olivier et al. 2001), and both dorsally derived and ventrally 
derived OPCs have been shown to exist in both the embryonic mid brain (Fu et al. 2009) and 
the hindbrain (Davies and Miller 2001). 
  
Although many of the markers of the oligodendroglial linage are conserved between lower and 
higher species, the point at which they appear frequently differs; for example, it has been 
shown that O4, the pre-myelinating marker in mammals, does not appear in the chick until 
fulminant differentiation has occurred making it a later stage marker in this species than in 
most mammals (Ono et al. 1995; Hall, Giese, and William D Richardson 1996; Bansal and 
Pfeiffer 1997).  The expression of A2B5 appears to label differing subsets of OPC in the rat vs 
the mouse (Fanarraga, Sommer, and Griffiths 1995). 
It is unclear if there is truly an increase the diversity of oligodendrocytes or their progenitors 
with increasing phylogenetic complexity, the absence of evidence for this diversity in the lower 
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orders cannot be assumed to be evidence of absence.  However, within complex vertebrates 
there is does appear to be an ever increasing body of evidence. 
Modern vertebrate myelin shows a highly organised structure of compacted encircling layers 
around an axon divided up into nodal structures that facilitate saltatory conduction.  There are 
many proposed models for how the wrapping of the myelin around the axon actually takes 
place these include the ‘carpet crawler model’ where the leading edge of the myelinating wrap 
progresses under the previous layer (Bunge et al., 1989), a bi directional ensheathment 
(Knobler et al., 1976,) the liquid croissant model proposed by Sobottka and colleagues 
(Sobottka et al. 2011) and a unidirectional coiling around the internode region (Pedraza et al., 
2009). 
Although the exact formation of the sheath is still hotly debated, a better understanding of the 
structure of the sheath has been achieved.  The layers of membrane which encircle the axon 
are of a uniform thickness of around 12nm with a characteristic  electron dense : electron light 
appearance by electron microscopy (Hartline 2008).  The electron dense, or major dense line 
is the formed by the compacted cytoplasmic myelin membrane, where as the electron light 
regions of the outer membranes (Figure 4B).  Each internode is approximately 150µm 
(Aggarwal, Yurlova, and Simons 2011) in length with the node of Ranvier, where sodium 
channels are concentrated being approximately 1µm. 
Myelin is composed largely of fats and proteins.  The functional role of these has been best 
illustrated by mouse mutants.  For example, mice which lack the ability to synthesise 
galactosylceramide and sulfatide die prematurely, with disorganised paranodes (Coetzee et al. 
1996), however, by and large, changes in lipid composition bring out functional redundancy in 
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the system and are compensated for by other structural lipids (Aggarwal, Yurlova, and Simons 
2011).  Conversely, the proteins, which are often membrane spanning or intermembrane, 
appear to show far less redundancy, with mouse mutant models such as the shiver and jimpy 
showing significant dysmyelination and functional impairment (Readhead and Hood 2018; 
Nave et al. 1986). 
1.3 Myelination and Remyelination 
 
Myelination is a complex sequence of events that we believe to be recapitulated almost exactly 
in the regenerative process of remyelination (Fancy et al., 2011).  The over-all sequence of 
events can be summarised in seven steps (1) proliferation and migration of oligodendrocyte 
precursor cells (OPCs) in white matter tracts, (2) recognition of target axons and axon – glia 
signalling, (3) differentiation of OPCs into oligodendrocytes, (4) membrane outgrowth and 
axonal wrapping, (5) trafficking of membrane components, (6) myelin compaction, and (7) 
node formation (Simons and Nave 2016); (Barres and Raff 1999); (Baumann and Pham-Dinh 
2001); (Emery 2010); (Simons et al. 2012); (Bakhti et al. 2013); (Freeman and Rowitch 2013). 
 
In development, OPCs migrate away from the neuroepithelium of the ventricular and 
subventricular zone of the brain into the developing white matter, in which they proliferate.  
In vivo time-lapse imaging in transgenic zebrafish and mice show that OPCs continuously 
extend and retract processes as they migrate throughout the CNS (Kirby et al., 2006); 
(Hughes et al., 2013).  It is thought that these processes contribute to self repulsion; a 
phenomenon that allows OPCs to distribute with a uniform density throughout the CNS.  
(Czopka et al., 2013); (Hines et al., 2015); (Koudelka et al., 2016); (Mensch et al., 2015).  
Following distribution throughout the developing parenchyma OPCs will undergo one of two 
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fates; some will remain in the progenitor state, whilst the others will undergo differentiation 
to form myelin making oligodendrocytes, any excess cells are later eliminated by apoptosis 
(Raff et al., 1993); (Barres and Raff 1994); Trapp et al., 1997). 
  
One mechanism that determines the final number of oligodendrocytes is the competition for 
target-derived growth and survival factors, such as PDGFa, and FGF-2, amongst others 
(Barres and Raff 1994).  During development OPCs are highly proliferative with cell cycle 
times around 6hours at embryonic day 14 and 24hours at around birth (Calver et al., 1998); 
(Young et al., 2013), this may be as a result of an excess of mitogenic factors (Noble et al., 
1988); (Raff et al., 1988); (Richardson et al., 1988).  Overall approximately twice as many 
OPCs are made as will ultimately survive (Barres et al., 1992). 
 
It appears that OPCs ‘decide’ which axons to myelinate on the basis of a number of factors, 
however axon diameter appears to be, potentially, the most significant (Lee et al., 2012).  
OPCs cultured in the presence of synthetic axons were able to differentiate and wrap around 
these synthetic fibres suggesting that oligodendrocytes (unlike Schwann cells) do not require 
axonal adhesion molecules and growth factors to initiate the formation of myelin (Lee et al., 
2012).  The diameter size appeared to be critical; nanofibres under 400nm were rarely 
myelinated.  Although larger axons appear to be preferentially myelinated in vivo, axons as 
small as 200 – 300 nm can be myelinated in some regions of the CNS.  It is likely that 
oligodendrocytes receive specific signals from small diameter axons to initiate myelination. 
(Umemori et al., 1994). 
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Once an oligodendrocyte process has engaged with an axon its plasma membrane process 
undergoes a remodelling (Butt and Berry 2000); (Pedraza et al., 2009); (Sobottka et al., 2011); 
(Ioannidou et al., 2012) resulting ultimately in the formation of compact myelin.  During this 
remodelling he various membrane components are synthesized and transported from a variety 
of subcellular location (Simons and Nave 2016).  For example, in development MBP is located 
to the process by transportation of its mRNA within cytoplasmic granules (Colman et al., 1982; 
Ainger et al., 1993).  Subsequently there is location translation of the mRNA in the process 
(White et al., 2008); (Laursen et al., 2011); (Wake et al., 2011).  Myelin compaction is mediated 
by the progress of the MBP protein from the outside of the sheath to the inside as wrapping 
occurs (Snaidero et al., 2014).  CNP is thought to act as a break to allow compaction to occur 
distant to the site of translation: mice lacking CNP exhibit more rapid compaction extending to 
the innermost layers of the sheath whereas transgenic overexpression of CNP results in areas 
of myelin that lack compaction (Gravel et al., 1996); Snaidero et al., 2014).  It can therefore be 
seen that there must be an equilibrium between MBP expression and CNP in early 
development in order to achieve orderly compaction.  Once MBP is bound to two adjacent 
cytoplasmic membrane surfaces, it appears to polymerize by lateral interactions with 
previously deposited MBP monomers, thereby driving membrane closure at the cytoplasmic 
surfaces of the myelin bilayer (Aggarwal et al., 2013).  Myelin wrapping of single axonal 
segment has been demonstrated (in the zebrafish) to take only a few hours (Czopka et al., 
2013). 
 
Once compacted the membrane is relatively stable (Aggarwal et al. 2011); myelin membrane 
components have been shown to have half lives in the order of weeks to month. Cholesterol 
was shown by Smith and colleagues to have a half life of 7-8months (Smith and Eng 1965), 
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and MBP a half life of 19-22 days minimum (Sabris, Bone, and Davison 1974).  Recent studies 
using radioactive nitrogen isotopes have demonstrated that myelin proteins, alongside 
histones, nucleoporins, and laminins are some of the most long-lived proteins in the mouse 
(Toyama et al., 2013).  
 
Myelination as a developmental process continues well after birth in most species.  In humans 
for example the brain continues to myelinate in to the adolescent years (Giedd and Rapoport 
2010), and white matter volume continues to increase in to middle age, a phenomenon which 
is likely to be largely as a result of on going myelination (Timmler and Simmons, 2019).   
 
Historically the focus of myelin biologists has been on the white matter where myelin is a 
dominant feature, however in recent years there has been an increased understanding of the 
role of myelin in grey matter (Timmler and Simmons, 2019).  Here the role of myelin is 
thought to range from metabolic support for fast spiking basket cells (Micheva et al., 2016), 
to co ordinate spiking, and conduction velocities (Pajevic, Basser, and Fields, 2014); (Ford et 
al., 2015); (Seidl, Rubel, and Harris, 2010), and to play a role in plasticity and learning 
(Mckinzie et al., 2014). 
 
Remyelination is a rare example of regeneration within the CNS (Franklin and ffrench-Constant 
2008).  The myelin sheath facilitates both saltatory conduction (Smith, Blakemore, and 
McDonald 1979; Felts, Baker, and Smith 1997) and axonal maintenance (Blakemore and Irvine 
2008).  Remyelination efficiently restores conduction velocity (Smith, Blakemore, and 
McDonald 1979) and reverses functional deficits (Jeffery and Blakemore 1997; Duncan et al. 
2009).  It is the normal physiological response of the body in both spontaneous disease and 
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experimental models of demyelination (Smith and Jeffery 2006; Franklin and ffrench-Constant 
2017).  
 
Remyelination in the CNS is carried out by the differentiation of the OPC in to mature 
myelinating Oligodendrocytes.  OPCs are a stem cell like cell (Crawford et al. 2014) widespread 
throughout the CNS (5-8% of CNS cells), which are found both in white and grey matter. 
 
Evidence for the role of the OPC in de novo and repairing oligodendrogenesis comes from a 
variety of experimental studies.  Transplantation of oligodendrocytes in to demyelinated 
lesions has been shown to result in no remyelination (Targett et al. 1996), and CNS which has 
previously been denuded of its OPC population by irradiation, has been shown to be unable to 
remyelinate regions of toxin induced demyelination (Keirstead and Blakemore 1997; 
Blakemore and Patterson 1973) suggesting that it is not the mature oligodendrocyte, but a 
progenitor population which is responsible for the formation of new oligodendrocytes 
(Zawadzka et al. 2010).  In response to a demyelinating insult local OPCs become activated in 
response to signals produced by activated astrocytes and microglia at the site of injury.  
Following activation OPCs migrate towards the site of injury and proliferate (Franklin and 
ffrench-Constant 2008).  OPCs then make contact with the denuded axon and differentiate 
into mature myelin forming oligodendrocytes (Zawadzka et al. 2010).  Each newly 
differentiated oligodendrocyte expresses myelin genes, and produces the myelin sheath, 
which is wrapped and compacted around multiple surrounded axons (Franklin and Goldman 
2015).  The myelin sheath is a plasma membrane structure comprising a mixture of proteins 
and lipids.  Proteolipid Protein (PLP), Myelin basic Protein (MBP), Myelin Associated 
Glycoprotein (MAG), and Myelin Oligodendrocyte Protein (MOG) are the main protein 
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components of the myelin sheath with Proteolipid Protein being the most abundant (Deber 
and Reynolds 1991). 
 
Although robust, and usually complete, there are some instances where remyelination fails.  
These instances are significant because they are characteristic of many diseases of myelin 
discussed in brief previously, most notable amongst them being the chronic failures typical of 
chronic progressive multiple sclerosis (Franklin and ffrench-Constant 2017).  The underlying 
cause of this failure has not been fully elucidated however it is likely to be multifactorial and 
include factors such as ageing (Sim et al. 2002).  
 
In order for remyelination to take place OPCs must first be recruited to the lesion site, then 
proliferate, before finally differentiating as shown in Figure 3.  Remyelination is a recapitulation 
of developmental myelination (Fancy et al. 2011), with the only notable difference being that, 
following injury in the adult brain, remyelinated axons are encircled with a thinner myelin 
sheath (Blakemore 1974; Franklin et al.  2002; Franklin and ffrench-Constant 2008).   
 
In response to injury (Figure B&C), microglia and astrocytes first become activated (Figure D) 
(Carroll and Jennings 1994; Emery et al. 2009), and as a consequence of, amongst other things,  
PDGF and FGF-2 signalling OPCs are recruited to the lesion site where they undergo 
proliferation (Figure E&F) (Woodruff et al. 2004);(Murtie et al. 2005).  Following recruitment 
OPCs enter in to a differentiation phase (Figure G), this is initiated through contact with a 
denuded axon and a variety of growth factor signals such as IGF-1 amongst others (Hinks and 
Franklin 1999); (Zhao, Li, and Franklin 2006) this triggers a change in their genetic profile and 
they begin down regulating the classical OPC genetic markers such as PDGFRa, and being up 
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regulating genes which are required in the production of myelin such as CNPase and myelin 
basic protein (MBP).  Following differentiation, new oligodendrocytes mature and are largely 
indistinguishable from the de novo cells, save only the formation of thinner sheaths (Figure 
H)(Blakemore 1974). 
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Figure 4: The process of Remyelination following a demyelinating Injury. 
A: Normal Appearing White Matter comprising of Oligodendrocytes, Oligodendrocytes 
Progenitor Cells, Astrocytes, and neuronal axons. 
B: Injury to the white matter, this may be primary inflammation, as in MS; or secondary 
inflammation resulting from ischaemia as seen in stroke, or dysmyelination; or direct injury 
as seen in many models of demyelination such as cuprizone, lysolecithin, or Ethidium 
bromide. 
C: The inflammation (primary or secondary),or toxin leads to degeneration of the myelin 
membrane and oligodendrocyte death 
D:  microglia and astrocytes first become activated(Carroll and Jennings 1994);(Emery et al. 
2009) leading to the activation of local OPCs (E). 
F: PDGF and FGF-2 signalling lead to OPCs being recruited to the lesion site and proliferating 
(Woodruff et al. 2004);(Murtie et al. 2005).   
G: Following recruitment OPCs enter in to a differentiation phase, this is initiated through 
contact with a denuded axon and a variety of growth factor signals such as IGF-1 amongst 
others (Hinks and Franklin 1999) (Zhao, Li, and Franklin 2006) this triggers a change in their 
genetic profile and they begin down regulating the classical OPC genetic markers such as 
PDGFRa, and being up regulating genes which are required in the production of myelin such 
as CNPase and myelin basic protein (MBP).   
H: Following differentiation, new oligodendrocytes mature and are largely indistinguishable 
from the de novo cells, save only the formation of thinner sheaths(Figure H)(Blakemore 
1974). 
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1.4 Diseases of Myelin 
Diseases of myelin occur for a number of reasons: they may result from inherent defects in the 
oligodendrocytes; genetic errors in genes encoding myelin proteins or lysosomal structures, 
ischemic injury which kills off a region of oligodendrocytes and OPCs, or immune targeting of 
antigens expressed by oligodendrocytes.  These diseases are of considerable significance.   
 
1.4i Multiple Sclerosis 
Most significant amongst the immune mediated myelin diseases is Multiple Sclerosis (MS) 
which is the most common neurological condition of young adults in the western world 
(Compston and Coles 2008).  First described by Jean Marie Charcot, a French neurologist, MS 
is a chronic inflammatory disease of the CNS in which myelin is lost from the axons of neurons 
(Compston and Coles 2008).  In MS oligodendrocytes are targeted by an autoreactive T cell 
response that results in the denuding of axons (Goverman 2009).   The normal physiological 
response of the body to this insult is to resolve the inflammation and remyelinate the denuded 
regions.  New myelin sheaths are formed by the differentiation of endogenous OPCs in to 
mature oligodendrocytes.  This is usually a robust and complete response, however, in MS the 
repeated demyelinating insults, and the inherent decline in efficiency of the repair response 
result in the persistence of denuded axons leading to a chronic accumulation of pathology and 
loss of function.  Failure to remyelinate leads to a block in salutatory conduction (Felts, Baker, 
and Smith 1997); and in the long term eventually results in axonal degeneration, due to loss of 
trophic support (Griffiths et al. 1998) (Figure 5). 
 22 
 
Figure 3:  Repair vs Neuronal loss following demyelination.  Following an insult to the myelin 
sheath, and subsequent demyelination the usual response of the CNS is to undergo 
spontaneous repair; laying down a new myelination sheath and achieving a functional 
recovery through the differentiation of OPCs in to Oligodendrocytes.  However, it is clear that 
this scenario fails to occur in certain disease processes, and appears to fail with increasing 
frequency with age.  A key question remains as to what triggers this failure, and how this can 
be overcome.  Based upon a similar diagram in Franklin & ffrench Constant 2008. 
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The consequence of repeated bouts of demyelination is the accumulation of neurological 
deficits, characteristic amongst these are weakness, spasticity, pain fatigue, tremor, and motor 
or co-ordination difficulties (Compston and Coles 2008).  MS affects over 2.5 million worldwide, 
but shows a distinct geographical and demographical distribution (Compston and Coles 2008).  
The clinical presentation is categorised in to three main forms; Primary Progressive (PPMS), 
Secondary Progressive (SPMS) and Relapsing Remitting (RRMS), with RRMS being the most 
frequently diagnosed (Fisniku et al. 2008).  Primary progressive is characterised by an onset of 
clinical symptoms which show continuous deterioration, Relapsing Remitting (RRMS) on the 
other hand, is characterised by periods of remission of clinical symptoms between clinically 
active disease episodes.  In most patients relapsing remitting MS will progress on to the final 
categorisation of secondary progressive which is defined as a period of continuous clinical 
decline which follows a prior period of RRMS (MacDonald et al. 2001).  A majority of relapsing 
remitting patients will progress to the secondary progressive form between the ages of 40 and 
50.  Patients newly diagnosed with MS after this age are only rarely diagnosed with RRMS, and 
are more commonly diagnosed with primary progressive.  This suggests that age plays a 
significant role in the development of the disorder (Fisniku et al. 2008; Compston and Coles 
2002; Franklin et al. 2002; Ruckh et al. 2012). 
 
The aetiology of multiple sclerosis is complex; however, the current consensus is that there are 
environmental and genetic risk factors, and that these interplay with immune system 
dysregulation.  Multiple sclerosis, despite its worldwide distribution, is most commonly 
diagnosed in Caucasian populations in the northern hemisphere with ‘hot spots’ in 
Scandinavia, Scotland and Sardinia (Simpson et al. 2011; Ahlgren, Odén, and Lycke 2014).  
Diagnoses are more common in women than in men, twin studies have demonstrated a familial 
 24 
recurrence rate of 20% (Compston and Coles 2008), and various genome wide association 
studies have identified genetic loci in immune regulatory regions including the Major 
Histocompatibility Complex (MHC), in particular HLA-DRB1*1501.  This is unsurprising given 
the role the MHC has been demonstrated to play in other diseases of autoimmunity.  Equally 
the distribution of this allele is most common in countries with a high geographical instance of 
MS (Sawcer, Franklin, and Ban 2014).  Additionally infectious agents such as the Epstein Barr 
virus, amongst others, have been suggested to be triggers potentially via a molecular mimicry 
mechanism (Serafini et al. 2007). 
 
Current treatments for multiple sclerosis centre around control of the inflammatory cascade.  
These include interferon beta which is thought to stablise the blood brain barrier, modulate T 
cell function, and up regulate of adenosine production (Airas et al. 2007; Stuve et al. 1996; 
Kraus et al. 2004), and immunosupressives including corticosteroids which act on the 
ecoisanoid pathway  and mitoxantrone and chemotherapeutic which intecalates in to DNA 
thus reducing proliferation of immune cells (Fox, E.,J. 2004).  Additionally monoclonal 
antibodies such as alemtuzumab, an antibody against CD52, have been employed in the 
treatment of relapsing remitting multiple sclerosis (Coles 2012).  There are no therapies which 
target the repair process of multiple sclerosis, however this is an area of significant current 
investigation.  At the time of writing there are 25 clinical trials looking at molecules or therapies 
which may improve the remyelination and repair of lesions, for a list of currently active 
clinically trials into remyelination therapies see Appendix 1. 
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1.4ii Leukodystrophies 
Distinct from MS are the leukodystrophies; diseases of central white matter that result in 
dystrophic formation of myelin due to defects in the myelinating cells themselves.   These 
largely result from inherited defects, or spontaneously arsing mutations in genes which code 
for components of myelin or the myelin:axon interaction (Knaap and Bugiani 2018).  They arise 
at any stage of myelination from prenatal to established myelin and are usually fatal (Aubourg 
1993).  
 
Broadly speaking, the leukodystrophies can be grouped in to disorders of myelin 
(hypomyelinaiting, demyelinating, and myelin vacuolisation), astrocytopathies, leuko-
axonopathies, microgliopathies, and leukovasculopathies (Knaap and Bugiani 2018).  A variety 
of recessive and dominant mutations are responsible for these disorders.  Unlike multiple 
sclerosis, where autoimmunity is thought to drive myelin damage and loss, in the 
leukodystrohies genetic abnormalities result in disordered or dysregulated myelination which 
is progressive, and unlike MS, does not undergo spontaneous and efficient repair (Köhler, 
Curiel, and Vanderver 2018). 
 
The first of these disorders to be identified was Pelizeus Merzbacher’s Disease (PMD); an X-
Linked leukodystrophy resulting from mutations in the gene encoding the myelin protein 
Proteolipid Protein (PLP).  Males who inherit this disorder show a range of dysmyelination 
ranging from moderate hypomyelination to severe hypomyelination.  These children have 
severe and progressive disability and many will not live beyond their teenage years (Gupta et 
al. 2012). 
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Treating these diseases is a huge challenge for the biomedical community.  In diseases such as 
MS, where the cell type responsible for repair is intact and normal, research is focused on 
identifying and overcoming the barriers to successful differentiation of the OPC into the newly 
myelinating oligodendrocyte.  These may be drugs or small molecules that block inhibitory 
pathways aberrantly activated, or that up regulate one or many of the cascades of cellular 
process that lead to successful remyelination.  These therapies are known collectively as Pro-
Remyelination-Therapies and are distinct from the current wave of treatments currently 
available for diseases such as MS that are only able to target the immune damage which results 
in the initial demyelination.  In contrast, however, such therapies are of little use where the 
myelinating cell type is inherently defective, such as in PMD.  Here a source of unimpaired 
myelin forming cells is required.  In some cases this may require exon skipping technologies 
such as those used in Duchene Muscular Dystrophy, or in CRISPR techniques to correct the 
genetic defects.  However, transplantation of new cells is widely thought to be one of the most 
promising potential therapies.  This dichotomy can be summarised by the endogenous vs 
exogenous therapy paradigm shown Figure 6. 
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1.5 Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) is based on the physics of nuclear magnetic resonance first 
demonstrated by Purcell and Bloch in 1946 (Purcell 1946; Bloch 1946).  MRI exploits the 
magnetic properties of atomic nuclei to create an imaging modality that can produce three 
dimensional images of tissue structure that can be applied to clinical diagnostics as well as 
research questions. 
 
MRI creates contrast between different tissues by exploiting the magnetic properties of atomic 
nuclei, most commonly the proton in the form of the hydrogen atom.  The proton lends itself 
Figure 4: Exogenous vs Endogenous Therapies Exogenous therapies. 
Endogenous therapies dichotomy.  Where there are inherent defects in the target cell 
population, such as in PMD, where mutations in the PLP gene lead to dysmyelinaton, 
therapies that replace these cells or correct these defects are required.  This is in contrast to 
diseases where there is no inherent defect in the target cell, such as in MS, where there is an 
aberrant immune response, where pharmaceuticals targeting cellular pathways can be 
directed at promoting repair. 
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to use with this technique because it is abundant in all biological tissues, and because of its 
inherent magnetic properties; namely the presence of spin.  Any atomic nucleus which 
possesses the property of spin can be exploited in a magnetic resonance experiment.  Spin is 
an inherent property of an atomic nucleus based on an imbalance between the number of 
protons and neutrons in the nucleus (Levitt, 2001).   A nucleus with an even number of protons 
and neutrons will have no spin, whereas a nucleus with more protons than neutrons (such as 
hydrogen (1H): one proton no neutrons) or more neutrons than protons (such as carbon-13 
(13C): six protons seven neutrons) will have spin. 
 
Spin is expressed in units of Planck’s constant, h.  Planck’s constant is the quantum mechanical 
property that links the amount of energy a photon carries to its electromagnetic wavelength.  
It has a value of 6.6260 x 10-34 m2 kg / s or 6.6260 x 10-34 Js.  Essentially, it is a measure of 
energy, and with regard to spin, indicates the amount of angular momentum the nucleus 
possesses.  The property of spin, combined with the property of mass causes these nuclei to 
have a magnetic moment. 
 
MRI manipulates the spin properties of these protons using magnetic fields.  The behaviour of 
the protons when exposed to a magnetic field, and their subsequent relaxation, or return, to 
their original or equilibrium state, is known as spin relaxation.  Different tissues with different 
distributions or densities of protons will demonstrate differing spin relaxation behaviour.  This 
provides tissue contrast. 
 
Spin relaxation behaviour is a description of how nuclei behave when exposed to a magnetic 
field.  In any given substance, in the absence of a magnetic field, the spins of adjacent atoms 
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will be in disarray.  If a magnetic field (Bo) is applied the spins will align with the applied 
magnetic field Figure 7.  
 
 
 
 
 
 
 
 
 
The combination of spin and a magnetic dipole leads to precession; where the spins don’t align 
exactly with the field but precess about the field axis.  The precessional frequency is defined 
as the Lamor frequency (w), and is based on the relationship between the strength of the 
magnetic field, and the gyromagnetic ratio of the nucleus (g).  This is described by the Lamor 
equation: 
w = g B0 
B0 is the applied magnetic field in Tesla (T).  The gyromagnetic ratio represents the ratio of a 
particles magnetic moment to its angular momentum and is specific to a nucleus.  
A B 
Figure 5: Magnetic Spin.  
Spin is a nuclear property caused by imbalances in sub atomic particles. It causes nuclei to have 
rotation (like the rotation around the axis of a planet); A. Hydrogen nuclei, in the absence of a 
magnetic field have spins which are in disarray.  When a magnetic field is applied the spins of 
Hydrogen nuclei align; B.  The total spin is the vector sum of all the spins. 
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Table 2 shows the different spin quantum numbers, gyromagnetic ratios, and relative 
concentrations in human tissue of a variety of different nuclei.  It can be seen from this table 
that it is a combination of these properties that are required when selecting an element for 
nuclear magnetic resonance techniques.  Protons have a non integer spin (a requirement for 
detection), a high gyromagnetic ratio (a large magnetic moment), and have both high natural 
abundance and high concentration in biological tissues. 
 
 
 
 
Figure 6: Magnetic Precession. 
Precession is the phenomena of off axial rotation (like the rotation of the north or south pole of 
a planet as it spins around its axis, or the precession of a gyroscope in the earth’s gravitational 
field).  Hydrogen nuclei will precess around their axis in aligmnet with a magnetic field when a 
second magnetic field is applied, perpendicular to and oscillating around a static magnetic 
field. 
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Table 2: Magnetic properties of a selection of biologically relevant nuclei.   
The subatomic characteristics of the  nucleus of an isotope will dictate their magnetic 
properties. For a nuclei to be useful in MRI they must have a non integer spin.  For conventional 
MRI it is also beneficial for the isotope to be abundant biologically and at reasonably high 
concentrations in tissue such that it can be detected. Adapted from James, T. L. 1975. Nuclear 
Magnetic Resonance in Biochemistry. Academic Press, New York.  
 
1.6 Acquisition of the MR image 
 
When a magnetic field is applied (Bo) the 1H spins will either align with, or against the field 
(Figure 7).  Furthermore, they will precess around the B0 field direction with the z component 
Element Number 
Protons 
Number 
Neutrons 
Spin Gyromagnetic 
Ratio  
 
Abundance Concentration  
(human tissue) 
Hydrogen  
1H 
1 0 ½ 42.58 (MHz/T) c.100% 88M 
Deuterium  
2H 
1 1 1 6.53 (MHz/T) 0.015% 13mM 
Carbon-13  
13C 
6 7 ½ 10.81 (MHz/T) 1.1%  
Sodium  
23Na 
11 12 3/2 11.27 (MHz/T) c.100% 80mM 
Fluorine 
19F 
9 10 ½ 2.627 (MHz/T) c.100% 4mM 
Oxygen  
17O 
8 9 5/2 -5.77 (MHz/T) 0.04% 16mM 
Phosphorous 
 31P 
15 16 ½ 1.131 (MHz/T) c.100% 75mM 
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of the magnetization aligned with B0 (lower energy state) or against B0 (higher energy state).  
The number of spins in each orientation (with or against the B0 field) can be estimated from 
the  Boltzman distribution: 
!"#$"	!&'(   = e-DE/kT 
N represents the number of nuclei in the low or high energy states (spin parallel or anti 
parallel), k is a constant, T is temperature in Kelvin and DE is the difference in energy between 
the states.   An unequal distribution of spins results in a net magnetization that is aligned with 
the field. 
 
If a second magnetic field is applied orthogonal to B0 (B1), which oscillates around the sample 
at the same frequency as the Lamor frequency of the nucleus of interest, then for a spin ½ 
nucleus it will induce transitions between the two allowed energy levels.  When B1 is applied 
in the form of a radio frequency (RF) pulse (a 90 degree pulse), it flips the net magnetization 
out of alignment with the Bo field (the z axis) into the xy plane. The spins then dephase (the 
spins loose synchronicity or coherence) and relax back into alignment with the z axis. This 
dephasing, characterised by the T2, or spin-spin relaxation time, is influenced by the properties 
of the tissue and the presence of other magnetic or paramagnetic compounds.  The relaxation 
back towards the z axis is termed T1, or spin lattice relaxation.   
  
Rotation of the net magnetization vector in the xy plane induces a current in the receiver coil  
(RC).  This decaying signal (the free induction decay or FID) is converted into a spectrum by 
Fourier Transformation.  As the Lamor frequency of each nucleus is dependent on the strength 
of the magnetic field the use of magnetic field gradients allows the position in space of each 
nucleus to be encoded.  Using frequency and phase encoding gradients allows the spatial 
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location of a nucleus to be extracted by using the Fourier transformation in two dimensions. 
Three-dimensional information is acquired by combining the frequency and phase data in two 
dimensions with either multiple slices through the sample, or by using a gradient across the 
sample in the third dimension.  An example sequence is shown in Figure 7.   
Figure 7: Example of an MRI pulse sequence showing the TE and the TR. 
A sequence is made up of three gradient pulses and a radio frequency pulse.  The 90° Radio 
Frequency pulse (yellow) tips the net magnetization in to the plane orthogonal to the static field, 
and this is refocused using the second 180° Radio Frequency pulse to form the echo. These are 
timed at TE/2 ie half the echo time).  The echo time will be selected on the basis of the tissue 
being imaged. Signal is collected at intervals separated by the TE. 
The three gradients, formed by gradients of a magnetic field, are aligned with the x,y, and z axis 
in this example, but in reality are aligned relative to the slice selected.  They are switched on and 
off to create a pulse sequence that enables information to be encoded spatially.  To collect a full 
image the sequence is repeated multiple times. 
 34 
For an object imaged in a standard MRI experiment this means that upon application of the 
90° pulse, the net magnetization vector that was previously aligned with the static magnetic 
field B0, will move in to the x-y plane.  This net magnetization vector will decay due to spin-spin 
relaxation and the loss of phase coherence owing to magnetic field inhomogeneity.  The loss 
of phase coherence which results from inhomogeneity can be refocused by the use of the 
second pulse, this time at 180°.  This forms the spin echo.  Application of a phase-encoding 
gradient along the y axis between the 90° pulse and the 180° pulse results in the phase of the 
resulting echo varying as a function of the location in space of the nuclear spin relative to that 
gradient (the y axis).  Multiple acquisitions of signal with incremental phase encoding leads to 
phase modulation of the decay profiles at frequencies which are dependent upon on the 
position of the spins in the gradient. By applying the Fourier transformation to this phase 
modulation, a profile of the sample in the y axis can be established.  Images are usually 
acquired with T1 or T2 weighting, meaning that repetition and echo times are adjusted so that 
signal intensity is a function of spin lattice or spin spin relaxation. 
 
T1 or T2 weighting affects image contrast.  By using a combination of different sequences which 
are differentially T1 or T2-weighted, an understanding of the composition and architecture of a 
tissue can be gained. 
 
The degree to which an image is T1 or T2 weighted will depend on the pulse sequence used for 
image acquisition, notably the timing of the Radio Frequency (RF) pulses and the signal readout. 
Pulse sequences can have several variable parameters, but two of the most important are the 
TE (echo time) and the TR (repetition time).  The TE is the time between the RF pulse and the 
readout of the signal from the echo. The TR is the time between the successive applications of 
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the pulse sequence.  
 
MR images can be produced in vivo with high spatial resolution eg. a 3D voxel size of 0.27nL 
(Howles et al. 2009), or 2D in-plane resolution of < 30nm (Boretius et al. 2009), allowing highly 
detailed whole body images to be produced with anatomical detail. 
 
1.7 T1 weighted imaging 
 
T1 relaxation time is the longitudinal relaxation, or spin lattice relaxation time,  and is a measure 
of the rate at which the net magnetization returns to the z axis after the RF pulse which flips it 
into the xy plane (Figure 10).  The term lattice refers to the local environment of the nuclei.  
The T1 value of a tissue is the time take for 63% of the net magnetization to realign with the z 
axis (with the Bo magnetic field).  To acquire a T1 weighted image a pulse sequence with a short 
repetition time TR), and a short echo time (TE) are used.  Typical T1 values for various tissues 
are given in Table 3. 
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Tissue Type T1 /ms (approx.) T2 /ms (approx.) 
Liver 812 ± 64 42 ± 3 
Skeletal Muscle 1412 ± 13 50 ± 4 
Heart 1471 ± 31 47 ± 11 
Kidney 1194 ± 27 56 ± 4 
Blood 1932 ± 85 275 ± 50 
Optic Nerve 1083 ± 39 78 ± 5 
Spinal Cord 993 ± 47 78 ± 2 
White Matter 1084 ± 45 69 ± 3 
Grey Matter 1820 ± 114 99 ±7 
 
Table 3: Values for T1 and T2 for different tissues. The typical relaxation rates for biological 
tissues in milliseconds in a 3Tesla magnet (Stanisz et al. 2005). These values act as a guide 
around which sequences will be designed depending on the tissue or region of the body being 
imaged. 
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Figure 10: Spin Lattice relaxation.  
Protons exist in an environment made up of other protons and their associated magnetic 
dipoles, referred to as the lattice. In the absence of an external magnetic field, there is no 
alignment of the proton spins (A). When an external magnetic field is applied, B0, the protons 
will align either parallel or anti parallel to the field(B), and they precess about this field at the 
Lamor frequency; (ci and cii), their net magnetization can be represented as a net magnetization 
vector (ciii) where the magnitude of the net magnetization is M0. When an RF pulse (B1) is 
applied, the net magnetization vector moves from the z axis into the xy plane (D). When B1 is 
removed (E), the magnetization vector relaxes back along the z axis.  T1 relaxation is the time 
constant for the recovery of the net magnetization along the z axis to 63% of M0 (F) 
A B 
C 
D 
E 
F 
ci cii ciii 
 38 
1.8 T1 weighted contrast agents 
Contrast agents are used to provide greater insight into the architecture or physiology of a 
given tissue.  In MRI, a T1 contrast agent is one that causes the spins in a tissue to return more 
rapidly to alignment with the z axis.  A more rapid return results in a higher signal, which 
corresponds to a brighter image, therefore T1 contrast agents give positive contrast in an MR 
image.  Short TR times result in signal being collected when the nuclei have not fully relaxed 
back to their equilibrium distribution; they remain partially saturated.  T1 contrast agents cause 
shortening of the T1 by increasing the relaxation rate of water molecules in their vicinity, 
resulting in the loss of the partial saturation and an increase in signal.   
 
T1 contrast agents most commonly exploit the presence of unpaired electrons, which cause 
them to be paramagnetic.  The resultant large magnetic dipole causes a local oscillating 
magnetic field which interacts with neighbouring spins to promote spin lattice relaxation.  The 
faster return of the spins back to their equilibrium state increasing the amount of signal that 
can be captured and therefore creating a greater positive signal. 
 
Substances with a higher number of unpaired electrons have a greater paramagnetic effect.  
The most commonly used contrast agent is the gadolinium ion (Gd3+) which has seven unpaired 
electrons.  Gadolinium is extremely toxic and therefore it is administered as a tightly bound 
chelate.  Another ion commonly used is Manganese (Mn2+), which has 5 unpaired electrons. 
 
The effect of a paramagnetic ion on surrounding water protons will have three different types 
of interaction, these interactions bring about a shortening of the T1.  These interactions are 
known as: 1) inner sphere interactions, 2) outer sphere interactions, and 3) local magnetic field 
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effects (Lauffer 1987).  
 
Inner sphere interactions result from the binding of a water molecule in the primary co-
ordination sphere of the paramagnetic ion and exchange with bulk water.  This occurs when 
water molecules are within 1-2 angstroms (Å), (1 Å is 0.1 nanometers) of the paramagnetic ion.  
 
Outer-sphere interactions occur when the water molecule is within 5 Å of the paramagnetic 
ion, and involve an interaction between the water molecule and another molecule that is 
interacting with the paramagnetic ion.  These sorts of interactions are more common in 
chelated forms of the contrast agent, and less common with the free paramagnetic ions which 
can more easily interact via the inner-sphere mechanism.  
 
The difference in the magnitude of T1 enhancement between the inner-sphere and the outer-
sphere relaxation is proportional to )*+ , where r is the distance between the metal ion and the 
water proton.  The effect of the local magnetic field from paramagnetic ions is the smallest of 
the three effects in its contribution to T1 relaxation.  
 
The strength of T1 enhancement that a compound has on water is linearly dependent on its 
concentration.  As a result of this relationship a value can be calculated for its relaxivity by 
taking the gradient of the line when R1 (
),)) is plotted against the contrast agent concentration, 
which is expressed in mM-1 second-1.    
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1.9 T2 weighted imaging 
 
T2 weighting is obtained by using a long TE and long TR, this is because a long gap between 
excitations (ie a long TR) minimises T1 effects by allowing time for all the protons to relax fully.  
Unlike T1, which describes the rate of return of the magnetization vector along the z axis.  T2, 
also known as spin-spin or transverse relaxation, describes the rate at which the net 
magnetization is lost whilst still in the xy plane (Figure ).  The T2 value is the time taken for the 
signal to decay to 37% of its initial value.  This loss results from loss of coherence in the spin 
isochromats as they precess in the xy plane, resulting in a decrease in the net magnetization. 
 
Tissues with a high macromolecular content, or high concentrations of paramagnetic centres, 
tend to have shorter water proton T2 relaxation times, whereas tissues with more free water 
tend to have longer T2 values.  Tissues where water has a long  T2 are more bright in a T2-
weighted image.  
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Figure 11: Spin-Spin, or Transverse, T2 relaxation.   
When a magnetic field B0 is applied across a substance the proton spins align parallel or anti 
parallel to the applied field and precess about the axis of the field. In the presence of a second 
magnetic field, B1, rotating at the Lamor frequency of the nuclei, the spins will precess in phase.  
When B1 is applied as a pulse orthogonal to B0 it moves the net magnetization into the xy plane 
(B). When B1 is removed, the spins relax back along the z axis and lose phase coherence in the 
xy plane (C).  Spin-Spin relaxation describes the energy exchange between neighbouring spins 
(true T2) or local magnetic inhomogeneities as they lose phase coherence in the xy plane. The 
combination of the effects of spin-spin interactions and field inhomogeneities gives a relaxation 
time called T2* relaxation.     
B1 
B1 
A 
B 
C 
D 
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1.10 T2 contrast agents  
Like T1 weighting, T2 effects can be enhanced by using paramagnetic agents.  However, unlike 
T1 agents, which increase signal intensity in T1-weighted images, T2 agents decrease signal by 
shortening T2 relaxation times.  This leads to hypointensities; darker areas on an image known 
as negative contrast.  Most T2 contrast agents are based on super-paramagnetic compounds.  
Like paramagnetic compounds used for T1 contrast agent, these have unpaired electrons, 
however, unlike paramagnetic agents, super paramagnetic particles have a net magnetization 
in the absence of an external magnetic field.  Most commonly these compounds exploit iron 
in the form of superparamagnetic iron oxide nanoparticles. 
 
1.11 NMR 
 
 
In addition to the production of anatomical images, magnetic resonance can also be exploited 
to elucidate chemical structures.  For example, a proton bound to an oxygen atom (as in water), 
will have a different magnetic environment to a proton bound  to a carbon atom (as in glucose 
for example).  This difference in the strength of the magnetic field around individual protons is 
due to the shielding effect of surrounding electrons and is known as chemical shift.  As a result 
protons in different chemical environments (in different chemical entities) resonate at slightly 
different frequencies.  The spectra that result are characteristic of different chemical 
compounds. 
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1.12 Gene reporters 
 
A reporter gene is one which, when expressed, can be detected to provide a quantifiable signal.  
They are used to make inferences about the qualitative or quantitative state of another genes 
expression in a cell or tissue. 
 
A reporter gene construct will most commonly consist of the reporter gene under the control 
of a cell specific reporter sequence such that one promoter sequence is activated the 
expression of the reporter gene will be switched on.  Once expressed the reporter gene gives 
off a signal detectable by imaging equipment, an example is depicted in Figure 12.  This 
methodology differs from other mechanisms of gene expression measurement, such as 
polymerase chain reaction (PCR), western blotting or northern blotting, in a number of key 
ways.  Firstly they allow longitudinal and real time monitoring of gene expression rather than 
snap shots, and importantly, are minimally invasive. 
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The field of optical gene reporters really began with beta galactosidase and the LacZ operon, 
and this system has been commonly used to monitor cellular processes ever since. LacZ, 
remains one of the most widely used and useful of all gene reporters (Price, Turner, and Cepko 
1987; Mulder et al. 2012; Lyons, Patrick, and Brindle 2013).   
 
New substrates have been developed to convert this system for in vivo use, but numerous 
technical and practical issues have limited the use of these systems 
(Debacq-Chainiaux et al. 2009; Degenfeld, Wehrman, and Blau 2009).  However, with the 
description of green fluorescent protein (Chalfie et al. 1994) in the 1990’s this field expanded 
exponentially.  GFP and reporter genes like it offer superior resolution to that achieved by 
Figure 12: Example of gene reporter systems, commonly reporter genes encoding detectable 
proteins (such as GFP), or enzymes which catalyse the production of a detectable product (such as 
horse radish peroxidase) are used. 
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traditional light microscopy, and enable high levels of temporal resolution (Nakano 2002).  
However, these methodologies rely on the penetration of light, and therefore are not very 
applicable to in vivo systems where signal attenuates rapidly due to tissue depth.  The optical 
window is the range of wavelengths which will travel through a tissue Figure 13, the optical 
window for visible light is relatively limited in normal tissue due to minimal light penetration. 
 
Near infra red imaging (NIR) achieves greater tissue penetration as the wave length of this part 
of the electromagnetic spectrum has greater tissue penetration. This reduces the amount of 
signal attenuation through tissue however the brightness achievable with these is still far 
inferior to that of the traditional fluorescent proteins such as GFP (Shu et al. 2009).  
 
Tissue clearing techniques aim to overcome the narrow optical window for visible light 
wavelengths by reducing the signal attenuation due to the presence of opaque tissues.  Unlike 
transparent models such as the zebra fish (Buckley, Goldsmith, and Franklin 2008), these 
techniques reduce light scattering, and therefore signal loss, by transforming tissue in to a 
hydrogel-tissue hybrid by removing lipids whilst leaving microstructure and gross anatomy 
intact.  These techniques have achieved far superior resolution of neuroanatomy, in the region 
of 10s of micrometers (Tomer et al. 2014), in comparison to other three dimensional 
techniques, however, as with all histological techniques they are only applicable to post 
mortem tissues and so can only answer a limited array of questions. 
 
Bioluminecense; the property of producing visible light by an organism, usually via a redox 
reaction between luciferin and oxygen and catalysed by a luciferase enzyme, have been 
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harnessed in imaging through combination with gene reporter systems to achieve expression 
of detectable light by biological systems (Badr and Tannous 2011).   
 
Bioluminecent imaging (BLI) can be used to probe gene expression (Patrick, Lyons, et al. 2014), 
protein-protein interactions (Pichler et al. 2008), protein folding (Suzuki et al. 2007) and to 
trace stem cells (Sacco et al. 2008).  In the latter study muscle stem cell were traced following 
transplantation in to the tibialis muscle of a mouse, this study clearly demonstrates the 
potential for BLI to be used in stem cell fate mapping, however the interrogation of model 
systems of greater tissue depth than the relatively superficial hind leg of a mouse, may 
highlight the major limitation of this technique which is signal attenuation though the tissue, 
common to all optical imaging techniques.  Techniques to increase luciferin signal may help to 
overcome this limitation such as the use of OATP (Patrick, Lyons, et al. 2014). 
 
Intravaital microscopy can be used to detect fluorescence proteins and dyes a few hundred 
micrometres beneath the skin with high resolution in vivo, but at greater depths the sensitivity 
and resolution are greatly reduced (Weigert, Porat-Shliom, and Amornphimoltham 2013).  IVM 
encompasses a variety of different modalities including one, two and three photon imaging, 
however currently non of these techniques offer more that 500µm depth penetration into 
tissues (Masedunskas et al. 2014).  This tissue penetration may pose few issues when utilising 
mouse disease models, however, larger species pose greater depth challenges, and there are 
very clear challenges for translations in to man. 
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1.13 Imaging Remyelination: The Status Quo 
 1.13i Diagnostic Clinical Imaging  
 
Magnetic Resonance Imaging 
 
The diagnosis of MS relies heavily on diagnostic imaging techniques, alongside neurological 
examination, and a relevant clinical history.  MRI is the most commonly performed 
investigation in the work up of a patient were MS is considered a potential differential 
diagnosis (Polman et al. 2011; Filippi et al. 2016)  
 
Figure 13: The Optical Window. The efficiency of light transmission through a biological tissue 
is reduced by the presence of light absorbing molecules including blood (Heamoglobin (Hb) in 
its various oxygenation states), pigment etc.  Wavelengths towards the red end of the visible 
spectrum, and in the near infrared region, overlap more with the optical window; the 
wavelegths where light has its maximal tissue penetration.  Light emitting reporters in these 
ranges will be more effective in biological systems than those whose wavelengths sit outside 
the optical window. Adapted from Lyons et al 2013.666 
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Diagnostic criteria for MS focus on white matter lesions, their number, location and temporal 
frequency, however these alone are not unique to MS, with similar lesions appearing in many 
other disorders, therefore more subtle characteristics such as Dawson fingers, juxta- cortical 
lesions and short partial and eccentric spinal cord lesions are necessary to support a diagnosis 
of MS (Toledano, Weinshenker, and Solomon 2015; Chen et al. 2016).  Additionally tests which 
are able to help rule out some of the MRI mimics of MS, such as the antibody mediated 
Neuromyelitis Optica Spectrum Disorders (NMOSDs) or Acute Demyelinating 
Encephalomyelitis (ADEM) for which Anti auaraporin 4 and anti myelin oligodendrocyte 
protein antibodies can be detected, are important in making definitive diagnoses (Geraldes et 
al. 2018). A summary of the current diagnostic criteria for MS are given in Table 4. 
Table 4: Diagnostic criteria for multiple sclerosis generated by International Panel on the 
Diagnosis of MS in 2001 with subsequent revisions in 2010 and, most recently in 2017; known 
as the MacDonald criteria (revised).  Figure adapted from Thompson, Banwell, Barkhoff et al. 
2017.  These criteria are used in the clinical diagnosis of multiple sclerosis and in the 
differentiation of Multiple Sclerosis from other potential differential diagnosis such as 
neuromyelitis optica. 
Primary criteria: Plus two or more of the following: 
1 year of disability progression, 
retrospectively or prospectively 
determined independent of clinical relapse 
One or more T2-hyperintense lesions 
characteristic of multiple sclerosis in one or 
more of the following brain regions: 
periventricular, cortical or juxta cortical, or 
infratentorial 
 
Two or more T2-hyperintense lesions in the 
spinal cord 
 
Presence of CSF-specific oligoclonal bands 
Unlike the 2010 McDonald criteria, no distinction between symptomatic and 
asymptomatic MRI lesions is required. 
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White matter lesions are the classical hallmark of MS, although lesions can be found 
throughout the CNS.  Spinal cord imaging poses distinct challenges to imaging in the brain.  This 
is largely as a result of the small cross sectional area of the cord, its proximity to the large 
vertebral bodies which can cause susceptibility artefacts, alongside interference that the 
pulsatile flow of CSF can cause to certain sequence types.  Its specific imaging modalities and 
their inherent challenges will not be further examined here. 
 
White matter lesions are typically visualised using T2 weighted imaging and pre and post 
contrast T1 weighted imaging.  MS plaques are typically imaged with T2 weighted sequences.  
Here lesions are detected as hyperintensities. However the sensitivity for detecting the 
underlying pathology is poor (Tillema and Pirko 2013).  In particular it is challenging to 
differentiate between the various features associated with MS, and hallmarks of other 
pathological processes for example remyelination inflammation oedema and axonal loss, all 
part of the pathology seen in MS can be almost impossible to differentiate from cell infiltration 
or neoplasia as all these have similar characteristics on T2 weighted imaging (Group 1993) 
(Tillema and Pirko 2013).  Fast spin echo sequences and fluid attenuation inversion recovery 
(FLAIR) sequences are the most common sequences to use in T2 weighted imaging.  FLAIR 
imaging supresses the water signal from CSF thus giving improved tissue contrast, however it 
can obscure lesions in certain locations, and for this reason FLAIR sequences alone are 
insufficient to make diagnoses (Stevenson et al. 1997). 
 
Contrast agents are rarely used in T2 weighted imaging, iron oxide nanoparticle-based contrast 
agents that can give hypointense signal changes on T2* weighted imaging, but most of these 
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are experimental and with limited use in human studies (Dousset et al. 2006; Pirko et al. 2004;  
Vellinga et al. 2008)  
 
In addition to the difficulty in correlating imaging findings with pathology there appears to be 
a weak correlation between the T2 lesion load, and clinical disability (Molyneux et al. 1998; 
O'Riordan et al. 1998; Zivadinov and Leist 2006).  This difficulty may result from the inability to 
reliably identify a remyelinated lesion (Tillema and Pirko 2013). 
 
T1 weighted imaging alone offers little specific support for the diagnosis of or identification of 
MS lesions, however some T2 hyperintensities are hypointense on T1 (Uhlenbrock and Sehlen 
1989), these T1 black holes arise as a result of two main disease processes: 
1)  A majority of T1 black holes are seen early in lesion formation (Bagnato et al. 
2003);(Levesque et al. 2010) with cellular infiltration in newly forming lesions associated with 
focal oedema.  Lesions of this type often resolve (Brex et al. 2002; Losseff et al. 2001) 
2)  Approximately 30% of T1 ‘black holes’ will persist, becoming a lifelong feature 
(Ciccarelli et al. 1999; van Waesberghe et al. 1999).  These are thought to represent severe 
tissue loss with areas of axonal injury or loss (Bitsch et al. 2001).  Here the degree of 
hypointensity is thought to be proportional to axonal density (Bitsch et al. 2001), with the most 
hypointense black holes having little in the way of remaining neuronal structures (van 
Waesberghe et al. 1999).  The presence of the T1 black hole is better correlated with clinical 
disability than the T2 weighted image. 
 
T1 post contrast enhancement is considered to be the hallmark of the ‘active lesion’ as it 
represents the presence of a permeable blood brain barrier through which the contrast agent 
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(and therefore inflammatory infiltrates) can pass in to the parenchyma.  Gadolinium post 
contrast enhancement are typically present in the first 4-6 weeks of a lesions lifecycle (Miller 
et al. 1988) . However, the presence of post contrast enhancement does not necessarily 
indicate an imminent clinical relapse.  Thompson and colleagues identified T1 post contrast 
enhancement 5-10 times more frequently than clinically observable relapses (Thompson et al. 
1992).  Therefore, despite the fact that post contrast enhancement is the only conventional 
imaging tool we have that correlates directly to the pathological state of a lesion, its correlation 
to clinical state is limited. 
 
Diagnostic criteria are clearly focused on the identification of existing pathology and the 
correct elimination of other differentials.  However, monitoring of patients once a diagnosis 
has been made is of critical importance both in assessing their relative severity of disease, but 
also in monitoring of response to treatment. 
 
Conventional imaging modalities rely on the characteristics discussed above, however 
advanced MRI techniques are being developed in order to address the shortfalls in correlation 
between imaging finds and histopathology.  It is simply not possible to reliably identify 
remyelination with any current conventional MRI techniques (Absinta, Sati, and Reich 2016). 
 
Myelin Water Fraction 
 
Mapping of Myelin water content (the Myelin Water Fraction (MWF)) has been developed as 
an advanced MRI technique for detecting myelin (MacKay and Laule 2016; Sati et al. 2013).   
This technique relies on different T2 relaxation times of water in different anatomical 
environments.  It has been shown that protons in water within the myelin membranes have a 
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short T2 relaxation time of 10-55ms (usually around 20ms),(McKay et al 1994)..  By examining 
the relationship between the short (water T2 times, and the total water signal a ration of myelin 
water content can be extrapolated.  This myelin water fraction has histopathological 
correlation with lesion changes and is unaffected by axonal degeneration or inflammatory cell 
infiltration and oedema (Laule et al. 2006) 
 
 This methodology it is limited by poor signal to noise ratios and reproducibility between 
scanners (Alonso-Ortiz, Levesque, and Pike 2014), additionally in order to get adequate brain 
coverage long sequence acquisition times are required when using sequences such as T2 prep 
three dimensional SPIRAL, a gradient echo sequence suitable for whole brain imaging if the 
MWF (Nguyen et al. 2012). 
 
Magnetisation Transfer Ratio 
 
 
Magnetization Transfer Ratio (MTR) may offer more specific insights in to the 
demyelination:remyelination relationship (Levesque et al. 2010).  Magnetisation transfer  
imaging is a semi quantitative technique  which uses traditional magnetic resonance physics 
but exploits the physiology of the anatomical environments in which the proton (1H nuclei) 
exist; namely  a free ‘liquid’ pool, in which protons are mobile, and a restricted ‘semisolid’ 
where a protons mobility is restricted as a result of its relationships with macromolecules it 
comprises with or it interacts with.  
 
Transfer, or the exchange, of magnetisation takes place between these two pools, by using an 
additional radio frequency pulse in the sequence.  The bulk of signal in conventional MRIs 
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comes from the free proton pool because the restricted proton pool has a such a short T2 
relaxation that signal decays prior to sampling making this compartment relatively invisible on 
conventional sequences.  By exploiting the exchange of magnetisation which occurs as result 
of the specialised pulse sequences Magnetisation Transfer Ratio Imaging gives insight into this 
previously ‘invisible’ pool of protons.  This is particularly pertinent to remyelination as myelin 
is a major source of ‘semi solid’ or restricted protons. Magnetisation Transfer imaging provides 
access to the restricted protons, which are located in biologically interesting tissue regions.  
The main factors which influence Magnetisation Transfer Ratio are shown in 
Table 5:  
 
 
Table 5: Factors which influence MTR relevant to remyelination and demyelination. 
 
Using MTR white matter lesions show a reduction in transfer in comparison to NAWM, with 
remyelinated lesions showing an increase in Magnetisation Transfer Ratio relative to lesions 
(Schmierer, Wheeler-Kingshott, et al. 2007).  In MS the MTR shows the following relationship 
(Barkhof et al. 2003);(Chen et al. 2008);(Schmierer, Wheeler-Kingshott, et al. 2007): 
       Demyelinated>Remyelinated>NAWM>Control healthy white matter of non MS patient 
 
Factor CHANGE Reference 
Myelin loss ¯ Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407–15. 
Oedema 
¯ 
Rai, Ahuja, Agrawal, Kalra, et al Reversal of Low-Grade Cerebral Edema After 
Lactulose/Rifaximin Therapy in Patients with Cirrhosis and Minimal Hepatic 
Encephalopathy. Clinical and Translational Gastroenterology (2015) 6, e111 
Low axonal 
density ¯ 
Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in 
postmortem multiple sclerosis brain. Ann Neurol 2004;56:407–15. 
Cell Infiltration 
¯ 
Gareau, Rutt, Karlik and Mitchell. Magnetization Transfer and Multicomponent T2 
Relaxation Measurements With Histopathologic Correlation in an Experimental Model 
of MS. J. Mag. Res. Im. 2000:11;586-595 
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Although very sensitive to myelin Magnetisation Transfer Ratio, is only semi-quantitative, and 
shows a degree of variability in its quantification between different sequences and scanners 
(Mallik et al. 2014).   Magnetisation Transfer Ratio has been shown not to correlate with myelin 
content in a murine model of of MS; the MOG-EAE model (Fjær et al. 2015).  Mathematical 
modelling to extract the quantitative features is possible, and overcomes this issue to a great 
extent (Levesque et al. 2010; Schmierer, Tozer, et al. 2007;  Cercignani et al. 2005), however 
the degree to which these values can be used as biomarkers is not fully established as oedema 
in particular can attenuate the reduction in Magnetisation Transfer Ratio following 
demyelination, and as sequential readings are required on a per lesion basis, this attenuates 
any increase in Magnetisation Transfer Ratio which might be expected as a result of repair (Ou 
et al. 2009) 
 
Diffusion Tensor Imaging 
 
 
Diffusion Tensor Imaging is a quantitative technique which measures the motion of water 
molecules in their different anatomic environments inferring information about 
microstructural anatomy though changes in this water motion.  Similar to Magnetisation 
Transfer Ratio it relies on the fact that a majority of MRI signal is obtained from protons bound 
as water, and that water exists in different anatomical environments be that fixed or free.  The 
motion calculated in DTI is not flow, but the Brownian motion of the proton as a particle.  Free 
water will have 100% random motion, however when anatomical structures such as axons or 
myelin are introduced the degree and direction of this motion will be constrained by the 
macromolecular structures and their orientation. DTI takes three main measurements; the 
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fractional anisotropy, the radial diffusivity and the axial diffusivity with the addition of the 
mean diffusivity which is a global measure of water motion. 
1) FA is a fractional measure of the freedom with which water can diffuse or move. An FA 
of 0 indicates unimpeded motion in all directions. And FA of 1 indicates uniplanar motion, 
i.e. it is restricted along a single axis. FA is thought to correlate with axonal density and 
myelination (Gouw et al. 2008). 
2) Radial Diffusivity is the rate of diffusion perpendicular to the main axis, or in the 
transverse plane.  It is thought to reflect the degree of myelination (Song et al. 2005). 
3) Axial Diffusivity is the rate of diffusion in the longitudinal plane or in plane with the 
main axis, it has been correlated with axonal integrity (Winklewski et al. 2018).  
 
The major limitation of this technique however, is that it relies on accurate tractography and 
calculation of fibre orientation (Mallik et al. 2014), and again is a proxy measure for myelin 
rather than a direct quantification. 
 
 
  Magnetic Resonance Spectroscopy 
 
Magnetic Resonance Spectroscopy (MRS) works analyses the proton in its chemical 
environment giving parts per million read out for different metabolites.  It is able to detect 
Factor FA RD AD Reference 
Inflammation 
(usually reported as 
astrogliosis, or cell 
infiltration and 
oedema) 
­ - ¯ (Tu et al. 2016; Xie et al. 2010) 
(Wang et al. 2011) 
Demyelination ¯ ­­ -- (Song et al. 2005) (Song et al. 2002)  
Loss of axonal 
density 
¯ ¯ ¯¯ (Song et al. 2003) (Winklewski 
et al. 2018) 
Table 6: Relationships between DTI factors  
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active lesions as it will demonstrate peaks in lipid and choline spectra associated with 
demyelination and the break down of the myelin sheath (Narayana 2005), however it offers 
little insight into intact myelin (Laule et al. 2007), though some suggest that it more accurately 
represents instability, suggesting that peaks could represent demyelination or remyelination 
(De Stefano et al. 2005; Lin et al. 2005). Either way, it is a non specific measure of myelin 
activity. 
 
Positon Emission Tomography 
Positron Emission Tomography, in contrast to all the previously described techniques is a 
nuclear modality which relies on ionising radiation.  A radioactive ligand is piggy backed into 
the body on a tissue relevant biologically active molecule, this allows tissue metabolism and 
regional blood flow to be probed on the basis on the rate of uptake and decay of the ionising 
radiation (Niccolini, Su, and Politis 2015).  The most commonly used ligand for brain imaging is 
18F-FDG a fluorinated glucose tracer used to investigate tissue metabolism, its main diagnostic 
role is to aide division of lesions in to active or chronic (Schiepers, Van Hecke, and 
Vandenberghe 1997).  A few myelin specific ligands have been designed (Stankoff et al. 2011),  
however, there is significant research in to developing a wider array of molecules for clinical 
use (Niccolini, Su, and Politis 2015). 11C PiB, in particular shows promise as an agent capable of 
differentiating remyelination (Bodini et al. 2016), however currently it is challenging to 
synthesis and has a prohibitively short half life (Sormani and Pardini 2017).  Somewhat more 
common is the PET imaging of microglia which gives insights into microglial activation and 
inflammation (Takano et al. 2013).  However, all PET imaging processes are limited by their 
relative expense and the concerns over imaging chronically ill patients repeatedly with multiple 
doses of ionising radiation. 
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 1.13ii Preclinical Imaging of Remyelination 
A majority of clinical imaging technologies have gone through often considerable development 
in preclinical models, however at the current time none of them are used for routinely 
evaluating remyelination therapies in clinical models of MS or toxin induced demyelination. 
 
There are a wide range of modalities available for pre clinical evaluation of myelin, these 
techniques are largely light and electron microscopy techniques, these modalities require post 
mortem tissue and will not be further examined here.  The focus instead will be on longitudinal 
imaging modalities, with particular emphasis on those which have the potential to be 
translated in to clinically applicable techniques. 
 
Stem cell transplant therapies are being widely explored for a range of CNS conditions including 
MS and spinal cord injury (SCI), current molecular imaging to trace these cells falls in to two 
main categories, physical cell labelling and the use of gene reporters.  Current physical 
strategies include T2 contrast agents such as USPIOs and SPIO, radionuclide labelling for SPECT 
or PET, and nanoparticle labelling for fluorescent imaging.  Currently available gene reporters 
include the bioluminescent proteins including firefly luciferase and the fluorescent protein 
gene reporters discussed previously such as GFP.  A range of gene reporter systems for MRI 
exist, discussed in section 1.14.  However, to date, none of these have been used to probe 
myelin dynamics. 
 
Labelling of endogenous progenitors and the interrogation of their remyelinating potential has 
been widely studied with a variety of genetic fate mapping techniques, as well as a number of 
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viral introduced reporter gene systems, these systems rely on optical imaging methodologies 
which are   no clinically translatable and therefore not examined further here.  
 
SPIO 
Superparamagnetic iron oxide (SPIO) particles, are composed of multiple magnetite crystals, 
each particle is 200 nm in diameter.  Ultra Small SPIO (USPIO), consist of a single crystal core 
and have an average particle diameter of 50 nm (Modo, Hoehn, and Bulte 2005).  Relaxivity 
increases with increasing crystal density, and so SPIO – with several magnetite crystals per core 
and a large magnetic moment – can generate more contrast per mole of iron than USPIO 
(Wáng and Idée 2017; Modo, Hoehn, and Bulte 2005). 
 
SPIOs are taken up in to the target cells by endocytosis, with particles localising in endosomes, 
this increases susceptibility effects (Kraitchman and Bulte 2008).  Long term the SPIO is broken 
down by intracellular lysosomes, or alternatively phagocytosed by monocyte lineage cells 
where they may be degraded in turn.  The liberated iron then enters endogenous iron 
homeostatic pathways and may be stored as hemosiderin or ferritin in tissues (Wáng and Idée 
2017). 
 
USPIO and SPIO in myelination/remyelination SPIO particles have been used to label NPCs, 
OPCs, OECs and mesenchymal cell transplants into damaged CNS without deleterious effects 
to cellular function (Sandvig et al. 2011; Lin et al. 2013; All et al. 2012; Kobayashi et al. 2012; 
Luo et al. 2013; Bottai et al. 2010; Amemori et al. 2013; Hu et al. 2012; Jung et al. 2009; Lepore 
et al. 2006; M. E. Cohen et al. 2009; Dunning et al. 2006; Franklin et al. 1999).  These cells have 
been detected by T2 MRI sequences, and in some studies functional improvements following 
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transplantation have been recorded in models of spinal cord injury.  Oligodendrocyte 
precursors have also been labelled with SPIOs and successfully transplanted with detection at 
over one week post transplantation (Bulte et al. 1999; Franklin et al. 1999), and similarly 
labelled Schwann cells have been shown to form functional myelin following transplantation 
(Dunning et al. 2006).  To date this study, alongside Bulte and colleagues (Bulte et al. 1999) 
recapitulation of this study in the myelin deficient rat, remains the only examples of a 
myelinating cell type being detected successfully by MRI with confirmed myelin formation.  
However, like all SPIO studies, functionality is not detectable by MRI and requires 
histopathological processing.  Equally SPIO particles can persist in phagocytic cells following 
cell death thus impairing their specificity as a cell survival indicator (Kraitchman and Bulte 
2008). 
 
PET and SPECT in myelination/remyelination 
 
Preclinical PET and single photon emission computed tomography (SPECT) operate on the 
same principles as the clinical imaging modalities.  Cell identification is feasible in the short 
term, however imaging for periods long enough to visualise remyelination is limited due to the 
short half live of the radio ligands available (Scarfe et al. 2018).   
 
High Field MRI 
High field imaging (using scanners above 3 tesla) may also offer greater insight, (Chmierer et 
al. 2009).  However, there are limitations on the availability of these scanners for clinical use 
and sequences are not directly transferable from lower field strength scanners.  
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1.14 Reporter Genes for MRI 
 
Gene reporter systems are used to visualize or quantify the expression or activity of genes in 
biological systems.  First developed in 1985, firefly luciferase is still widely used today.  The 
repertoire of gene reporters has since been expanded and includes GFP, and creatinine kinase 
which can be used in magnetic resonance imaging (de Wet et al. 1985).  However, despite 
much work on the development of new MR reporter genes, very few advances have been 
made with their use (Gilad, McMahon, et al. 2007). 
 
The first reporter gene used for MRI was creatine kinase (Koretsky et al. 1990) in 1990, since 
then over 20 other systems have been published. See Appendix 2.  However there are many 
challenges to their development (Gilad, Winnard, et al. 2007). 
 
Possibly due to the almost ubiquitous usage of the T2 sequence in clinical and pre clinical MR 
work, ferritin, which can be used to provide T2 weighted contrast enhancement, is one of the 
most widely used reporters (Genove et al. 2005).  However, it has many disadvantages, in 
particular it provides negative contrast (a reduction in signal below background levels), and is 
not hugely specific due to the presence of other iron containing tissues (blood) in the body. 
 
The development of the Urea Transport Protein reporter system (Schilling et al. 2016) has 
facilitated relatively low resolution (0.93mm x 0.93mm x 3mm), but highly specific imaging of 
reporter genes in the murine brain providing an imaging modality which does not require a 
contrast agent using apparent water exchange as a measure for the reporter genes expression.  
This methodology lends itself well to translation in to the human imaging as it relies on 
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endogenously generated contrast (water movements), however the relatively low spatial 
resolution may be too low to allow cell fate mapping, and resolution is likely to decrease in 
lower field clinical scanners 
 
Few reporter genes have been developed to provide T1 weighted contrast (Bartelle et al. 2013) 
Koretsky and Silva 2004).  T1 contrast is preferable as it is positive (increased signal relative to 
background).  Until recently the few reporter systems that did exist provided poor resolution 
and suffered from toxicity issues.  However with the development of the OATP reporter gene  
system now exists which provides excellent spaciotemporal resolution (Patrick, Hammersley, 
et al. 2014). 
 
Based on the current literature, it is clear that there is a predominance of MRI reporter gene 
systems for use in T2 weighted imaging (Weissleder et al. 1997); (Weissleder et al. 2000); 
(Moore et al 2001); (Alfke et al 2003), (Cohen et al. 2005); (Genove et al. 2005); (Tannous et 
al. 2006); (Zurkiya, Chan, and Hu 2008); (Cui et al. 2010); (Niers et al. 2012); (Patrick et al. 
2016); (He et al. 2016); (Wu et al. 2018). Cui and colleagues achieved a 3.5 fold decrease in 
signal using a LacZ:S-Gal plasmid system under a cytomegalovirus promoter (Cui et al. 2010), 
however this required direct transfection of tumour cells by intra tumoral injection and this 
system has not yet been replicated in a systemic delivery model.  Many of the T2 weighted 
systems make use of iron or ferritin reporter systems, the most effective of these, reported 
by Weissleder and colleagues reported a 5.3 fold decrease in signal in vivo (Weissleder et al. 
2000).  The approach used by Weissleder and colleagues aimed to overcome previous 
requirements for high levels of over expression of the Transferrin receptor, and for the 
potential toxicity of high levels of free iron seen in some previous studies.  This was achieved 
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by the use of monocrystalline iron oxide particles coupled to holo-transferrin, and an 
engineered transferrin receptor over expressed on tumour cells.  This would result in the 
accumulation of non toxic iron oxide particle in the cytosol of cells expressing only the 
engineered receptor in a tumour cell line.  Such particles require systemic intravascular 
administration, marking their use completely inappropriate for imaging within the CNS. As 
discussed previously, a T2 contrast enhancement usually result in a reduction in the signal 
collected and therefore in ‘negative’ contrast on an image.  This can be challenging to 
identify visually on an image and therefore significant efforts have been made to develop 
positive contrast modalities applicable to T1 weighted imaging or to more advanced imaging 
techniques such as Chemical Exchange Saturation Transfer MRI (Meier et al. 2018) or 
Apparent Water Exchange Rate MRI (Schilling et al. 2017). 
 
Attempts have been made to exploit manganese, an alternative paramagnetic metal to 
gadolinium which also provides T1 weighted contrast.  Manganese contrast has been 
reported with both exogenously delivered contrast in the form of manganese chloride 
(Bartelle et al. 2013), and manganese loaded ferritin(Patrick et al. 2016), however both these 
systems suffer from the toxicity of manganese, and in first instance of significant levels of 
background contrast as Manganese can be taken up in to neurones due to its similarities to 
calcium, and the divalent metal transporter over expressed in the study is present on a all 
CNS cells to some degree (SkjÃ rringe et al. 2015).  The later of these studies aims to 
overcome this background issue by using a T cell immunoglobulin and mucin domain 
containing protein which is an alternative form of ferritin receptor, coupled with either iron 
or manganese loaded ferritin for both T1 and T2 weighted imaging, and achieves a significant 
change in both T1 and T2 signal in vitro, however despite loading the manganese in to 
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apoferritin particles, the toxicity of manganese is still a significant challenge and the in vitro 
T1 imaging could not be recapitulated in vivo. 
 
The only system to date which is reported in the literature of t1 weighted contrast agent, 
already approved for use in humans with acceptable toxicity profiles (as judged by Food and 
Drug Administration (USA) and National Institute for Clinical Excellence (UK) approval, and 
widespread clinical usage) is that of the OATP transporter proteins reported by Patrick and 
colleagues (Patrick et al. 2014).  This system, discussed in more detail in the next section uses 
viral delivery of the transgene to facilitate the cytosolic uptake of the paramagnetic ion 
gadolinium and aims to overcome many of the issues around toxicity, low resolution and 
background or endogenous contrast with have contributed to relative obsolescence of many 
of the other techniques previously reported. 
 
Of the techniques that target more advanced MRI imaging sequences the UDP reporter used 
by Schilling and colleagues is one of the most exciting developments in the field as it as no 
toxicity associated with the contrast agent as it makes use of endogenous water movements 
for imaging using AXR sequences(Schilling et al. 2017).  Like the OATP vector it uses a 
lentiviral system, and like any other viral gene therapy technique there are challenges around 
the translation of lentiviruses in to clinically applicable tools, however these are likely to 
surmountable as viral vector technologies improve.  Equally as exciting is a Lysine rich protein 
promoter(Meier et al. 2018) which again uses endogenous contrast and MTR imaging, 
although not amenable to longitudinal imaging this technique makes use of an adeno-
associated viral vector which is potentially less problematic for translation to the clinic due to 
their increasing use in other forms of gene therapy (Keeler, ElMallah, and Flotte 2017).  This 
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lysine rich protein reporter requires MTR sequences which can be challenging to standardise 
and do not form part of the standard range of diagnostic sequences therefore it is unlikely 
that this, or the UDP system will find an application in clinical diagnostics in the near future.  
They may however be useful tools in refining and standardising these sequences such that 
they can be transitioned to clinical tools more rapidly. 
 
1.15 Organic Anion Transporter Proteins 
 
The Organic Anion Transporter Proteins (OATP) are a family of transmembranous proteins 
expressed on the membranes of a wide range of cells throughout the bodies of mammalian 
species.  They serve to transport a range of uncharged organic molecules into the cells 
cytoplasm including thyroid hormone and oestrogen.  Oatp1a1 is the protein isoform 
expressed on the basolateral membrane of hepatocytes, its expression is highly restricted 
(Hagenbuch and Meier 2003; Roth, Obaidat, and Hagenbuch 2012). 
 
The restricted expression of Oatp1 has been harnessed by clinical hepatologists as its 
expression is up regulated in certain forms of hepatic carcinoma.  A contrast agent has been 
designed which is specific to the Oatp1 chanel.   Primovist (Bayer) is a gadolinium containing 
linear chelate (Gd-EOB-DTPA) which is specifically transported by the Oatp1a1 channel (van 
Montfoort et al. 1999).  In cases of hepatic carcinoma this results in an accumulation of this 
contrast agent intracellularly which is visible as contrast enhancement on T1 weighted MRI. 
 
By expressing this protein ectopically in xenografts the Brindle group have demonstrated that 
Oatp1a1 can be used as a specific and sensitive gene reporter which provides positive contrast 
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on MRI.  It is also able to enhance uptake of luciferase resulting in a ten fold increase in signal 
(Patrick, Lyons, et al. 2014).  The expression of the Oatp1a1 has been linked to a fluorescent 
reporter gene; mStrawberry, by an E2A sequence facilitating equimolar expression.   
 
Preliminary work by Patrick et. al. using recombinant mammalian expression vectors have been 
used to transfect a variety of cell lines to demonstrate selective and reversible take up of 
gadolinium contrast agent (Figure 14).   Xenografts expressing Oatp1a1 have been shown to 
result in reversible contrast enhancement specific to administration of Primovist (Bayer) Figure 
15; here the expression of Oatp1a1 is under the control of the constitutively active promoter 
sequence Phosphoglycerokinase (PGK). 
 
 
Figure 14: Primovsit Uptake in vitro. Primovist (Gd-EOB-DTPA) uptake and washout in cells 
transfected to express Oatp1a1. Measurements of uptake (A) and washout (B) in un 
transfected cells, cells stably transfected with empty vector, and cells stably transfected with 
an oatp1a1-expressing vector. From Patrick et al (2014). 
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Figure 15: Primovist uptake in vivo. A. T1 images after contrast agent injection. Left are 
control xenografts, right side xenograft express Oatp1a1. B. R1 before and following 
injection of Gd-EOB-DTPA were significantly greater compared to controls.  From Patrick 
et al (2014) PNAS. 
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2. Aims 
 
This project aims to develop a novel technique which is able to non invasively, and 
longitudinally identify the expression of new myelin in an experimental model of 
demyelination. 
 
The project aims to 1) image differentiation of endogenous OPCs into remyelinating 
oligodendrocytes in vivo, and 2) to image differentiation of transplanted OPCs into 
remyelinating oligodendrocytes in vivo. 
 
This will be achieved by using the novel imaging strategy first developed by the Brindle group: 
the OATP transporter channel.  By controlling the expression of this channel in OPCs and 
Oligodendrocytes using constitutively active, and lineage specific promoters, cells will take up 
gadolinium based contrast agents detectable by nuclear resonance imaging techniques.  The 
uptake of the contrast agent will therefore be directly related to the expression of these genes.  
This project will use the EB-CCP lesion as an experimental model of demyelination and 
remyelination in which to develop this technique.  It will use two different paradigms in its 
development: The first, looking to achieve OATP expression in endogenous OPCs as they 
differentiate in to myelinating oligodendrocytes.  This methodology might form the foundation 
of an outcome measure for therapies for diseases such as multiple sclerosis were new 
therapies are likely to revolve and pharmacological manipulation of the immune and 
inflammatory cascades.  The second, looking to achieve OATP expression in to OPCs 
differentiating in to oligodendrocytes following transplantation in to demyelinating lesions.  
This methodology might form the foundation for an outcome measure for new therapies to 
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treat diseases such as Pelizeus Merszbacher Disease, where new therapies are likely to require 
cell based therapies. 
 
Specifically this project aims to address the following questions: 
1) Can OPCs and Oligodendrocytes be infected by, and express a viral vector carrying the 
OATP1a1 transporter channel? 
2) Can OPCs or Oligodendrocytes expressing OATP take up imaging contrast agents? 
3) Can imaging protocols be developed to detect these contrast agent in vitro and in vivo? 
4) Is it possible to detect demyelination and remyelination in the EB-CCP model system? 
5) Can outcome measures and techniques for the new methodology be developed to allow 
validation of the new technique? 
 
In the future it is hoped that full in vitro and in vivo models can be generated in which 
oligodendrocyte lineage cells, expressing the OATP channel under the control of a myelin 
promoter, take up contrast as they differentiate in to the myelinating oligodendrocyte.  This 
contrast agent will be detectable by non invasive imaging and can be used to monitor 
remyelination.  Specifically it can be used as a non invasive outcome measure for assessing the 
efficacy of new myelin regenerative therapies. 
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3. Materials and Methods 
3.1 Molecular Biology Protocols 
3.1i Restriction Enzyme Digestion 
 
To confirm the structure of the plasmids inherited from Dr. P.S. Patrick, restriction enzyme 
digestions were performed.  Over ice, 1µL of restriction enzyme was added to 1µg of DNA 2µL 
of the appropriate buffer (CutSmart, New England Biolabs (NEB) B7204S) and dH2O up to a 
volume of 20µL, the solution was then incubated at 37°C for one hour.  Digestion products 
were then mixed with 5µL loading dye (New England Biolabs B7024S) and run on a 1% agarose 
gel electrophoresis for 35 minutes at 110 volts with a DNA Ladder (New England Biolabs 
N3232S).  A list of restriction enzymes is given in Appendix 5. 
 
3.1ii Vector Construction 
 
Five plasmids were inherited from Dr. P.S. Patrick; a three vector lentivirus packaging system 
containing pRev, V-VSG, and pMDL, and two pBOBI lentiviral transfer plasmids; one expressing 
OATP under the PGK promoter and one under an MBP promoter.  Restriction enzyme 
digestions confirmed that the inherited packaging and PGK plasmids matched existing maps; 
however, the MBP vector did not, and not did it appear to work in initial trial infections.  
Therefore, the MBP fragment was sequenced and synthesised using PCR.  The fragment was 
ligated in to the vector using 40 ng of cut vector and a 1:3 molar ratio of vector to insert, 0.5μL 
of T4 DNA ligase, 1μL of ligase buffer, and Milli Q water to make a final volume of 20μL.  Prior 
to ligation the vector was dephosphorylated using Antarctic phosphatase (NEB) together with 
the supplied buffer in order to prevent re-circularisation of the plasmid in the absence of the 
insert.  Following the dephosphorylation step, the phosphatase was inactivated by incubation 
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at 65°C for 15 minutes.  Ligations were incubated at room temperature for 1 hour, before 
being used to transform competent bacteria (New England Biolabs: C2987I). 
 
3.1iii Bacterial Transformation and Plasmid Purification 
 
In order to obtain concentrated pure plasmid competent bacteria (New England Biolabs 5-
Alpha: C29871) were transformed and expanded before protein extraction.  50μL of 
competent E.coli were thawed on ice for 10 minutes.  50ng of plasmid DNA was added to the 
solution which was mixed by flicking the tube 5 times before being incubated on ice for 30 
minutes.  The bacteria were then heat shocked for 30 seconds and then returned to ice and 
incubated for a further five minutes.  950 μL of SOC media (NEB: B9020S) was added at room 
temperature and then incubated at 37°C and 250 rotations per minute(rpm) for 60 minutes.  
Serial dilutions of the competent bacterial solution were added to pre warmed selective LB 
Agarose Plates and incubated overnight at 37°C to allow colony expansion. 
 
Single colonies were then selected and added to 5ml of selective LB Broth in a 15mL loosely 
capped falcon tube, and incubated at 37°C, 250 rpm for 6 hours to form starter cultures, these 
were then expanded seeding 1mL in to 100mL of pre warmed selective LB Broth in 250mL 
conical flasks and incubated overnight. 
 
Bacterial pellets were harvested from the expanded cultures by centrifugation at 6000g for 20 
minutes at 4°C, supernatant was carefully removed prior to protein extraction or freeze 
storage at -80°C. 
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Protein extraction was performed using Qiagen Mini, Midi, or Maxi QIAprep (QIAGEN: 10023) 
kits according to manufacturers guidelines. 
 
3.1iv Lentivirus Production 
 
Plasmids for production of the lentivirus were inherited from Dr. P.S. Patrick via the Verma lab, 
Stalk Institute, California.  HEK293T Cells were plated on 15cm dishes (Sigma CLS430599) in 
Mixed Glia Media to achieve a confluence of 80% on day one of transfection.  22.5ug of pBOBI 
vector, 14.7µg pMDL plasmid, 8µg VSV-G plasmid and 5.7µg pRev plasmid were added to 
600µL OptiMEM (Lifetech 31985062) in one tube.  In a second tube 80µL of lipofectamine 
2000 (Invitrogen 11668-019) was added to 600µL OptiMEM.  Tubes were incubated for 5 
minutes at room temperature.  The second mix was then pipetted in to the first and allowed 
to incubate at room temperature for 30minutes. The transfection solution was then added to 
13ml of pre equilibrated OptiMEM and added to the cells.  12 hours later 5mL of nOPC media 
(serum free) was added.  48 hours after vectors were added supernatant is collected and fresh 
nOPC media was added. 
 
Virus for use in vitro was concentrated using Millipore Centricon Plus-70 filters (Merck 
Millipore, UFC710008), and aliquots frozen at -80°C.  Virus for use in in vivo experiments was 
concentrated using ultracentrifugation. 
 
 
 
3.1v Virus Concentration 
 
Virus for use in vitro was concentrated using Millipore Centricon Plus-70 filters (Merck 
Millipore, UFC710008)according to the manafacturers instructions, and aliquots frozen at -
80°C.   
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Virus for use in in vivo experiments was concentrated using ultracentrifugation. Supernatant 
was collected and filtered through a 0.45μm syringe filter (Millipore) to remove debris.  A 20% 
sucrose cusion was pipetted in to the bottom of a 30mL conical ultracentrifugation tube 
(Beckmann Coulter) beneath the filtrate.  The filtrate was centrifuged at 24 000 rpm in for 2 
hours at 4°C, using a swinging bucket rotor (SW28, Beckmann).  This process was repeated 
removing supernatant and adding fresh filtrate multiple times to concentrate the virus.  After 
the final centrifugation, the supernatant was removed, and the conical tubes left to dry in a 
sterile environment.  Pellets were then re-suspended in PBS, and vortexed gently every 20 
minutes for 2 hours. The virus was then aliquoted and stored at – 80°C. 
 
 
3.1vi Viral Tire Quantification 
 
Viral titres were calculated by infecting HEK cells using a limiting dilution series.   HEK293T cells 
were infected at 70% confluence in OptiMEM media using a 10 fold serial dilution of the stock 
virus, 72 hours following infection cells were detached from the plates using trypsin and 
stained with DAPI for flow cytometry.  The percentage of mStrawberry fluorescing cells was 
calculated and the number of viral particles per ml calculated using the equation: 
% mStraw+ x total number of cells at time of infection x dilution factor x 1000 
volume of virus used to infect in µL 
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3.2 In Vitro Cell Culture Protocols 
3.2i Media Recipes 
HALF See appendix 3i 
SATO See appendix 3ii 
Modified MWB See appendix 3iii 
nOPC Media See appendix 3iv 
CSC Media See appendix 3v 
MG Media See appendix 3vi 
LB Broth See appendix 3vii 
Selective Bacterial LB Agar See appendix 3viii 
MACS Dissociation Solution See appendix 3ix 
Mixed Glia Dissociation Solution See appendix 3x 
CryoProtectant Solution See appendix 3xi 
 
3.2ii Cell Culture 
HEK293T cells and OPCs were seeded at densities according to Table 7.  HEK293T Cells were 
cultured in Mixed Glia Media, nOPCs were cultured in serum free defined media; nOPC Media, 
see appendix 8.3.  Cells were incubated at 37°C and 5% CO2. 
 
Surface Area (cm2) OPC HEK 
24 well plate (/well) 2 10,000 n/a 
T25 25 200,000 n/a 
T75 75 500,000 500,000 
150mm dish 152 n/a 1,000,000 
Table 7: Cell densities for plating of HEK and nOPCs 
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3.2iii HEK293T Cell Freezing 
Cells were grown to approximately 80% confluence, trypsinised, resuspended in Mixed Glia 
Media, and pelleted by centrifugation at 3000g for 5 minutes.  The supernatant was removed 
and the pellet was resuspended in freezing medium (80% growth medium, 10% Fetal Bovine 
Serum (FBS) and 10% DMSO), and transferred to 2mL Cryovials (Corning).  The vials were then 
placed in a cell-freezing container (Mr Frosty, Nalgene), before being stored at -80°C.  
 
3.2iv HEK Cell Thawing 
Frozen Cryovials of HEK cells stored at -80°C were heated to 37°C in a water bath, until no ice 
remained. The content of the vial was then diluted 1 in 10 using growth Mixed Glia Media, and 
centrifuged at 300g for 5 minutes, to form a cell pellet. The supernatant was removed and the 
cells were resuspended in an appropriate volume of Mixed Glia Media and transferred to a cell 
culture flask 
 
3.2v Trypsin Dissociation of HEK Cells 
HEK cells were grown to 70 to 80% confluence, washed with PBS (Gibco), trypsinised (0.5% 
trypsin, Invitrogen in DMEM(Gibco)), and mechanically agitated until they were separated 
from the surface of the flask.  Cells were then diluted in Mixed Glia Media to neutralise the 
trypsin, before being diluted further to an appropriate concentration for plating. 
 
3.2vi Papain Dissociation of nOPCs 
To dissociate OPCs from plasticware a milder dissociation protocol was required than that used 
for HEK cells (Trypsinisation - see above).  Media was removed from flasks and washed with 
pre warmed PBS (Gibco), and Mixed Glia Dissociation Solution Activated by warming to 37°C 
for 15 minutes. 3ml of Mixed Glia Dissociation Solution were added per T75 flask and incubated 
 75 
for 3 minutes at 37°C.  Flasks were agitated by tapping the side of the flask five times, flasks 
were checked to ensure cells were fully detached, agitated or incubated further as necessary.  
Dissociation Solution was inactivated by the addition of 6ml of Mixed Glia Media and the 
solution collected in to 15mL Falcon tubes.  Flasks were washed with a further 6mL Mixed Glia 
Media which was added to the Falcon tube, and the solution was centrifuged at 250g for 8 
minutes.  Cells were resupended in nOPC Media with 4µg/mL Insulin and 30ng/mL of FGF and 
PDGF added and incubated for 30-60minutes before being diluted as appropriate. 
 
3.2vii Cell Counting 
 
HEK cells were washed with PBS, trypsinised until separated from the surface of the flask, and 
resuspended in PBS.  100μL of the cell suspension was put into a cuvette, and made up to 10 
mL using cell counting diluent (1 in 100 dilution).  The cuvette was placed inside a Z2 Particle 
counter (Beckmann Coulter), and the number of cells per mL estimated.  Alternatively, and 
always with OPCs diluted cell suspensions were counted using Trypan Blue in a manual 
haemocytometer and cells per ml calculated based upon the average of four counts 
 
3.2viii nOPC isolation – MACS 
Neonatal OPCs were isolated from wild-type Sprague Dawley rat pups at post natal day 0-7.  
Pups were sacrificed according to Schedule 1 methods of humane killing, using a lethal dose of 
pentobarbitol 0.7mL/kg (Animalcare, 01452) intra-peritoneally, followed by decapitation.   
 
Following euthanasia, the whole brain was dissected out and the brain placed immediately in 
HALF on ice.  The meninges and olfactory bulbs were removed and the dissected brains were 
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chopped using a scalpel.  The HALF containing the tissue was placed into a 15mL falcon tube 
and spun for 1 minute at 100g (Eppindorff 5810 R).  The HALF was aspirated, and the pelleted 
brain tissue re-suspended in activated filtered Dissociation Solution, added in equal volume to 
the volume of the pelleted tissue. The brains were then placed on a 55 RPM orbital shaker at 
35  ̊C for 30 minutes (Thermo Fisher; SHKA4000), and incubated for 30 minutes.  
 
The tissue was then centrifuged at 300g for 5 minutes, the supernatant was removed, and the 
homogenate was resuspended in HALF containing 2mM sodium pyruvate, and 2% B27 (Thermo 
Fisher; 17504-001).  
 
Using a 5mL pipette, the dissected brains were gently titurated 10 times. Using fire polished 
pipettes of decreasing diameter, the homogenate was further titurated until appearing as a 
single cell suspension.  The cell suspension was then passed through 70μM filter (Corning; 
352350) to remove any remaining clumps of cells.  
 
To remove myelin debris from the suspension, 1 part 90% Percoll (GE; 17-0891-01), diluted in 
10 x PBS was added to 3 parts cell suspension.  The cell suspension was then spun at 800g for 
20 minutes, the pellet re-suspended in Modified MWB, and a cell count performed.   
 
The cells were pelleted at 300g for 5 minutes and re suspended in in 500μL Modified MWB and 
2.5μL A2B5 antibody (Millipore; MAB312) per 1x107
 
cells.  After a 30 minute incubation on a 
gentle rocker at 4 C̊, 5 times the volume of the cell suspension of Modified MWB was added, 
and the cell suspension was spun at 300g for 5 minutes.  The pelleted cells were then 
resuspended in 80μL Modified MWB and 20μL MACS beads (Miltenyi; 130-047-302).   
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After a 30-minute incubation on a gentle rocker at 4°C, the cell suspension was centrifuged at 
300g for 5 minutes and re-suspended in 1mL MWB.  An MS column (Miltenyi; 130-042-201) 
was placed in a MiniMACS Separator (Miltenyi; 130-042-102), and washed 3 times with 500μL 
MWB, waiting each time for the liquid to pass completely through the column.  The cell 
suspension (max 5x108
 
cells) was placed in the column, 1mL of MWB was added to the column, 
the column was removed from the stand to remove the magnetic field, and the plunger 
depressed.  The positive fraction suspended in OPC media and counted and the volume 
adjusted for plating according to densities shown in Table 7. 
 
 
3.2ix nOPC isolation – Mixed Glia 
Neonate OPCs were isolated from wild-type Sprague-Dawley rat pups at post natal day 0-3.  
Pups were sacrificed according to Schedule 1 methods of humane killing, using a lethal dose of 
pentobarbital 0.7ml/kg (Animalcare, 01452) intra-peritoneally followed by decapitation.   
 
Following euthanasia, the whole brain was dissected out and the brain placed immediately in 
HALF on ice.  The meninges and olfactory bulbs were removed and the dissected brains were 
chopped using a scalpel.  The HALF containing the tissue was placed into a 15mL falcon tube 
and spun for 1 minute at 100g (Eppindorff 5810 R).  The HALF was aspirated, and the pelleted 
brain tissue was re-suspended in 2mL of activated filtered Mixed Glia Dissociation Solution. The 
brains were then placed on a 55 rpm orbital shaker at 35°C for 60 minutes (Thermo Fisher; 
SHKA4000).   
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The tissue is then homogenized through a P1000 filter pipette.  An equal volume of Mixed Glia 
Media is added to stop the papain, the solution is pelleted at 300g for 5 minutes and 
resuspended in fresh pre equilibrated Mixed Glia Media.   
 
The brain homogenate is distributed between T75 flasks 1 - 1.5 brains per flask.  Media is 
changed on alternate days and the mixed culture is maintained for ten days before mechanical 
dissociation and fractionation known as ‘Shake Off’. 
 
On the day of Shake Off, flasks are sealed and secured on the orbital shaker at 37°C for 1 hour.  
Media is aspirated after 1hour and fresh pre equilibrated media added.  The flasks are returned 
to the shaker at 37°C for 16 to 20 hours.  The supernatant is then placed in to an untreated 
10cm petri dish for microglia depletion.  The dish is incubated at 37°C and 5% CO2 for 30 
minutes. The supernatant is removed, a cell count performed, and cells pelleted by 
centrifugation at 300g for 5 minutes.  The pellet is resuspended in nOPC media and diluted as 
appropriate for plating at densities as per Table 7. 
 
3.2x Maintenance and Differentiation of nOPCs 
 
Cells isolated by MACS or by mixed glia shake off (MGSO) were plated as follows for use in in 
vitro studies and in preparation for transplantation studies. 
 
Glass 96 well plates (In Vitro Scientific; P96-1.5H-N), 13mm cover slips (VWR 631-1578) or T75 
flasks (Greiner BIO One 658175) were coated with 200µL of PDL in 40mL dH2O (Sigma; P6407) 
and incubated at 37°C for 1 hour.  Plates were washed twice with dH2O.  Isolated OPCs were 
plated at a densities as per table F.  For proliferation media was changed on alternate days 
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with OPC media supplemented with 30ng/mL bFGF (Peprotech; 100-18b) and 30ng/mL PDGF 
(Peprotech; 100-13a).  To differentiate the cells, media was aspirated off the cells, and replaced 
with OPC media supplemented with 40ng/mL Triiodo-L-Thyronine (Sigma, T2877).  The cells 
were kept in an incubator at 37°C and 5% CO2.  
 
3.2xi Cerebellar Slice Culture 
 
P10 Sprague Dawley neonatal rats were euthanized by intra peritoneal injection of 
pentobarbital (0.7mL/kg).  The brain was dissected out and sagittal section 300µm thick of the 
cerebellum were taken using a microtome.  Sections were incubated in HALF on ice before 
being individually separated and placed onto MilliCell 0.4µM membranes (Merck Millipore 
PICMOR50) in a six well plate in pre equilibrated CSC Media.  Slices were incubated at 37°C 
5%CO2, and media changed every second day for ten days prior to demyelination in 25mg/mL 
Lysolecithin (Sigma L1381).  Lysolethocin was applied directly to the slices and incubated 
overnight before being washed twice in PBS and then being returned to normal CSC Media. 
 
For slices infected with lentivirus work was carried out in a CL2 tissue culture hood. 
1µL/1000µL media of concentrated virus was added to media and incubated for 8 hours before 
being washed three times in PBS and then return to normal CSC Media. 
 
Slices were then fixed at the appropriate time point and frozen in Cryoprotectant Solution at  
-80°C until staining. 
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3.2xii Cell Viability Assay 
nOPCs were obtained by MACs sorting and expanded by proliferation on 15cm PDL coated 
dishes. Following five days of proliferation cells were infected with lentivirus carrying the 
Oatp1a1 gene under the PGK promoter.  Some nOPCs were left uninfected as a negative 
control.  1µL of concentrated virus was added to nOPC Media without antibiotics and cells 
were incubated for 8 hours before media was aspirated and the cells were washed with PBS 
and fresh, pre equilibrated, media added.  48 hours following infection, Primovist was added 
to all cells at a final concentration in media of 5mM.  Cells were incubated for five hours in the 
gadolinium containing media.  Media was aspirated and cells washed 3x with, pre warmed, 
sterile PBS.  
 
Cells were incubated in Trypan Blue (Sigma T8154) and cell counts performed accounting for 
total number of cells, dead cells (Trypan Blue positive), and alive cells.  5 samples were taken 
from each condition and counts were expressed from an average of four counts per sample. 
 
3.2xiii Cell Fixation 
Cover slips and glass 96 well plates with nOPC and oligodendrocyte cultures, or HEK293T 
cultures were fixed in 4% PFA in PBS for 10 minutes at room temperature.  PFA was aspirated 
and samples were washed in PBS three times, 10 minutes per was.  Cover slips and plates were 
stored fully immersed in PBS, sealed with Parafilm and protected from light at 4°C until 
staining. 
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3.2xiv Cerebellar Slice Culture Fixation 
CSCs were removed from the Millicell insert using a paintbrush and were fixed in 4% PFA in 
PBS for 60 minutes minutes at room temperature.  PFA was aspirated and samples were 
washed in PBS with 0.05% three times, 10 minutes per wash.  Slices were stored at -80°C in 
Cryoprotection Solution protected from light. 
 
 
3.3 In Vivo Procedures 
3.3i Animal Husbandry 
Sprague Dawley (SD) rats were bred in the Innes Building and Mira Building Animal Facility;  
University Biological Services at the University of Cambridge.  Adult Sprague Dawley rats were 
also purchased from Harlan Laboratories and housed at the Biological Resource Unit, 
Cambridge Institute, Cancer Research UK.  All animals were fed a standard diet and were kept 
on 12 hour light;dark cycles.  All procedures were performed in accordance with the 
regulations of the Animals in Scientific Procedures Act 2016, and the requirements of the 
Home Office of the United Kingdom. 
 
3.3ii Caudal Cerebellar Peduncle Focal Demyelination 
 
12 week old SD rats were anaesthetised by inhalation of 1.5-3.5% isoflurane in oxygen, once 
anaesthetised animals received preoperative multimodal analgesia with buprenorphine 0.02-
0.05mg/kg by subcutaneous injection, and local anaesthetic in to the external auditory canal 
(EMLA), they also received subcutaneous fluids with 1mL of warmed compound sodium 
lactate, 
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Animals were prepared for surgery by the removal of hair from the dorsal aspect of the skull 
from the level of the dorsal orbit to the neck, including removal of hair from the aboral aspect 
of the pina, and the skin prepared aseptically. 
 
Animals were placed in a sterotaxic frame (Stoetling) such that the skull was secured in the 
horizontal position, and surgical drapes and anaesthetic monitoring applied.  A midline skin 
incision was performed over the caudal 2/3 of the skull and the subcutaneous tissues and 
periosteum removed such that the skull and its sutures could be visualised.  Co ordinates were 
taken with respect to the suture landmarks ‘bregma’ and ‘lamda’ (Figure 16) and craniotomies 
made uni- or bi-laterally through the skull at the location directly dorsal to the CCP.  Using a 
10µL Hamilton micro injection syringe with bevelled tip, 4µL of 0.01% Ethidium Bromide was 
injected slowly over 4 minutes.  The needle was left in situ for a further 4minutes to reduce 
backflow in to the needle.  The craniotomy site(s) were sealed with bone wax (Ethicon W31G), 
and a three layer closure of the soft tissues using soluble suture material in a simple 
interrupted or cruciate suture pattern was performed.  Animals were recovered in a 
temperature controlled recovery chamber.  Post operative analgesia was provided by means 
of oral transmucosal buprenorphine dissolved in Hartman’s jelly and post operative 
assessments were carried out daily for three days following surgery.  Particular attention was  
 paid to the development of neurological signs including head tilt or ataxia. 
 
 
 
 
 
 83 
 
 
 
 
 
 
 
 
Figure 16: Co ordinates used to identify the caudal cerebellar peduncle in the rat. Co ordinates 
for bregma and lamda are identified.  The skull is checked to be flat and straight (a leniency of 
+/- 0.2).  The location of the craniotomy site is calculated rostrocaudally and laterally relative 
to lambda, and dorsoventrally relative the flat of the skull at lambda. 
 
3.3iii Perfusion Fixation 
 
For the harvesting of tissue for analysis animals underwent perfusion fixation.  Animals were 
anaesthetised by inhalation using 5% isoflurane in oxygen, following the onset of deep 
anaesthesia animals were injected with pentobarbital 0.7mL/kg intraperitoneally.  Once all 
reflexes were lost a midline incision was made just caudal to the xyphisternum, the diaphragm 
insides and the rib cage opened by incising bilaterally along the costochondral junction.  The 
heart was exposed and stabilised using forceps and a 22 gauge butterfly catheter inserted in 
to the left ventricle.  Paraformaldehyde 4% in phosphate buffered saline was pumped in to the 
left ventricle at a rate of 22 rpm, immediately following the onset of trans radial perfusion with 
the fixative, the right atrium was opened to facilitate open drainage of blood and fluid. 1mL/g 
body weight of paraformaldehyde fixative was used, and following the onset of rigidity, tissues 
were collected for further procession. 
Bregma minus lambda: <8 8 - 8.2 8.2 - 8.5 8.6 - 9.0 9.0 - 9.4 9.5 - 10.0 10.0 -10.5 
Rostro-caudal (l-CCP) 2.1 2.2 2.2 2.2 2.3 2.4 2.5 
DV (l-CCP) 7.2 (7.1) 7.2 7.2 7.2 7.3 7.4 8.4 
Lat (l±CCP) 2.5 2.5 2.5 2.5 2.6 2.65 2.9 
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3.3iv Cell Transplantation 
12 week old Sprague Dawley rats underwent EB-CCP bilateral lesions 3-5 days prior to intended 
transplantation, an example timeline is given in Table 8. 
 
Mixed glia cultures were set up 15 days prior to intended date of transplantation.  OPCs were 
isolated from the mixed glia culture and plated in proliferation conditions for 24 hours prior to 
being infected with high titre virus (106-108).  Virus was added to fresh pre equilibrated OPC 
Media with 2µg/ml Polybrene (Sigma) and incubated for 8 hours.  Following this, media was 
changed, and fresh media with 30ng/mL growth factors (PDGF and FGF, Peprotech), and Insulin 
4µg/ml (Gibco) added.   Media was changed after a further 24 hours, again with the addition 
of 30ng/ml growth factors, and OPCs were maintained for a total of 48 hours following 
infection, before being dissociated by Papain Dissociation (see previous).   
The cell suspension was resuspended in HALF Media and concentrated by serial centrifugation 
at 450g for 5 minutes.  A variety of cell suspension concentrations were used, but most 
commonly 100,000 cells per 1µL.  Cells were transported on ice prior to transplantation in to 
the site of prior demyelination. 
 
Rats were anaesthetised and prepared as per EB-CCP protocol, cell suspensions were loaded 
in to 10uL Hamilton syringes, and injected in to the site of the prior lesion 3-5 days post lesion 
(dpl).  Animals were recovered.  1µL of cells were retained for immunohisotchemistry. 
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Table 8: Example Timeline of Transplantation surgeries 
 
3.3v Intracranial injection of Virus 
12 week old Sprague Dawley rats underwent EB-CCP bilateral lesions 5-7 days prior to 
intracraninal injection. 
 
High titre virus (106-108), was kept on dry ice prior to injection.  5µL was delivered unilaterally 
in to the site of previous demyelination 5-7 dpl. PBS was delivered contralatrally.  Animals were 
recovered. 
 
Days Cell Culture Surgeries 
1 Mixed Glia Set Up   
2     
3     
4     
5     
6     
7     
8     
9     
10 Shake Off Surgery 1 (for 5dpl transplants) 
11 Recovery   
12 Infection Surgery 1 (for 3dpl transplants) 
13 Recovery   
14 Recovery   
15 
Dissociation  
and  
Transplantation 
Second Surgery 
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3.4 Tissue Staining Immunostaining 
3.4i In Vitro Cell Culture Immunostaining 
Cells were fixed in 4% PFA (Thermo Fisher; 10131580) for 10 minutes at room temperature.  
The cells were then washed twice in PBS (Thermo Fisher; BP3994) and then blocked in PBS with 
0.1% Triton X-100 (Sigma; T8787) and 5% Donkey Serum (Sigma; D9663) for 30 minutes at 
room temperature.  Primary antibodies diluted appropriately (Appendix 8.4) in PBS with 0.01% 
Triton X-100 (0.1% for intracellular markers) and 5% Donkey Serum were then added to each 
well and cells were stained overnight at 4°C.  Cells were then washed twice for 10 minutes in 
PBS with 0.1% Triton X-100. Cells were then incubated or two hours in fluorescent secondary 
antibodies diluted appropriately (Appendix 4) in PBS with 0.1% Triton X-100 and 5% Donkey 
Serum. Cells were again washed twice for 10 minutes in PBS with. Following this cells were 
incubated with Hoechst 33342 (Thermo Fisher; H1399) diluted 1:10000 in PBS for 10 minutes. 
Cells were stored in PBS at 4°C. 
 
3.4ii Organotypic Slice Culture 
 
Slices were lifted from the membrane using a fine paint brush and immersed in 0.05% Triton 
in PBS in a 48 well plate. Slices were transferred from well to well for each step of the staining.  
They were equilibrated to room temperature.  Slices were blocked in PBS with 5% serum, 0.5% 
Triton. 
 
Slices were incubated in primary antibody (Appendix 4) overnight at 4°C, and then washed 
twice in 0.05% Triton in PBS for ten minutes per wash.  Slices were then incubated in secondary 
immunofluorescent antibodies (Appendix 4) in a 0.05% Triton PBS solution for two hours at 
room temperature.  Slices were then washed once in PBS before a 10 minute incubation in 
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Hoechst 33342 (Thermo Fisher; H1399) diluted 1:10000 in PBS.  Cells were than transferred to 
dH2O, and then mounted using Fluromount-G (eBioscience 00495802) on Polysine glass slides 
(VWR 6310107) and 22mm square cover slips (VWR 6310124). 
 
3.4iii Haematoxolin and Eosin, Luxol Fast Blue Staining of Paraffin Embedded Tissue 
Sections. 
 
Tissue was transferred from 4% PFA to 70% Ethanol.  Tissue was processed for sectioning my 
paraffin embedding and subsequent staining by the core facilities at Cancer Research UK, 
Cambridge Institute.  Sections were stained with Luxol Fast Blue overlaid by Haematoxolin and 
Eosin. 
3.5 Ex Vivo and Post Mortem MRI Imaging 
3.5i Cell Pellet Assay 
 
nOPCs were obtained by MACs sorting and expanded by proliferation on 15cm PDL coated 
dishes.  Following five days of proliferation cells were infected with lentivirus carrying the 
Oatp1a1 gene under the PGK promoter.  Some nOPCs were left uninfected as a negative 
control.  As a positive control HEK Cells (A gift from Dr. H Pohl, originally from Sigma 85120602) 
were simultaneously infected with the same lentivirus.  1µL of concentrated virus was added 
to serum free media and cells were incubated for 8 hours before media was aspirated and the 
cells were washed and fresh media replaced.  48 hours following infection, Gadolinium chelate 
(Pimovist, Bayer 3212461) was added to all cells at a final concentration in media of 0.5mM.   
 
Cells were incubated for five hours in the gadolinium containing media.  Media was aspirated 
and cells washed three times with pre warmed sterile PBS. Cells were dissociated from the 
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plates and pelleted and then fixed in suspension using 4% PFA for ten minutes.  Following 
fixation cells were washed counted and resuspended in an appropriate volume of PBS. 
A 4% agarose solution was made using low melt agar (Invitrogen 16520), using a modified 96 
well plate the cell suspension was added to agar to achieve a 2% agar suspension with wells 
containing 5 or 10 million cells.  The plates were rapidly cooled to allow the agar to set without 
the cells settling to the bottom of the wells.  A standard curve of gadolinium concentrations 
was pipetted around the cell pellets, Figure 17. 
The plate was imaged using an inversion recovery sequence at 7T (Oxford Instruments, UK) 
equipped with actively shielded gradients (Magnex) interfaced to a VNMRS (Varian Inc, Palo 
Alto, CA, USA) imaging console.  A quadrature volume coil (Rapid Biomedical, Germany, 
diameter 72 mm) was used in transmit/receive mode.  A 1 mm imaging slice was selected 
through a modified 96 well plate.  Experiments were performed with the help and support of 
Dr Tiago Rodrigues and Dr Alan Wright. 
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Figure 17: Modified 96 well plate layout used for MRI. A Photograph of layout with false 
colouring. B stylised map, concentrations of gadolinium in moles. 
 
 
3.5ii Ex vivo MRI of whole cerebllae 
 
Ex Vivo MR Images were acquired in a 9.4T horizontal magnet fitted with active shield gradients 
and interfaced to a VNMRS (Varian IN. Palo Alto, CA, USA) imaging console.  Following fixation 
in 4% PFA with and without gadoxetate in the perfusion and storage solution, tissue was 
suspended in fomblin (Sigma 317962) and packed in to a 50mL falcon tube (Corning 430828) 
and held in place by packing fomblin soaked cotton wool or gauze around the fixed brain. 
 
T1 and T2 values were calculated from the MR data by Dr Alan Wright using Matlab software 
(Mathworks, Cambridge, UK).  MR images were acquired with the help of Joseph Guy and Dr. 
Alan Wright. 
 
3.5iii Cell Transplant Titration using ex vivo MRI 
Ex vivo MRI was developed as a potential validation technique to assess post mortem brains 
which had received cell transplantations.  In order to assess what the lower resolution of the 
Gd 1e-3 Gd 1e-4 Gd 1e-5 Gd 1e-6 Gd 1e-7 Gd 1e-8 
Fomblin Sample sample Sample sample water 
water sample Sample Sample Sample Fomblin 
Gd 5e-8 Gd 5e-7 Gd 5e-6 Gd 5e-5 Gd 5e-4 Gd 5e-3 
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number of cells detectable by ex vivo MRI was titrations were performed where OPCs 
expressing OATP under the PGK promoter, previously incubated in Primovist, were injected in 
to cerebellae. 
 
Cells were incubated in Primovist for five hours and then dissociated and prepared as per the 
transplantation protocol.  Tissue was obtained from adult rats, and cells injected.  Volumes and 
cell concentrations were varied, see Results.  Brain tissue was either pre or post fixed in 4% 
PFA, and wherever possible, cerebellae were taken from rats sacrificed by Schedule 1 for the 
acquisition of other tissues to ensure that the principles of the 3Rs were observed. 
 
3.5iv Ex Vivo MRI of whole cerebllae transplanted with OATP expressing cells 
Cerebellae were fixed for 24 hours at room temperature in 4% PFA.  Ex Vivo MR images were 
acquired in a 9.4T horizontal magnet fitted with active shield gradients and interfaced to a 
VNMRS (Varian IN. Palo Alto, CA, USA) imaging console.  Following fixation in 4% PFA tissue 
was suspended in Fomblin (Sigma 317962) and packed in to a 50mL falcon tube (Corning 
430828) and held in place by packing Fomblin soaked cotton wool or gauze around the fixed 
brain. 
 
T1 and T2 values were calculated from the MR data by Dr Alan Wright using Matlab software 
(Mathworks, Cambridge, UK).  MR images were acquired with the help of Joseph Guy. 
 
 91 
3.6 In vivo MRI studies 
Control animals, both lesioned and unlesioned, and animals receiving transplantation and 
intracranial virus underwent in vivo imaging. Prior to scanning some rats received intravenous 
contrast agent or intravenous contrast agent and mannitol.  Imaging was performed under 
anaesthesia in 2% - 4% isoflurane in oxygen.  Body temperature was maintained using a 
controllable flow of warm air at 37°C, and was monitored using a rectal probe. Breathing rate 
was monitored using a pressure sensitive pad.  Imaging was carried out in a 7T horizontal 
system (Agilent) and VnmrJ software.  T1- weighted spin-echo images, T1 maps were acquired 
using a single slice inversion recovery Fast Low Angle SHOT (FLASH) pulse sequences.  In vivo 
imaging was performed with Dr Alan Wright. 
 
3.7 Nuclear Magnetic Resonance Assays 
NMR was explored as a potential method for validating gadolinium uptake experiments.  
Samples were transferred with minimal additional liquids and transferred to NMR tubes.  D2O 
was added in fixed volumes in to the NMR tubes using a 12 french urinary catheter.  Samples 
were capped and placed in the appropriate coils.  NMR imaging and analysis was carried out 
by Dr Alan Wright. 
 
3.8 ICP Mass Spectrometry 
Gadolinium containing samples and controls were weight matched and sealed in 2mL Cryovials 
(Corning).  Samples were shipped on dry ice to Dr. Simonetta Geninatti-Crich 
Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy. 
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3.9 Statistical Analysis 
All statistical analysis was performed in GraphPad Prism (GraphPad Software, Inc.).  For data 
derived from the quantification of immunohistochemical staining, comparisons between two 
groups were performed with Wilcoxon's non parametric Rank Test. For all statistical tests, 
differences were considered significant at p<0.05.  Animal work was performed on a pilot 
study basis therefore power calculations were not performed, they will however, inform 
future studies where power calculations will be used.
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4. Results 
 
The results presented in this thesis will be subdivided in to 4 sections: 
 
Results 4.1 Oligodendrocyte Progenitor Cells are able to express OATP without detriment and 
can take up gadolinium contrast agent 
 
Results 4.2: Oligodendrocyte Progenitors Cells are able to express Organic Anion Transporter 
Protein under the MBP Promoter 
 
Results 4.3: The Ethidium Bromide Caudal Cerebellar Peduncle model of demyelination can be 
characterised by Magnetic Resonance Imaging ex vivo and in vivo 
 
 
Results 4.4: Results 4: Rats receiving transplanted OPCs expressing OATP under the MBP 
promoter can take up gadolinium in vivo. 
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4.1 - Results 1: Oligodendrocyte Progenitors Cells are able to express 
Organic Anion Transporter Protein without detriment and can take up 
a gadolinium contrast agent 
 
4.1i Introduction 
OPCs arise from distinct anatomical regions during development migrating throughout the 
CNS to populate it the maturing brain, some of these OPCs differentiate in to the myelinating 
oligodendrocyte, and some remain resident in the mature brain as tissue resident stem like 
cells (Pringle et al. 1992; Crawford, Chambers, and Franklin 2013). 
 
It is recognised that OPCs in the neonatal rodent brain behave differently to those of the 
adult rodents (Wren, Wolswijk, and Noble 1992; Shi, Marinovich, and Barres 1998), and for 
this reason isolation of adult OPCs has been very challenging.  In contrast, neonatal OPCs 
have been isolated by enzymatic digestion of perinatal rodent cerebral cortex, followed by co 
culture and fractionation (The Mixed Glia Culture [MGC], (McCarthy and de Vellis 1980).  
More recently, cell sorting has been used to isolate OPCs more directly from tissue using 
targeted antibodies to positively select a population of OPCs.  These techniques have 
included magnetic cell sorting (MACS) (Cizkova et al. 2009), immunopanning (Barres et al. 
1992; Wren, Wolswijk, and Noble 1992), and Fluorecent Antibody Cell Sorting (FACS) (Sim et 
al. 2011).  Given that spinal cord MRI imaging is very challenging, a cranial demyelinating 
lesion is necessary, and as the rat EB-CCP lesion is a major toxin model in the rat used and 
developed in the Franklin lab, I elected to work with rat OPCs in a rat model of demyelination 
rather than a mouse model.  The corollary of this is that the OPC isolation techniques 
available where somewhat reduced as antibodies raised in rat are inappropriate (as are many 
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antibodies for use in FACS), and processing via FACS or immunopanning introduces elements 
of stress, such as multiple protease incubations or shear stress, which can affect proliferation 
and differentiation potential.  Thus a choice between MACS and MGC needed to be made.   
As the goal of my work was, ultimately, to transplant OPCs in to demyelinated lesions, criteria 
for successful isolations were defined as 1) high repeatable yields of OPCs per gram tissue, 
and 2) high percentage differentiation.  I therefore elected to first establish which of these 
techniques, MACS or MGC gave me the most optimal cell yield, and to establish if OPCs 
derived from either technique where more amenable to infection with a viral vector. 
For MACS isolation a magnetic associated antibody against a cell surface antigen is used.  
Commonly available antibodies relevant to the OPC lineage, include PDGFRa, NG2, and A2B5. 
The PDGFRa antibody is raised in rats, and therefore inappropriate for use against rat tissues, 
and NG2 has been reported to be expressed in other cells of the CNS including microglia and 
endothelial cells (Yokoyama et al. 2006).  Therefore, MACS isolation using A2B5 was selected.  
This is a protocol previously used by others (Wren, Wolswijk, and Noble 1992; Shi, 
Marinovich, and Barres 1998; Barres et al. 1992), and by other members of the laboratory 
(Segel et al. unpublished data, Neumann et al. unpublished data). 
Lentiviruses have previously been shown to successfully infect OPCs endogenously and 
exogenously (Zhao et al. 2003), additionally they allow labelling of progeny cells and 
therefore are more appropriate for transplantation studies than other potential viral vector 
systems such as adenoviruses where the viral genome does not integrate fully in to the host 
cells, and therefore does not result in progeny cells being labelled (Zhao et al. 2003).  A 
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lentiviral vector for the OATP1 protein has previously been constructed under the PGK 
promoter  therefore initially this viral system will be used and validated (Patrick, Hammersley, 
et al. 2014). 
 
4.1ii Experimental Strategy 
 
A lentiviral vector for OATP using a PGK promoter, inherited from P. Stephen Patrick of the 
Brindle group, was sequenced and free virus obtained and used as the basis for viral 
experiments. 
 
OPCs derived by MACs and MGC were isolated and maintained in proliferation and 
differentiation conditions.  Yields and rates of differentiation were assessed in naïve cells and 
in cells infected with a lentiviral vector.  MACs isolation was selected for some experiments 
where purity and proliferative ability were important, whereas MGC isolation was used when 
differentiation capacity was important, or where very large synchronous cell yields were 
required. 
 
4.1iii Results 
4.1iiia OPCs can be isolated and differentiated by both mixed glial dissociation and 
magnetic antibody sorting techniques. 
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OPCs were isolated using both the mixed glia and MACS techniques and were plated at a 
density of 20,000 cells per cover slip.  Cells were cultured in nOPC media, see Methods, in 
either proliferation, or differentiation conditions for up to 7 days before fixation and staining. 
Figure 18: shows an example of cells isolated by MACs which were morphologically 
indistinguishable from those isolated by MG dissociation. 
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Cells were further isolated for calculation of yields from both isolation techniques.  MACS 
isolation yielded by far the greatest number of OPCs per neonatal brain used, with a mean 
yield of 1.47 x 106 cells, whereas MGC yielded far fewer 1.12 x 106 cells (n of 5) (Figure 19).   
However there was considerably greater variation in the yields achieved with MACs, which 
showed a variance (F value) of 35.92 (p=0.0043).  Counts were performed using automated 
haemocytometers. 
injection into CNS regions undergoing remyelination (aim 1), or, to transfect cultured OPCs, which will then 
be transplanted into areas of demyelination (aim 2). In some instances labeled OPCs will also be co-labeled 
in vitro with SPIO. Animals receiving transfected cells or virus will receive systemic gadoxetate, which will be 
taken up by oatp expressing cells and then detected using a 9.4T magnet and T1 imaging (SPIO particles 
will be detected by T2). The lentiviral-vector will also express luciferase to allow detection by BLI[9]. 
Generation of and validation of PGK/MBP-oatp-luciferase lentiviruses.  I have built fluorescently-
tagged expression constructs comprising the oatp coding sequence, a 2A sequence, and mStrawberry. This 
produces equimolar quantities of oatp and mStrawberry from the same promoter so that cells can be 
checked for reporter expression. This arrangement also facilitates histological detection of oatp-expressing 
cells in tissues taken following in vivo imaging studies. For constitutive expression I am using the PGK 
promoter, while the MBP promoter will be used to detect differentiation into a myelinating phenotype.  I have 
now generated some of these vectors, including PGK-mStrawberry-OATP, PGK-Luciferase-OATP, MBP-
mStrawberry-OATP, and MBP-Luciferase-OATP.  I am using a 3.2kb sequence from the upstream region of 
the MBP gene.  In the future I may need to make further constructs containing alternative MBP promoter 
regions to achieve optimal expression. 
OPC isolation. I have grown OPCs from neonatal rat CNS using standard protocols[21] (Figure 3A). I am 
able to maintain these cells and to differentiate them into MBP-expressing cells Figure 3B. I will use this 
technique for vector validation in vitro, and for cell transplantation studies. 
 
 
 
 
 
 
 
                                                             
                   
 
 
 
 
I will transfect OPCs with the PGK vector to investigate reporter expression by: a) luciferase expression 
using BLI; b) immunocytochemistry); c) MRI of cells in gelatin phantoms. Cells transfected with MBP vectors 
will be induced to differentiate in vitro and reporter expression will be assessed using these techniques.  
Transfection of endogenous OPCs. To image remyelination by endogenous OPCs, I will inject the MBP 
vector into areas of demyelination created by the injection of ethidium bromide into the caudal cerebellar 
peduncles (EB-CCP) of adult rats[22]. This model, developed in the Franklin laboratory, creates focal areas 
of demyelination that undergo spontaneous remyelination following extensive OPC recruitment [23,24]. The 
Franklin laboratory has also shown that these cells are efficiently transfected by injected lentiviral-
Figure 3. A Neonatal OPCs taken from rat pnd2 undifferentiated. B Neonatal OPCs pnd2 and allowed to 
differentiate, showing markers of maturity including MBP (arrowed). !
A B MBP CNPase Olig 2 DAPi O4 Olig 2 DAPi 
Figure 18: Oligodendrocyte Progenitor C lls (A), and differentiated oligodendrocytes 
(B) isolated by MACS and cultured in nOPC media, stained with O4, Olig2, CNPase, 
and MBP. MACS and MGC isolated cells are morphologically identical. 
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Figure 19: Mean yields from MGC vs MACS from neonatal rat brains at p3.  Cells were 
isolated from p3 rat pups and cell counts to calculate yield carried out. MAC isolation gave 
higher average yields, but failure of the technique (and therefore 0 yield) was more 
common. n of 6 per technique 
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Following isolation and counting, cells were cultured in differentiation media for 5 days 
before fixation and staining.  Cover slips were stained with antibody combinations against 
OPCs; A2B5 and Olig 2, and Astrocytes; GFAP.  At 5 days in differentiation media the 
percentage of cells still expressing Olig2 lineage markers were calculated; Figure 20. 
 
 
 
Cells isolated via MGC retained greater purity than those isolated by MACS with 82% purity at 
isolation (A2B5 Olig2 double positive) dropping to 80% at day three, with a majority of the 
contaminents being microglia.  In MACS 91.4% of cells isolated were A2B5 double positive on 
day one, droping to 39% at day five, with a majority of the cells which were Olig2 negative 
being GFAP positive, or Olig2 negative and MBP positive, and where presumed to be dead. 
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Figure 20: Purity assay of Oligodendrocyte lineage cells at 5 days post culture.  Cells were 
isolated by Mixed Glia Shake Off, or by Magnetic Antibody Cell Sorting. Cells were fixed and 
stained at 1 and 5 days following isolation. A2B5 is a marker of the progenitor cell state, 
Olig2 marks the full lineage.  Three biological replicates per isolation technique 
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4.1iiib OPCs can be infected by a lentiviral vector, and express the OATP channel 
under the PGK promoter 
 
A third generation lentiviral vector system was obtained from Dr P.S. Patrick formerly of the 
Brindle Laboratory.  The vector was confirmed by multiple restriction enzyme digestions 
Figure 21, a map of which is shown in figure 5.  A table of expected products is shown in 
Appendix 5. 
…………….	
pBOBI MBP mStrawberry E2A OATP 
E2 A 
Figure 21:  Restriction Enzyme digestion confirmation of the lentiviral vector system. 
Restriction digests were carried out to confirm the vector maps were accurate.  The vectors 
were also sent for sequencing. 
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10kb 
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Virus was manufactured using HEK293T cells and serial dilution was performed to ascertain 
the optimal concentration of viral particles for use in oligodendrocytes.  This was performed 
a new for each batch of virus. 
 
Cultures were infected with 10µL of concentrated virus (titres of 104-106), and were cultured 
for up to 5 days before fixation and staining.  OPCs were stained with Olig 2 and anti RFP 
antibody against mStrawberry.  OPCs were found to express mStrawberry from 48 hours in 
culture.  As mStrawberry expression was equimolar linked to the expression of OATP via the 
including of the E2A sequence, RFP staining was taken to be equivalent to OATP expression.  
 
OPCs expressing OATP were then compared to control which had been infected with a sham 
virus; the PBOBi contrast with only the mStrawberry and PGK promoter.  They were 
dissociated from flasks and incubated with Trypan blue, at 5 days post infection, to assess if 
OATP affected cell survival.  There was no significant difference in cell survival between the 
OATP expressing group and the sham group.  
 
OATP expressing and control cells were further cultured in differentiation conditions and the 
number of cells which differentiated in to Olig2 MBP double positive cells were compared.  
There was no difference between the levels of differentiation (Figure 22). 
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Figure 22: (Overleaf) OPCs can express OATP under the PGK promoter.   nOPCs isolated by MACs can 
be infected with lentiviral vectors and express the OATP channel under a PGK promoter (A). 
Expression peaks around 48 hours post infection and remains stable for at least 5 days (B) around 
80% of cells in culture become infected (C), OPCs are able to differentiate and express myelin basic 
protein whist expressing OATP (D) and the levels of differentiation do not significantly differ between 
OATP infected cells and those infected with a sham virus (E).  Viability, as measured by cell exclusion 
of Trypan Blue, does not differ significantly between OATP infected, sham virus infected, or naïve, 
uninfected cells. Three biological replicates with representative microscopy images. 
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4.1iiic OPCs expressing OATP under the PGK promoter can take up gadolinium 
contrast agent 
 
Cultured OPCs were incubated in 15cm dishes with media containing 0.05mmol Primovist, a 
gadolinium containing substrate for the OATP channel, for 5 hours, before being washed 
three times in PBS, and suspended in low melting point agarose in a modified 96 well plate.  
The agarose phantoms where rapidly chilled over ice and surface bubbles removed.  Controls 
containing OPCs with sham virus, also incubated in Primovist, and HEK cells expressing OATP, 
and naïve HEK cells were similarly suspended in the modified 96 well plate.  HEK cells were 
used as a positive and negative control as they have previously been shown by Patrick and 
colleagues, to be successfully infected, and be capable of functional expression (Patrick, 
Hammersley, et al. 2014). 
 
The agarose phantoms were placed in the magnet of a 7 tesla horizontal bore MRI machine 
and T1 weighted images, and T1 maps were obtained.  The rate of T1 shortening was used to 
calculate the concentration of gadolinium contained within each phantom, Figure 23. 
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Figure 23: OPCs expressing OATP under PGK promoter is functional and takes up contrast 
reversibly. Cells suspended in agarose in 96 well plates as described in Methods 3.5i and imaged 
using T1 weighted imaging, a transverse image through the wells (orientated as in panel B) 
shows a heat map representation of the whole well, the scale bar is in R1; the T1 rates (1/T1).  
Fomblin which is ‘invisible’ on MRI due to an absence of protons is a negative control. It can be 
seen that HEK+ and OPC+ (cells expressing OATP) have much high rates of T1 than HEK- (control 
cells infected with sham virus) or water.  There appears to be some spillage of cells from the 
agarose in to the water well likely due to a pipetting error.  (D)shows a quantification of the 
amount of gadolinium in the cells based on the R1 values at time zero from three biological 
replicates, samples analysed with nonparametric Wilcoxan Rank Test. (E) Samples show 
reversible uptake with signal decaying over the five hours following removal of gadolinium from 
the media, each time point is a separate triplicate experiment with removal of Gd media at time 
point 0, and suspension in agarose according to the time point (eg 2 hours after removal), cells 
were maintained in un supplemented media during the intervening period. 
Diagrammatic representation of partial 
view of a 96 well plate viewed from 
above (A), and end on (B).   
A B 
C D 
E 
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4.1iv Discussion 
 
The data in this chapter show that OPCs can be isolated and cultured, and that they can be 
infected with lentiviral vectors without any obvious detriment to their function.  Although 
MACS isolations produced a higher mean yield of cells, these yields were highly variable, and 
the isolation protocol had a far higher absolute failure rate in my hands.  This is likely to be 
largely as a result of handling speed and accuracy as others in the group appear to achieve 
more consistent yields (mean 1.8 x 106-2 x 106 cells B. Neumann unpublished data).  
However, given the higher purity and the more robust differentiation, MGC appear to be the 
better choice for transplantation at a latter stage, therefore this isolation technique will be 
pursued for the remaining experiments. 
 
The use the MGC may have additional benefits in that it retains the heterogeneity of the OPC 
population.  By selecting on the early stage OPC marker, A2B5 in the MACS isolation, a 
potentially homogenous population whose behaviour and physiology may not be entirely 
representative of OPCs in general, may be selected.  The question of heterogeneity is a vast 
and complex one requiring considerable investigation, and is beyond the scope of the work 
presented here.  Therefore no further exploration will be attempted at this stage; however, it 
is a questions that may become increasingly pertinent at future stages of the project. 
 
Methods of assessing survival and differentiation are not fully standardised.  Most commonly 
Ki67 staining, an indicator of cellular division, is used as a marker for proliferating cells, 
equally EdU staining; a thymidine analogue, can be used as it incorporates in to DNA and can 
be detected by light microscopy.  TUNEL staining can also be used as a measure for 
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apoptosis.  Trypan blue exclusion, on the other hand, is a measure of cell membrane 
permeability, with negative staining cells having an intact, non porous membrane, dead or 
dying cells having a permeable membrane which therefore take up the stain.  This is a far 
more general, and less mechanistic measure of cell viability, but, whilst crude, given that 
there was no significant difference between cell populations, it seems unnecessary at this 
stage to confirm the myriad of cell proliferation and apoptotic measures agree.  Again, given 
the somewhat promiscuous nature of the OATP channel this may become increasingly 
relevant as the project progresses. 
 
The agarose phantoms demonstrate that the expression of OATP by OPCs is functional, and 
that OPCs are capable of taking up gadolinium reversibly.  As Primovist is a negatively 
charged compound it is unlikely, though not impossible, to be adhering to the surface of the 
cells even after three washes.  The OPC:sham virus control, showed no greater T1 contrast, 
than the HEK293T cells unexposed to gadolinium, therefore this ‘three wash’ protocol seems 
adequate at removing gadolinium from the surface. 
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4.2 Results 2: Oligodendrocyte Progenitors Cells are able to express 
Organic Anion Transporter Protein under the MBP Promoter 
 
4.2i Introduction 
 
Having demonstrated that a lentiviral OATP vector could be used to achieve OATP expression 
in OPCs, I next wanted to control expression of the channel under a differentiation-stage linked 
promoter.  OPCs express a range of different markers (Figure 24), as they differentiate from 
the progenitor state, into a mature myelinating oligodendrocyte.  
 
Figure 24: OPC, immature oligodendrocyte, and myelinating oligodendrocyte markers. 
Markers change as the OPC differentiates towards the myelinating mature phenotype.  In the 
OPC these markers include; transcription factors such as Olig1,and 2, Sox10, Nkx2.2, 
Mash1,MyT1, and Gli2, and cell surface antigens such as A2B5 and PDGFRa. The Pre 
myelinating and immature Oligodendrocyte is characterised by expression of the transcription 
factors Olig1 and 2, and early myelin proteins O4 and GalC.  The mature Oligodendrocyte 
retains these transcription factors, with the addition of the full myelin protein orchestra.  
Adapted from Miron et al 2011 and Levine et al 2001.  Cells are not to scale. 
 109 
Transcription factor promoters have been widely used in the creation of transgenic mouse 
lines (Richardson et al. 2011); (Dimou et al. 2008); (Kessaris et al. 2005); (Rivers et al. 2008); 
however, given the aim of imaging new myelin formation it seemed prudent to use a myelin 
associated promoter sequence in order to ensure that contrast enhancement was as closely 
related to myelin production as possible.  For this reason, a choice between the major myelin 
associated gene promoter sequences; MBP, PLP, MAG, MOG, GalC, CNPase and O4 needed to 
be made.  As can be seen in Figure 24, O4 and GalC are expressed in the immature and pre 
myelinating oligodendrocyte (Miron, Kuhlmann, and Antel 2011), and therefore do not 
exclusively label the mature myelinating oligodendrocyte.  Of the latter stage myelin genes, 
PLP is also expressed by Schwann Cells, albeit at very low levels (Puckett et al. 1987), as are 
MBP (Gow et al. 1992), MAG (Quarles 2007) and CNPase (Sprinkle 1989).  MOG, alone is 
restricted to the oligodendrocyte; however, as it makes up only 0.05% of the myelin sheath 
(Jaquet et al. 1999), it is unlikely to result in adequate expression of an OATP transporter to 
achieve detection.  The promoter sequence for MAG is 2.2kb, and has been successfully used 
in the oligodendroglial linage in an adenoviral vector (Jonquieres et al. 2016); however, it has 
not been reported in a lentiviral system.  Similarly, a 1kb CNPase promoter sequence has been 
used in a transgenic mouse line (Miyamoto et al. 2018); however, there are currently no 
reports of its use in lentiviruses.   
 
Conversely the MBP promoter has been widely used in both adenoviral and lentiviral vectors.  
Its promoter sequence contains a number of different regions which, when activated by a 
different pattern of transcription factors, direct expression in either the oligodendroglial 
lineage, or Schwann cell lineage, meaning an oligodendrocyte specific promoter sequence can 
be selected (Taveggia et al. 2004); (Gow, Friedrich, and Lazzarini 1992).  The PLP promoter 
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appears to have been widely studied (Yoshida and Macklin 2005; Hamdan et al. 2015), and PLP 
accounts for around 50% of the total protein content of myelin (Baumann and Pham-Dinh 
2001).  The human promoter sequence is commercially available via Addgene (Berndt, Kim, 
and Hudson 2001), it has however, been reported to be expressed outside the oligodendroglial 
lineage (Guo et al. 2009; Michalski et al. 2011).   
 
MBP, which has been widely reported in multiple vectors including lentiviruses (McIver et al. 
2005) (Li et al. 2010; Jonquieres et al. 2013), and whose promoter sequence is commercially 
available (mouse) via AddGene, has been shown to lead to more consistent expression in a 
range of oligodendroglial lineage cells (Miyao et al. 1997).   A sequence was obtained from Dr. 
Chao Zhao, and Dr. P.S. Stephen Patrick for which I am very grateful.  The sequence of the 
promoter used is homologous to that which is commercially available via adgene which was 
first published by Wei and colleagues. The sequence of the MBP promoter from mouse, rat, 
and human has been shown to be highly conserved across sepcies especially in the core 
promoter region (Wei, Miskimins, and Miskimins, 2003). This sequence retains both the Nkx2.2 
and Sox 10 binding elements as well as core regulatory elements that facilitate CNS expression. 
 
4.2ii Experimental Strategy 
 
My aim was to recapitulate the experiments undertaken with the PGK promoter.  Therefore I 
constructed a transfer plasmid containing the MBP promoter fragment inherited from Dr. 
P.S.Patrick.  Free virus was manufactured and used to establish if the expression of OATP could 
be controlled under the MBP promoter.  Assessing contrast uptake in cell pellets of OPCs was 
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challenging due to the numbers of OPCs required per well, therefore a cerebellar slice culture 
(CSC) was used to assess contrast uptake.  CSCs are a well established ex vivo model for 
remyelination and are thought to offer a more complete representation of the in vivo response 
(Zhang et al. 2011).  The uptake of gadoxetate was assessed by three different methods: MRI 
imaging, NMR Spectroscopy, and Inductively Coupled Plasma Mass Spectrometry (ICP-MS).  
Developing a reliable protocol to quantify gadolinium uptake by a non MRI methodology is of 
great importance as it will be necessary to have a secondary technique to asses in vivo samples. 
 
4.2iii Results 
 
4.2iiia OATP can be expressed under the control of the MBP promoter  
 
 
An MBP promoter transfer vector was constructed by replacing the PGK promoter in the 
original vector with the MBP promoter obtained from Dr S.P. Patrick.  A map of the synthesised 
Figure 25: Map of the MBP promoter transfer plasmid constructed containing a 600 base pair 
sequence specific to oligodendrocyte MBP expression. 
10.966kb 
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vector is shown in Figure 25, and the sequence of the MBP promoter sequence used is detailed 
in Appendix 7. 
 
OPCS were isolated by MACs and plated a density of 20,00 cells per well in a 96 well plate, they 
were cultured in OPC media in proliferation conditions for 24 hours, before being infected with 
MBP:OATP lentivirus.  OPCs plated at this density have a tendency to differentiate in to 
astrocytes as well as oligodendrocytes in culture depending on their seeding density.  Cells 
were cultured for up to 10 days in differentiation conditions before being fixed and stained for 
mStrawberry, MBP, Olig2, and GFAP Figure 26.  No GFAP positive cells were mStrawberry 
positive showing that expression is restricted to the oligodendrocyte lineage, and no Olig2 
positive MBP negative cells were mStrawberry positive either showing that expression is 
restricted to the stage of differentiation where MBP is being expressed.  
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Figure 26: OATP expression is restricted under the MBP Promoter 
OATP expression is restricted to cells expressing MBP (A).  By 10 days post culture up to 81% 
of Olig2 expressing cells differentiated in to MBP positive cells and also co expressed RFP(C). 
No GFAP expressing cells co expressed RFP (B), and no pre myelinating Oligodendrocyte 
lineage cells (those expressing Olig2 but not MBP) expressed RFP.  There were rare MBP+ 
Olig2+RFP- cells. A GFAP positive, RFP negative astrocyte (white triangle) can be seen (B), and 
several MBP+Olig2+RFP+ Oligodendrocytes can be seen (white arrow head) (A).  MBP and 
RFP expression increased over 10 days in differentiation conditions (C).  OATP is expressed at 
equimolar levels to RFP. Quantification was performed using Fiji (Image J) on three biological 
replicates per time point. 
 
A 
B 
C 
Olig2 merge RFP DAPI GFAP 
Olig2 merge RFP DAPI MBP 
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OPCs and oligodendrocytes expressing OATP under the PGK promoter had previously been 
cultured in vitro and phantom experiments performed using cells suspended in agarose for 
MRI.  However, this technique required 1 x 107 cells per well, meaning very large numbers of 
neonatal rat pups were required for a single well in these experiments.  In the spirit of the 
three Rs,(Reduce animal use, Refine experiments requiring animals, Replace animals with 
alternatives where possible), and to reduce the likelihood of handling errors, an attempt at 
refining the experimental design was made, and cerebellar slice cultures were used instead. 
 
Slice cultures were prepared from p10 rat pups, cultured for seven days in Cerebellar Slice 
Culture Media before being demyelinated using 0.5mg/ml lysolecethin as described by 
(Birgbauer, Rao, and Webb 2004), and then infected with the MBP:OATP lentivirus.  Slices were 
stained for Neurofilament (NHF), CNPase, and mStrawberry.  CNPase mStrawberry double 
positive cells were counted in the CSC at three and five days post infection Figure 27. 
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Figure 27: OATP was expressed by cells co expressing CNPase a marker of later stage 
oligodendrocyte differentiation. No mStrawberry staining was found in cells staining for GFAP , 
IBa1 or NFH. (A) 40x image of cerebellar slice culture showing MBP staining of axons, however co 
localisation of MBP with mStrawberry is challenging, therefore and alternative stain for late 
oligodendroglial lineage was used; CNP in (B), a representative image at 100x.  Quantification was 
performed in Fiji (ImageJ) on three biological repeats.  
 116 
4.2iiib Oligodendrocytes in CSCs expressing OATP can take up Gadolinium contrast 
agents detectable by Inductively Coupled Plasma Mass Spectrometry. 
 
CSCs were then incubated in 0.5mM Primovist in modified CSC media overnight, they were 
washed in PBS, before fixation in 4% PFA for 1hour.  Slices were then analysed for their Gd 
content by one of three methods: T1 weighted MRI, 10 slices/well (Figure 28), NMR 
spectroscopy 5 slices/vial (figure 29), or ICP-MS 3 slices/sample (Figure 30).   T1 imaging was 
carried out in 0.2ml PCR tubes in a 7 tesla horizontal bore magnet, NMR was carried out, both 
with the help of Dr Alan Wright, and ICP MS was carried out with the help of Dr Andre Neves,  
by Dr. Simonetta Geninatti-Crich, Department of Molecular Biotechnology and Health 
Sciences, University of Torino, Italy. 
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Figure 28:  CSC expressing OATP analysed using MRI.  
CSCs expressing OATP were incubated in Primovist and imaged by MRI A and B, A shows a 
diagrammatic map of the lay out of the wells in a 96well plate, shows a representative cross 
section (viewed from above) of the T1 weighted image from the MRI. C shows that there is no 
gadolinium in negative control CSC-0 and CSC-0+G, or in the MBP expressing slice incubated 
with gadolinium (GSC-mbp +G), the positive controls show so much gadolinium that shortening 
is too rapid to calculate the quantity.  Slices expressing PGK also show a similar, though slighltly 
slower rate of shortening still too rapid to calculate the gadolinium content. This may have 
resulted from incomplete washing, or excessive incubation  There are a number of reasons this 
experiment may have failed. 
Abbreviations: CSC: Slice culture, CSC-0: uninfected, CSC-pgk: infected with PGK:OATP virus, CSC-mbp: 
infected with MBP:OATP virus, +G: with gadolinium, (w): washed, (uw): unwashed 
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A B C 
Figure 29: NMR T1 rates for cerebellar slice cultures. Panel A-C: 5 slices were lifted from the 
Millicert insert membranes using modified probe (A) and were placed in the bottom of a 3mm 
diameter NMR tube (B), before being immersed in deuterated water which was added using 
a 12 Fr urinary catheter, one slice is shown above A-C. D; The  first iteration of this experiment 
was promising and showed a difference in T1 between rates for CSC incubated with Gd and 
without Gd, however repeats of this with positive control (0.5mM Gd) showed no significant 
difference (E). Experiments performed with Dr A. Wright, 1H-NMR spectra were recorded at 
400.13 MHz on a Bruker (Karlsruhe, Germany) Avance III console with a 9.4T vertical wide 
bore magnet from Oxford Instruments (Oxford, UK), equipped with a 10mm Bruker 
broadband probe. Analysis was performed in MatLab. 
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4.2iv Discussion 
 
The data presented here demonstrate that expression of OATP can be restricted by controlling 
expression under the MBP promoter and that CSCs expressing OATP in this fashion can take 
up gadoxetate.  Gadoxetate uptake was challenging to detect using MRI probably due to the 
small size of the CSCs, which are 1mm x 2mm x 300µm.  However, it may also be that samples 
were incompletely washed and therefore contained so much signal that they caused shim 
artefacts.  Shim artefacts occur when the T1 shortening is so fast that it is not detected by the 
sequence.  Therefore, further work on the protocol and the sequences will be required.  ICP 
proved a sensitive method for detecting Gadolinium in CSCs unpaired parametric t tests 
demonstrated that the uptake of Gadolinium was significantly greater than the detectable 
Figure 30: Cerebellar slice cultures expressing no OATP 
channel (CSC0), expressing OATP under the 
PGK(CSC:PGK:OATP) or MBP promoter (CSC:MBP:OATP) 
were incubated with 0.5mM Gd for five hours before 
being washed, fixed, and then analysed by ICP Mass 
Spectrometry.  There was a significant difference in the 
amount of Gd detected between both the CSC:MBP:OATP 
and negative control (p=0.0115), and CSC:PGK:OATP and 
negative control (p= 0.0045). Three biological replicates, 
analysed by Wilcoxon Rank Test. 
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levels of Gd in the OATP null CSCs(CSC0).  The OATP null CSCs which were incubated in 
gadolinium and washed according to the same protocol as the OATP expressing CSCs showed 
low, but detectable levels of Gd (0.00398 – 0.02311 µg/g), suggesting that the three wash 
protocol is sufficient, but the degree of variation suggests that it has the potential to be a 
confounding factor, and therefore future iterations of the protocol may require additional 
washing steps.  NMR spectroscopy also proved a difficult and unreliable method for detection 
of gadolinium.  Multiple protocols using a variety of different volumes of deuterated water, 
numbers of CSC slices, diameters and thicknesses of tube were attempted all with hugely 
variable and inconsistent results, an example of data from two of these experiments is included 
here.  Refinement of this protocol does not appear to hold sufficient promise of utility and 
therefore NMR spectroscopy will not be taken forward as a validation technique, or as an 
experimental outcome measure for assessing gadolinium levels in samples or tissues. 
 
The development of the CSC model for infection of endogenous OPCs with the MBP:OATP 
lentivirus has the potential to be further used as an ex vivo model system.  By refining this 
model, and using it as the foundation to develop a CSC transplant model: where exogenously 
infected OPCs are seeded on to a CSC, a complete ex vivo model system could be developed 
to model the in vivo system I hope to establish.  Alongside sequence development for MRI the 
exogenous/endogenous OPC:OATP system could be more thoroughly characterised, and 
modulators of remyelination trialled in this model prior to use in vivo.  It is hoped that 
developing this system more completely will be part of the future work of this project. 
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4.3 Results 3: The Ethidium Bromide Caudal Cerebellar Peduncle 
model of demyelination can be characterised by Magnetic Resonance 
Imaging ex vivo and in vivo 
 
4.3i Introduction 
 
In order to establish a model in which demyelination can be identified, and remyelination can 
be monitored, both by MRI, surgical protocols, imaging protocols, and image sequences 
needed to be established.  The MRI characteristics of the EB-CCP have not been previously 
reported.  The model has, however, been thoroughly characterised by more conventional 
modalities.   
 
The EB-CCP lesion was chosen because it has been demonstrated to be a highly stereotyped 
lesion with a predictable and reproducible pathophysiology.  As brain imaging at high 
resolutions can be challenging in vivo, the larger rodent species, the rat, seemed more 
appropriate than a mouse model.  Models of demyelination and remyelination can be broadly 
split in to two groups: The first; models which recapitulate pathological mechanisms of injury 
such as Experimental Autoimmune Encephalomyelitis (EAE) which models some aspects of the 
immune component of immune mediated damage to central myelin.  Secondly the toxin 
models which do not model any aspect of disease injury mechanisms, but instead provide a 
platform on which repair processes can be studied (Blakemore and Franklin 2008; Franklin and 
ffrench-Constant 2017).  This latter group offer the opportunity to elucidate true mechanisms 
of repair, but are not intended to recapitulate human diseases, or answer questions about 
their aetiopathogenesis.  As this study does not aim to elucidate mechanisms of pathology the 
former category of model is not necessary, leaving the toxin models. 
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Toxin models are divided in to the focal and the general or systemic toxins.  Cuprizone, the 
only systemic toxin for inducing demyelination, results in loss of myelin in the corpus callosum, 
internal capsule, anterior commissure and the cerebellar peduncles.  However, the results are 
somewhat variable, and only the corpus callosum is generally used for analysis.  This model is 
most commonly used in the mouse, though can be carried out in the rat (Adamo et al. 2006), 
but has been shown to lead axonal damage, and equivocal evidence of de and remyelination 
in corpus callosum, party due to the predominance of smaller diameter axons in this region 
(Stidworthy et al. 2003).  The model requires feeding of dietary cuprizone (Carlton 1967), a 
copper chelator, for around 8 weeks, with demyelination becoming apparent 2-3 weeks after 
induction (Blakemore 1972).  The model gives variable degree of demyelination with a sporadic 
pattern of remyelination across the various lesion sites(Blakemore 1974), and therefore does 
not offer an ideal paradigm in which to develop a new method of evaluating or monitoring new 
myelin formation.  It may however lend itself well to confirming the utility of the model once 
fully developed. 
 
The focal toxins models have the advantage of a localised and predictable lesion whose size 
and location can be controlled by the user.  The most common focal toxins in use are 
Lysolethocein and Ethidium Bromide; however, Anti-Galactocerebroside antibodies, 
endotoxin, and 6-Aminonicotinomide have also been used (Blakemore and Franklin 2008).  
Lysolecithin is a membrane dissolving agent usually injected in to the spinal cord where it will 
make a lesion up to 8mm long, but of <0.5mm in diameter.  It disrupts the myelin membranes 
preferentially sparing the cell membranes of most other cell types and may spare some mature 
oligodendrocytes and some progenitors (Arnett et al. 2004).  Ethidium bromide is an 
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intercalating DNA toxin, and when injected in to a white matter tract, will kill off all glia present 
whilst preserving axons.  The CCP lesion is around 0.6mm2 in cross section, and are 
remyelinated largely by oligodendrocytes  (Woodruff and Franklin 1999).  In the spinal cord 
however they have been shown to remyelinate with a higher proportion of Schwann cells 
(Franklin and Blakemore 1993). 
 
Spinal cord imaging is very challenging in MRI of rodents due to the significant movements of 
the thoracic region and the very small size.  Therefore, a cranial lesion offered the best chance 
of reliable imaging.  The larger rodent species; the rat, offered additional size advantages as 
well.  Both EB and Lysolecithin can be injected in to both the corpus callosum and the cerebellar 
peduncles.  As the CCP contains larger diameter fibres, confirming remyelination by electron 
microscopy is more reliable, therefore, lesioning this region has advantages for the 
development of a new methodology.  Equally, the slightly longer time course for remyelination 
seen in the EB lesion also offers more flexibility when trying to develop new techniques and 
protocols.  Therefore, the rat EB-CCP lesion was felt to be the most appropriate model system 
upon which to base the study. 
 
Ex vivo MRI can offer microscopic level imaging in three dimensions giving resolution in the 
tens of micrometers (Dashevsky et al. 2015).  A major concern in the development of this 
imaging modality is that the small size of the lesion will prove a challenge to image in vivo.  
Therefore developing an alternative outcome measure that can detect Gadolinium and the 
lesion is important.  There are no antibodies for gadolinium, so histological techniques will only 
partially address the question.  Microscopic ex vivo MRI therefore, offers a method of 
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addressing both arms of the question simultaneously.  The addition of gadolinium to perfusion 
protocols has been shown to increase tissue resolution significantly (Johnson, et al. 2002). 
 
Currently the imaging of demyelination and remyelination models using MRI appears to have 
been restricted to the Cuprizone and EAE models (Nathoo, Yong, and Dunn 2014; Song et al. 
2005).  Spinal cord imaging of lysolecithin lesions has been reported (Dunning et al. 2006; 
McCreary et al. 2009),  LPS in the rat brain has been reported by Deloire-Grassin and colleagues 
(Deloire-Grassin et al. 2000), and lysolecitiin in the centrum semiovale has been reported in 
primates (Dousset et al. 1995), however the MRI character of lysolecithin lesion in the 
peduncles, or EB lesion anywhere in the brain has not been reported. 
  
4.3ii Experimental Strategy 
 
In order to develop an in vivo imaging methodology, outcome measures and validation 
techniques for the final process needed to be established.  As no prior reports of the MRI 
character of the EB-CCP lesion existed in the literature it needed to be characterised and 
matched to histology.  Ex vivo imaging techniques were developed to ensure a post mortem 
method for imaging tissue was in place, and these images were mapped against the histology 
to ensure that similar patterns of damage and repair were detectable by MRI.  In vivo images 
of the lesions were then obtained.  This work was done in conjunction with Joseph Guy (ex vivo 
and in vivo), and Dr Alan Wright (in vivo). 
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4.3iii Results 
4.3iiia The EB-CCP shows characteristic demyelination followed by remyelination over 
four weeks which corresponds to conventional histology 
Rats who had previously undergone a unilateral EB-CCP lesion were perfused with either 4% 
PFA or 4% PFA with 1.0mM gadolinium contrast agent, and tissue collected for imaging or 
histology.  Haematoxylin & Eosin staining, overlaid with Luxol Fast Blue (myelin) staining was 
performed with the core facilities at CRUK on tissue fixed with only PFA. 
 
Ex vivo MRI techniques were developed for imaging the whole cerebellum of tissue fixed with 
both gadolinium and without.  First, reliable ex vivo MRI sequences were developed.  Figure 31 
shows an example of an early sequence, and an improved sequence.  It was of particular 
importance to ensure that air pockets were removed when submerging samples in fomblin as 
air artefacts caused significant disruption to the image, the fourth ventricle in particular was 
challenging to clear of air pockets, it was found that overnight submergence in fomblin packed 
with cotton wool soaked in fomblin in a 50mL falcon, before then re packing with additional 
pre packed fomblin worked best.   
 
Following this, based on reports by Johnson and colleagues (Johnson, et al. 2002), gadoxetate 
perfusion was attempted to help improved tissue contrast.  Figure 32 shows an MRI of 21dpl 
lesions perfused with or without gadolinium.  Both cerebellae were suspended in fomblin and 
scanned simultaneously using the same sequence (Figure 32).  Once reliable high resolution 
images could be obtained a time course of the lesion was established to characterise its 
appearance corresponding to the expected histopathology (Figure 33). 
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Figure 31: Example images of ex vivo MRI of cerebellae used in the development of the ex vivo 
imaging methodology. A shows early attempts using both T2 and T2* sequences, with B 
showing the more refined sequences and improved image quality. C shows the sequence 
development and the improvement in resolution.  Imaging was performed in the 9.4T horizonal 
magnet. Studies performed with J.Guy. 
A 
B 
C 
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Figure 32: Comparison of Gadolinium PFA Perfusion and standard perfusion both with post 
perfusion storage in PFA(A), a transverse image through the cerebellum. B; development of the 
sequence by varying TE times (shown along the top), and slice position (along the vertical axis). 
Imaging was performed in the 9.4 T horizontal bore magnet. A single brain was used for the 
development of these sequences 
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Unilateral EB CCP lesion imaged ex vivo by high resolution MRI, with corresponding H&E LFB staining
A B C 
Figure 33: Histological:MRI time course to characterise the lesion. Panels A-C show a time course from 10dpl to 28dpl with the lesion highlighted by the red triangle. 
Panels I-K show the corresponding histology with the region of the lesion expanded to show detail, the lesion is highlighted with the red triangle. The expansion is from 
the region of the boarder of the lesion and normal surrounding tissue.  MRI performed in the 9.4T horizontal magnet using the same sequence as shown in Fig.31B. 
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Having established that the CCP lesion could be easily identified and characterised using MRI 
in vivo images were obtained.  Rats were imaged in a 7T horizontal magnet with active warming 
and temperature and heart rate monitoring.  Images were obtained at 3, 5, or 7 days post 
unilateral CCP lesion, before being sacrificed and histopathology performed to confirm the 
location of the lesion.  Figure 4 show the in vivo imaging of the lesion. 
Figure 34: In vivo image of the CCP lesion. 10 days post lesion imaged with T1 and T2 weighted 
sequences, shown unlabelled, (top panel) and labelled (bottom panel). T1 image was acquired 
using a gradient echo sequence, T2 image was acquired with a Fast Spin Echo Sequence: TR of 
1.8ms, effective echo time of 40ms, 16 averages, 15 slices 1mm thick and matrix of 256 x 256, 
geometry 4cm x 4cm. Lesion highlighted in the second slice (bottom panels) with a red 
triangle. Experiment was repeated three times with similar results in all animals, 
representative images from one animal presented. 
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4.3iv Discussion 
The data shown here highlight the challenge of imaging such a small lesion in vivo.  The image 
is easily and reliably detected by ex vivo imaging, which correlates well the histology, but the 
in vivo lesions are small and only visible in 1-2 slices.  Some of these challenges could be 
overcome by making larger lesions with high concentration of EB, or larger volumes; however, 
this is likely to increase the number of adverse events in an already severe lesion model.   
Current in vivo imaging has all been performed using a surface RF coil, volume coils or phased 
array coils offer improved signal at depth.  Attempts to make a coil with greater CNR and SNR 
were made by Joe Guy, with some success; however, the coil was too fragile for repeated use. 
Commercially available alternatives do not appear readily available for use with Varian imaging 
systems.  It may, therefore, become necessary to revive the development of specialised coils 
if greater resolution is to be achieved. 
Alternatively relocating the lesion to the corpus callosum (CC) may offer improved signal given 
its proximity to the coil.  Although the CC has many draw backs in terms of analysis of 
remyelination, it may be necessary in the development phase to use the site as part of the 
proof of principle strategy in method development. 
Developing these methods has highlighted the technical challenges in tissue processing that 
whole brain imaging can cause, in particular, the degree of fixation required to obtain good 
MRI images is significantly greater than that for good immunohistochemistry or histology 
meaning that brains can not be dual processed.  Additionally, extraction and manipulation of 
the cerebellum in to the fomblin and the removal of air pockets can result in damage the 
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surface architecture of the tissue.  This does not pose significant problems at this stage, 
however it may become more relevant as cell transplantations are attempted. 
Overall these data show that ex vivo MRI is an important tool in the development of this 
imaging modality, and that it can provide high resolution images, comparable to histological 
processing.  Images in the region of 60-70µm isotropic are obtainable by ex vivo MRI which is 
far superior to the current in vivo resolution of 125µm isotropic.  This technique is not intended 
as a final outcome measure; therefore, it may not be necessary to finesse the techniques at 
this stage.  There is, however, significant scope for refinement in the methodologies.  In 
particular, co-registration of histology to the MRI imaging to ensure exact correspondence may 
be necessary for validating transplantation techniques.  This has proven a significant challenge 
in the field, with most groups using computational methods to overcome the 3D:2D, and 
resolution mismatches.   However, the use of 3D printing of bespoke cutting cradles may allow 
co registration far more simply and with absolute accuracy (Guy et al. 2016).  
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4.4 Results 4: Rats receiving transplanted OPCs expressing OATP 
under the MBP promoter can take up gadolinium in vivo. 
4.4i Introduction 
In vitro, and organotypic slice culture work detailed previously showed that OPCs were capable 
of expressing OATP and taking up gadolinium detectable by various techniques.  The aim of 
this thesis was to develop an in vivo imaging modality, capable of detecting contrast uptake by 
OPCS/oligodendrocyte lineage cells as they differentiated in to myelin forming cells, where the 
uptake of gadolinium could be correlated with the expression of the myelin protein MBP. 
In order to do this, an in vivo strategy was devised.  Figure 35 details the timeline for the 
protocol and highlights variables which required establishing. 
Based on the literature the following parameters were determined: 
-Cell number
-Infection day
-Transplant day
-Gadolinium contrast infusion protocol
-Protocol for allowing contrast to cross the blood brain barrier (BBB)
Cell transplantation in to the CNS is well established in rodents, previously studies have 
transplanted cell at concentrations ranging from 10,000/µl, total number 40,000 cells, in to the 
spinal cord (Chari et al. 2006) to 100,000 cells/µl, total number 100,000, in to the spinal cord 
(Brüstle et al. 1999), and 50,000cells/µl, total number 100,000 cells in to the cerebellum 
(Mendonça et al. 2014), to 900,000 total number in to the lateral ventricle (Brüstle et al. 1999). 
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The standard EB-CCP lesion is made with 4 µl of EB in saline, however volumes up to 6µL have 
been used without causing significant secondary damage (Woodruff and Franklin 1999). 
Therefore 500,000 cells in 5µl was chosen as the starting point for cell transplantations. 
Day zero of the experiment was the day of lesioning, prior to this cells and virus will be 
prepared.  Selecting the day on which to transplant cells or deliver intralesional virus may 
dictate the success of the engraftment or the number of cells infected.  Woodruff and Franklin 
showed that OPC density was at its highest at 7 days post lesion in the lysolecithin model 
(Woodruff et al. 2004), and at around 5 days in the EB model (Sim et al. 2002) (Fancy, Zhao, 
and Franklin 2004) with MBP expression peaking at around 30 days,  with cells beginning to 
migrate in to the lesion from 3 days (Sim et al. 2002).  Based on this an initial protocol of 
transplanting cells in to the lesion at 3 days, before the endogenous cells begin to dominate 
the area was chosen.  Intralesional virus will be injected at 7days post lesion when the greatest 
number of endogenous OPCs are present in the lesion in order to maximise the number of cells 
infected. 
The study upon which this work is based, that of Patrick and colleagues, showed that at five 
hours after an injection of gadolinium contrast agent T1 shortening of an OATP expressing 
xenograft was detectable, and was maximal between 5 and 10 hours depending on the cell line 
of the xenograft, and declines thereafter (SP Patrick Thesis, 2013) (Patrick et al. 2014). 
Therefore, a five hour contrast to imaging time lag was selected.  Similarly doses of gadolinium 
were based on this prior study and manufacturers guidelines. 
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The use of an agent to facilitate the crossing of gadolinium in to the xenograft was not relevant 
in these studies performed by Patrick and colleagues (Patrick et al. 2014).  In this work, 
however, the BBB poses a potential block to the passage of contrast agent into the extracellular 
fluid around the lesion.  In the early phase of the lesion the blood brain barrier is likely to be 
impaired, given that EB is an intercalating DNA toxin, it will kill of cells whose cell bodies are in 
the region of injection; in a white matter tract this includes the glia (including astrocytes, whose 
podocytic processes form the parenchymal boarder of the BBB), and the endothelial cells and 
pericytes of the vasculature (which contribute to the vascular wall of the BBB).  However, as 
the lesion remyelinates, the BBB will repair as well.  The contrast enhancement characteristic 
of acute lesions in MS is as a result of a similarly ‘leaky’ BBB, and the resolution of these lesions, 
and their transition into non contrast enhancing, is equally characteristic of their repair.  It is 
likely, therefore, that a methodological paradox may occur: As the BBB becomes increasingly 
impervious to contrast, expression of MBP is likely to increase.  Therefore the lesion will be 
expressing the most OATP at the point at which the least contrast agent is available in the extra 
cellular fluid to be transported in to the cytoplasm.  Consequently, methods for opening the 
BBB may be required.  Most commonly used is the delivery of the synthetic sacchride mannitol 
(Cosolo et al. 1989), (Rapoport 2000), which opens the BBB via an osmotic disruption of the 
tight junctions (Rapoport 2000).  The exact protocol to be used in conjunction with the contrast 
agent will need to be established; however, initially contrast will be delivered immediately 
following mannitol infusion as Cosolo and colleagues showed reversal of the osmotic opening 
within five minutes of infusion (Cosolo et al. 1989). 
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4.4ii Experimental Strategy 
The intention was to begin translating the in vitro work into live animals.  A protocol was drawn 
up in which rats would receive bilateral EB-CCP lesions, receive either intracranial virus to infect 
endogenous OPCs, or receive a cell transplant of exogenously infected OPCs.  Following 
transplant/intracranial virus injection, they were to undergo serial imaging by MRI with the aim 
of detecting gadolinium contrast uptake by the cells.  However, early attempts failed, and 
therefore trouble shooting was required.  A majority of this chapter details the process by 
which trouble shooting and validation was carried out. 
4.4iii Results 
Based upon the work in Chapter 4.3, in vitro imaging was attempted.  Rats underwent bilateral 
EB-CCP lesions, and then received exogenously infected OPCs expressing OATP under the PGK 
promoter or intracranial virus.  Imaging was carried out with contrast agent administered with 
or without mannitol 5 hours prior to imaging.  Figure 35 shows an example of the lesion imaged 
following viral injection and transplantation, despite multiple repeats there is no evidence of 
contrast enhancement.  Therefore, the processes were broken down in to its components and 
attempts to optimise each step were taken. 
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 Figure 35 (continued from overleaf): in vivo imaging of OPC transplants and viral infection of 
endogenous OPC.  In vivo imaging following transplantation of OATP expressing cells, and 
intracranial (intralesional) infusion of PGK:MBP:OATP virus.  Animals were imaged at 3 days 
post lesion (Pre) with no contrast administration, and then 21 days post lesion (Post with 
contrast administration 5 hours prior to imaging). T1 maps were acquired using IR FLASH 
sequences with TR 2.98seconds, TE 1.46 ms, Trelax 12ms, Flip Angle 10 degrees, 32 averages, 
1 slice of 1mm thick and matrix of 256 x 256, geometry: 4cm x 4cm. T2 weighted images were 
acquired using a Fast Spin Echo Sequence with TR of 1.8ms, effective echo time of 40ms, 16 
averages, 15 slices 1mm thick and matrix of 256 x 256, geometry 4cm x 4cm.  Lesions are 
highlighted with red triangles where they can be confidently identified. Representative image 
from one animal, experiment performed in three animals with similar results. 
In order to establish if cells expressing OATP could be detected at all, the ex vivo MRI of tissue 
was returned to.  Cells were injected into, fixed cerebllae before being imaged, and the 
protocol refined from there.  Figure 36 shows a cerebellum in transverse section in to which 
fixed HEK cells expressing OATP under the PGK promoter were injected.  HEK cells were chosen 
for this as they are easier to manipulate and can be grown in large numbers far more rapidly 
than OPCs.  As these experiments were largely trouble shooting and protocol optimisation, it 
seemed prudent to use a rapidly growing cell type which could withstand significant handling, 
rather than the OPC which requires significant numbers of animals to be sacrificed in order to 
isolate, and requires very gentle handling. 
138 
Cells imaged in the syringes (C and D) in Figure 36 clearly show T1 shortening consistent with 
containing gadolinium.  A small region marked by the arrow head may be some of these 
transplanted cells.  Further refinements were made to the injection technique and image 
sequences.  Under these refined protocols Figure 7 was generated using fixed cells and fixed 
tissue as in Figure 36. 
Figure 36: Ex vivo MRI of fixed HEK cells injected in to post mortem tissue.  HEK cells expressing 
OATP (A) and infected with sham virus (B) were incubated in Primovist, before being fixed, 
washed and then injected in to a pre fixed cerebellum.  The cerebellum was then imaged, ex 
vivo, as previously described. The syringes containing remaining cells were simultaneously 
imaged (C-expressing OATP, and D infected with sham virus, and therefore not expressing 
OATP) as a control.  The injection tracts can be seen in both A and B, and contrast enhancing 
cells can be seen (red triangle, below the A injection tract. Distal to the B injection tract a hypo 
intensity can also be seen, this is likely to be the non expressing cells which do not contrast 
enhance. 
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Figure 37: Ex vivo MRI of transplanted cells with improved technique and image sequences. 
Fixed HEK cells expressing OATP(A), and sham infected cells (B) injected in to fixed tissue.  
The ‘lightening bolt’ distribution can be seen on the T1 sequences. The top panel shows the 
cerebellum in transverse section, the bottom panels show the corresponding right and left 
sagittal images with the slice positioned over the injection site (A), and the anatomical 
equivalent on the contralateral side of the cerebellum.  The T2 panels show the cells are 
isontense to the tissue as would be expected.  Red arrouw heads highlight the contrast 
enhancing cells on the T1 sequence images.  T2 images were acquired using the following 
parameters: TE 11.94ms, TR 60ms Flip Angle 15 degrees 70us gauss, 8 acquisitions, 1 
average per acquisition T1 images were acquired using the following parameters: TE 
3.82ms, TR 11.0ms, Flip Angle 90 degrees, 70us gauss 32 acquisitions, 4 averages per 
acquisition. 
As can be seen in the image T1, shortening is detectable in a linear ‘lightning bolt’ pattern.  This 
does not well represent the in vivo transplantation where it would be expected that, following 
initial injection, cells stayed localised to the injection site.  Therefore, fixed HEK cells were 
injected in to un fixed tissue and then post fixed (Figure 38). 
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T1 Sequence: 
TE 3.82ms 
TR 11.0ms 
Flip Angle 90 70us gauss 
32 Acquisitions,  
4 Av per acquisition 
14mins 27sec/acquisition 
7hr 43 mins total 
T2 Sequence 
TE 11.94ms 
TR 60ms 
Flip Angle 15 70us gauss 
8 Acquisitions,  
1 av per acquisition 
44mins 21sec per acquisition 
5hr 55mins total 
R1
 
Figure 38: Ex vivo MRI of un fixed cells in to un fixed tissue. Following injection of cells, the tissue 
was post fixed before being imaged by MRI using T1 and T2 weighted sequences (A), 
representative sagittal images shown.  A heat map with the R1 values (1/T1 in seconds-1) was 
made from a transverse section through the cerebellum.  It can be seen that the ‘hot spot’ 
coloured red on the R1 corresponds to the anatomical location of the contrast enhancing cells in 
the T1 image (slice 2).  The syringes used to inject the cells (with some remnants left in them) 
were imaged simultaneously to act as a control. N of 1. 
A 
B C 
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The method used in Figure 38 re capitulated the in vivo transplantation, and showed T1 
shortening in the region of cell injection showing cells could be detected.  Therefore the 
protocol was repeated using OPCs expressing OATP under the PGK promoter (Figure 39). 
Having demonstrated that cells could be detected in post mortem tissue a titration of cell 
number was performed to establish to lower limit of detection (Figure 40). 
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Figure 39: OPCs expressing OATP under the PGK promoter in post mortem tissue, imaged by 
ex vivo MRI. Sequence as described previously.  A composite image (centre) comprising two 
false colour images which have been overlaid where yellow is T1 signal, and blue for T2 . This 
image shows that the red triangle area on the T1 image to the right (where the lesion is hyper 
intense and therefore bright), when flase coloured appears yellow, this region overlaps with 
an iso intense T2 region (red and white triangle), the overlaying of the T1 hyperintense in 
yellow, and T2 isointense(no colour) highlights the colocalisation of the transplant.  The upper 
images represent transverse images through the cerebellum whereas the bottom panels 
represent sagittal images where the slice in line with the injection tract has been selected. N 
of 1. 
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Figure 40: Titration of cell numbers injected in to post mortem tissue and imaged by ex vivo 
imaging showing false colour composite images.  The minimum number of detectable cells was 
1million in 5uL. Image A shows a dorsoventral view on to the cerebellum highlighting the 
locations of the injection sites through which cells were injected in to the un fixed tissue.  B and 
C show coronal sections in which the transplanted cells can be identified.  As in Figure 39, false 
colour images have been used to show co localisation of T1 and T2 signals.  Cells containing Gd 
are expected to be hyper intense on T1 and iso intense on T2.  Hyper intense signal on T2 would 
be expected from water.  Therefore areas corresponding to transplants  which appear blue on 
the composite are highlighting the transplant medium, but not the cells, and areas 
corresponding to transplants  which appear yellow are highlighting detectable T1 contrast 
enhancement associated with Gd containing cells.  From these data it can be seen that the 
smallest detectable number of cells in 5uL of media is 1 million cells. N of 1. 
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Following the cell titration a single repeat of the in vivo protocol was attempted.  Three rats 
underwent a bilateral EB-CCP surgery, one received OPCs expressing OATP under the MBP 
promoter five days post lesion, on one side, and un infected cells on the other, the second 
received a single transplantation of OPCs expressing OATP under the PGK promoter, incubated 
prior to transplantation in gadoxetate, and sacrificed by perfusion fixation under terminal 
anaesthesia, this was used as a positive control, and the third animal received a single injection 
of transplant media (vehicle) with no cells, this was used as a negative control, and was 
perfusion fixed under terminal anaesthesia following intracranial injection of vehicle.  The first 
rat which had received OPCs expressing OATP under the MBP promoter received an injection 
of mannitol, followed by an infusion of gadolinium, and were then perfusion fixed 5 hours 
following administration of contrast agent.  Tissue was then sent for analysis by ICP-MS, Figure 
41.
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4.4iv Discussion 
Figure 35 shows that in vivo imaging of transplanted, exogenously infected cells, and of 
endogenously infected cells did not work.  This could be for many reasons including cells not 
surviving, insufficient cells becoming infected, imaging at a time point when expression was 
suboptimal, failure of contrast agent to reach cells, insufficient contrast agent, or inappropriate 
imaging sequences being used; any one, or any combination of these may have been at play. 
Figure 41: Gadolinium concentration in post mortem 
tissue analysed by ICP MS following transplantation 
and contrast agent delivery. Three rats underwent 
bilateral CCP lesions. One (the ‘experimental animal’) 
received a transplant of OPC expressing cells under 
the MBP promoter (OPC+) on one side and uninfected 
OPCs in to the contralateral lesion (OPC-).  The second 
animal received a transplant of OPCs expressing OATP 
under the PGK promoter which had been incubated in 
Gd containing media directly prior to transplantation, 
this transplant was performed directly before being 
sacrificed by perfusion fixation (OPC+ + Gd), this was 
a positive control. A third animal received Gd free 
transplant media only as a negative control.  The 
experimental animal received Gd and Mannitol co 
injection three weeks after the transplant and was 
sacrificed 6 hours post injection. Following sacrifice 
tissue sent for analysis by ICP-MS.  These data show 
that OPC+ (cells expressing OATP under the MBP 
promoter) were able to take up detectable levels of Gd 
following intravascular injection with Gd: Mannitol. 
Groups were analysed with Wilcoxon Rank Test. Error 
bars represent technical repeat values provided by the 
ICP-MS facility 
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In order to establish which element of the protocol needed adjustment a table of possible 
problems and ways to detect them was constructed; Table.  The data in the remainder of this 
chapter details attempts to address some of these areas.  The remaining areas will be 
addressed in future work. 
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Potential bottleneck / Failure 
point Reasoning Method for troubleshooting 
Cells not expressing prior to 
transplantation 
Cells unsuccessfully infected transplanted will not express OATP • Check cultures for fluorescence using light microscope prior to
detachment and pelleting > refinement: calculate the number of cells
expressing prior to detachment and pelleting, and how many are lost in
the dissociation and resuspension protocol
• Check cells for expression by retaining a sample from the Hamilton,
fixing and staining this sample for Olig2 and mStrawberry
Cells dying following transplantation Transplantation in to an inhospitable environment (too much 
myelin debris in the lesion etc.) may increase cell death following 
transplantation 
Transplantation technique may cause pressure necrosis if too large 
a volume is used or excessive shear stress if inappropriate 
technique or cell concentrations are used 
• Design a qPCR for the OATP gene and run a genotype style tissue
characterisation on tissue post transplantation or intralesional virus
injection
• Carry out tissue clearing (Tomer et al. 2014) and stain sections for cell
cycle markers eg BrdU/Ki67, and co staining  of a cell tracker
Cells failing to differentiate If cells are transplanted or infected at an in hospitable stage in the 
pathophysiology of the demyelinating lesion this may alter their 
propensity to differentiate 
• Carry out tissue clearing (Tomer et al. 2014) and stain sections for
markers of differentiation and create a time course to establish when
differentiation and MBP expression is maximal > refinement: optimise
imaging sequences and protocol based on this timeline
Cells dispersing or being ‘off target’ Cells may be transplanted off target if stereotactic surgeries are 
not carried out correctly 
Cells may migrate throughout the CNS following transplantation 
reducing their density in the target region 
Virus may distribute throughout the CNS resulting in either 
inadequate focal infection or in widespread low level infection and 
expression 
• Carry out tissue clearing and stain sections for mStrawberry, to identify
dispersal of transplanted cells or the spread of infectivity in 3D.  Other
transplantation studies have not identified this as a cause for failure
[references]
• Use tissue clearing to refine surgical protocols to ensure cells or virus
are being delivered to the optimal location, this may not be in to the
centre of the lesion
• Develop histological and MRI co registration using 3D printed cutting
cradles to validate imaging and ensure MRI corresponds precisely with
histology (Guy et al. 2016)
Viral titre too low to infect 
endogenous cells 
In vitro infections have used polybrene to improve infectivity, 
however polybrene is not suitable for use in vivo.  Very high titres 
may be required to achieve adequate tissue expression (Schilling et 
al. 2016). 
• Refine virus manufacture to improve titres
• Perform in vivo titration of virus to establish necessary titre level,
confirm with conventional IHC
Too few endogenous progenitors 
infected 
Even at high titres, numbers of progenitors infected locally may be 
too low to detect 
• Make an adenovirus for systemic delivery to allow whole brain
progenitor targeting (Chan et al. 2017).  This may offer a positive
control against which the focal infection with lentivirus can be
compared.
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Table 9: Trouble shooting process for in vivo imaging method development 
Infection causes masking 
inflammatory response 
Unpublished observations by the Brindle group has found that 
OATP can cause significant inflammatory respone up to 14 days 
following infection, this may affect cell survival, differentiation or 
proliferation, it may result in overlaying of inflammatory signals on 
MRI imaging obscuring contrast enhancement.  It may also 
potentiate opening of the BBB facilitating contrast uptake further 
in to the lesions repairing state 
• IHC characterisation of the lesion (post transplantation/infection) to
establish if the lesion behaves differently to those previously
characterised in the literature.  OATP is a relatively promiscuous
transporter capable of carrying various hormones including thyroid
hormone, this may result in different behaviours of cells expressing
OATP in vivo, than were seen in defined media in vitro.
Gadolinium not crossing the BBB Gadolinium contrast agents are used in conventional diagnostic 
imaging in their ‘vascular’ or acute post vascular phase – when 
they are in the blood, or having exited the vasculature through 
leaky blood vessels in to the parenchyma.  In this study we are 
taking advantage of OATP to sequester gadolinium in to the 
cytoplasm long after vascular clearance has occurred.  If 
gadoxetate can not cross out of the blood vessels in to the 
parenchyma it will not be available in the ECF to be sequestered by 
OATP. 
• Mannitol can be used to open the blood brain barrier > refinement:
develop a protocol which optimises time of mannitol administration to
gadolinium infusion to achieve maximal uptake.  This may require use
of a Oligodendroglial cell line such as CG4 (Chari et al. 2006) to ensure
large numbers of robust cells being transplanted, this will necessitate
immunosuppression and may therefore fundamentally alter the
character of the lesion model.
Gadolinium delivered too late or too 
early relative to imaging time point 
Work by SP Patrick showed that peak T1 shortening was xenograft 
dependant and that it was between 5 and ten hours.  Current 
protocols have been carried out at 5 hours post contrast, this may 
be too early. 
• Carry out imaging time course once the full protocol is in place >
refinement: tissue from multiple time points can be analysed by  ICP-
MS in order to most accurately define the time points to be used 
OATP not active OATP has been demonstrated to be active in xenografts (Patrick et 
al. 2014), and in cell pellets and endogenously infect cells in vitro, 
however nothing in the literature confirms its expression in 
transplanted cells, though there is no logical reason for it to loose 
function in this paradigm. 
• Develop the Cerebellar Slice Culture model to include a transplantation
on to the organotypic slices
• Repeat the ICP-MS of tissue infected and transplanted having been
exposed to contrast in vivo, as in Figure 41.
Imaging sequence not detecting 
Gadolinium 
Shim artefacts, inadequate resolution, inappropriate slice 
placement may all impede detection of T1 shortening 
• Once a pipeline can be reliably established to get rats to the point of
undergoing serial imaging studies, sequence development and coil
development can take place.
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In order optimise the ex vivo transplant model various methods of tissue processing were 
attempted.  The first was to inject HEK cells, expressing OATP under the PGK promoter, and 
then fixed in 4% PFA, in to fixed cerebellar tissue.  As  Figure 7 shows, this resulted in fissure 
formation and the cells distributing linearly rather than staying in at the injection site, and in 
Figure 36, cells probably leaking back up the injection tract.  In Figure 36, only a small region 
of T1 enhancement is visible.  This may, in part, be due to the inappropriate sequence used 
(the linear artefact probably resulting from the inversion pulse being too close at 4.4ms), and 
as noted above, cells coming out of the injection site and being washed away by the processing. 
Figure 38 and Figure 39 show refinements of this protocol, both in terms of the imaging 
sequences, and in the tissue processing.  In Figure 38, fixed cells were injected in to unfixed 
tissue, left to rest for 10 minutes and then fixed.  The fixation of cells appeared to cause 
significant clumping and blocking of needles, making the concentration of cells by serial 
centrifugation very difficult.  Figure 39 shows unfixed OPCs expressing OATP under the PGK 
promoter injected in to unfixed tissue, left to stand, the injection site sealed with a small 
amount of tissue glue, and then fixed, this appears to be the optimal technique. 
Before returning to in vivo imaging a titration of cell number was performed, as shown in Figure 
40. This along with the other ex vivo imaging confirms that cells expressing OATP, containing
gadolinium, in tissue can be detected by MRI.  However, the lower threshold for this detection 
was 1 million cells.  This number is significantly higher than the number usually transplanted in 
most studies. 
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In vivo imaging was attempted using both transplanted cells, and endogenously infected cells, 
as mentioned above, neither were detectable by MRI. 
A major challenge of refining this protocol was that post mortem imaging required significant 
fixation in PFA, and probably as a result, the use of the anti RFP antibody to detect the 
mStrawberry fluorescence failed, detection without the antibody in cryosectioned samples 
variably showed a few expressing cells; however, samples bleached rapidly.  A reliable method 
for confirming the survival of the cells post transplant has therefore not yet been found.  Prior 
to transplant, cells were examined under light microscopy to check mStrawberry expression.  
However, it remains unclear how many of these cells survived transplantation.  In order to 
refine the transplantation protocol in the future an adjustment to the protocol will be required, 
and an additional experiment will be carried out prior to the next iteration.  Of the former, a 
fluorescent cell tracker will be used; cells will be incubated in it prior to transplantation, and 
samples kept back for appropriate staining at each step of the protocol, including retaining a 
sample from the needle following transplantation to confirm the cells transplanted were, in 
fact, expressing.  With regard to the latter, before any further in vivo imaging is attempted, a 
tissue clearing protocol will be carried out in order to identify, quantify and locate transplanted 
cells.  This experiment will be repeated with brain tissue which received intracranially injected 
virus. 
In order to address the question of whether gadolinium contrast agent was penetrating the 
BBB and thus able to be taken up by the transplanted cells post mortem tissue from an in vivo 
protocol was examined by ICP-MS.  This ‘n of 1’ experiment, which shows that OPCs expressing 
OATP under the MBP promoter can take up gadoxetate in vivo, is far from unequivocal 
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confirmation that the technique works.  It is however a significant step forwards in that 
direction. 
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5. Discussion
As new therapies are being developed for diseases of myelin, in particular the development of 
therapies which look to enhance (re)myelination there becomes a more urgent need for 
outcome measures to assess these therapies.  Currently there are no non-invasive techniques 
for assessing, specifically, the production of new myelin.  Although in vitro, this may not be a 
rate limiting factor, when it comes to translating new molecules or techniques in to in vivo 
models and therapies, it certainly limits the certainty with which we can pronounce a 
technique to be truly effective in enhancing remyelination. 
This project looks to address this issue by developing a technique which harnesses concepts 
previously developed in the field of cancer biology, and applies them to the study of myelin. 
By using a technique; MRI, widely used in clinical imaging, and a contrast agent already in wide 
spread use in the National Health Service, and approved by the FDA, I intend to develop a 
method which can be applied to both the preclinical and the clinical investigation of 
myelinopathy treatments.  The ultimate aim is to develop a tool and protocol in which 
exogenously infected transplanted, and endogenously infected, progenitor cells in a 
demyelinated lesion can be imaged by MRI, longitudinally and non invasively, and that over 
time, a change in T1 weighted imaging can be correlated with contrast uptake and therefore 
with remyelination.  
The non-invasive nature of this technique may also allow us to reduce the number of animals 
used in screening of molecules as serial imaging could replace the sacrifice of multiple animals 
at longitudinal time points.  This also has the advantage of potentially allowing the translation 
to use in clinics; allowing patients to under go serial imaging to assess their response to a 
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treatment, potentially opening up the possibility for personalised medicine if and when a raft 
of pro remyelination techniques become available.   
The methodology may also have applications in assessing the treatment of transplantation 
therapies now being developed for diseases such as MS and PMD.  PMD in particular, can be 
such a debilitating disease, that any intervention which provides clinical improvement may be 
of benefit.  However, given the potential concerns over safety and oncogenicity of stem cell 
transplants, it is vital that we have evidence to support their functional use, and that we 
understand if such transplants are truly forming new myelin, or if it is other, paracellular 
effects, which are causing any clinical improvements seen.  Work by Ruckh and colleagues 
using the heterochronic parabiosis model demonstrated the rejuvenating capacity of young 
cells entering a lesion in an old mouse leading to a degree of ‘rescue’, in these studies migratory 
monocytes were implicated (Ruckh et al. 2012), and this, and a raft of studies like it has fuelled 
renewed interest in the potential of cell therapies for a variety of diseases and age related 
declines (Rebo et al. 2016).  However, direct evidence of the contribution of the cell itself, as 
opposed to its secretome or other paracellular effects is still lacking.  Indeed Wagers and 
colleagues demonstrated further that it was likely to be humoral factors, and not the cell itself 
which contributed to the rescue (Loffredo et al. 2013).  For an understanding of a cells role in 
these putative therapies, cell tracking, lineage, and fate mapping is required, and whilst this is 
well established in mouse models for the study of development, few techniques exist for 
integrating function in disease models.  
There have been many challenges in developing this technique, not least the inherent 
challenges of generating primary cell cultures of oligodendrogilal cells.  Although the 
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components of the model were established across both laboratories, their combination was 
entirely novel, and required adaptation of already complex methodologies.  The data 
generated so far provides a starting point for translation of this method to in vivo models, 
However, refinement of many of the in vitro techniques is still required. 
A lot of effort has been put in to the ex vivo techniques, for which I am very grateful to my 
colleague Joseph Guy for his support and assistance.  In particular, the development of 
sequences which achieve high resolution, and suitable coils for this work has allowed us to 
generate a knowledge base which we hope we can apply to validating the method as it 
develops. 
At the outset of this project it was hoped that a fully established in vivo imaging protocol would 
be in place, as a result stepwise characterisation was traded off against progress towards that 
final goal.  In hindsight, this may have been an inappropriate trade off, with a thorough 
understanding of the biology and behaviour of OATP expressing progenitor cells in vitro, in 
CSCs, and in vivo, remaining patchy and incomplete.  However, broad proof of principle 
progress has been made towards the end goal of an in vivo imaging modality. 
The data presented here demonstrates that progenitor cells can be infected by lentiviral 
vectors leading to the functional expression of the OATP channel and that cells can reversibly 
take up gadoxetate.  The refinement of the agarose phantom experiments provided a reliable 
and repeatable model system in which to assess cells by MRI.  It was found that achieving 
uniform distribution of cells in the agarose, and removing air bubbles, was of significant 
importance in obtaining representative results, the use of a cut down 96 well plate was 
154 
significant in the streamlining of the method as it allowed the uniform arrangement of 
standards and samples which would be rapidly cooled on ice and mixed simultaneously. 
Previous studies have used eppindorfs but handling multiple samples and standards 
simultaneously led to uneven setting of the agarose which made slice selection and sequence 
optimization difficult.  Having established a reliable and repeatable protocol for this technique 
it can be used in the future development and refinement of the method. 
The premise of this model is that OATP expression can be directly correlated to MBP expression 
by differentiated progenitors, and that, to as great an extent as any imaging modality can, this 
can be interpreted as evidence of remyelination.  Pre-requisite therefore, are two key 
elements; that OATP expression can be restricted to progenitors and controlled under the MBP 
promoter, and that these progenitors contribute to the repair of a demyelinated lesion.  The 
latter point has been widely studied by others in the field, and a general consensus exits that 
remyelination is carried out by the differentiation of oligodendrocyte progenitors in to 
myelinating oligodendrocytes.  Direct evidence that progenitors expressing OATP under the 
MBP promoter, contribute to the repair of demyelination in the context of this lesion paradigm, 
is however, still to be established.  On the former point, chapter 4.2 attempts to demonstrate 
that expression can be restricted to MBP expressing cells, confirming in the process, that GFAP 
positive cells, and the axonal region of neurones do not express OATP.  Direct evidence that 
OATP is not expressed by endogenous microgila has not been shown, but there is no reason to 
expect that it would be.   
The restriction of OATP expression by the use of the MBP promoter offers two distinct 
advantages, the first being cell selectivity: no other cell in the CNS expresses MBP aside from 
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the myelinating oligodendrocyte, the second being: phenotypic restriction: only mature 
oligodendrocytes, not the full lineage will express OATP.  The questions to which this 
methodology is intended to apply are therefore restricted to those around MBP expression.  
However, once established, there is no reason why OATP, under tissue or phenotypic 
expression restriction, could not be applied to a wide range of other questions.  For example, 
tracing the distribution of bone marrow derived haematopoetic or mesenchymal stem cell 
transplants now being widely trialled in the treatment of myelinopathies See Appendix 1.   
Currently, the proposed rational for the use of haemtopoetic stem cells is the replacement of 
a patients autoreactive immune system with a new non-autoreactive immune system by 
ablating their bone marrow, and then infusing an autologous transplant isolated from the 
patient, pre ablation, at an early stage of haematopoietic differentiation, prior to T cell 
selection (Atkins et al. 2016).  The rational for mesenchymal stem cell therapies, However, is, 
their potential immunomodulatory effect whereby they supress the proliferation and 
differentiation of the resident B and T cells (Yamout et al. 2010), clinical improvement in these 
patients was not correlated with radiological improvements therefore evidence of the fate and 
function of transplanted cells is very important (Akiyama et al. 2002).  By controlling OATP 
expression under a promoters associated with this immunosuppressive phenotype such as the 
promoters for MHC-II expression (Masternak and Reith 2002), associated with the antigen 
presenting phenotype, atypical to MSCs but seen in these transplantation studies (Chan et al. 
2006), or the production of certain elements of the secretome (Zappia 2005) may offer insights 
in to their function, fate, and utility. 
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When developing this method it was of great importance to have a clear characterisation of 
the EB-CCP lesion, and its appearance and behaviour when imaged by MRI.  Its cellular 
characteristics are well documented, and the mechanistic insights it use has provided, have 
contributed significantly to the field of remyelination biology in the years since its first 
publication.  Chapter 4 aims to document the MRI characteristics of the lesion, and in so doing 
has optimised the ex vivo imaging modality providing levels of tissue resolution comparable to 
those available with conventional histology.  This technique has the potential to be used for 
the validation of the method as it is developed, in particular its use for examining post mortem 
tissue alongside conventional histology and ICP-MS, can be used to detect the presence of 
gadolinium.  This will be key in overcoming some of the challenges discussed in Chapter 4. 
The data presented in the final results chapter, Chapter 4.4, offer little progress towards the 
final methodology.  However, in spite of this, its generation has occupied a significant portion 
of the project time thus far.  Instead, However, it represents the process of trouble shooting 
the initial failure of the in vivo imaging.  As is discussed in the next chapter, this is the area of 
the project which still requires the most work.  Table 2 in Chapter 4.4 currently summarises 
the main potential reasons for this failure, all of which will need to be addressed.  The biggest 
challenge in this trouble shooting process has been the lack of established positive and 
negative controls.  Therefore, these need to be developed for each step of the protocol and 
validated against other techniques if a reliable methodology is to be generated.  For example, 
without definitive evidence that mannitol is opening the blood brain barrier, the time, degree 
and anatomical distribution of this opening, and the free passage of gadolinium out of the 
vasculature and in to the ECF in the region of the lesion, any continued failure of contrast 
enhancement cannot be attributed to any one aspect of the protocol, but could be as a result 
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of failure of gadolinium entry, uptake, OATP expression, or, of contrast detection.  This is one 
aspect of complex protocol which needs to be optimised, but every element will require similar 
optimisation and validation. 
Once fully established this method will hopefully provide evidence for the differentiation of 
progenitors in to myelinating oligodendrocytes non invasively over a time course.  However, in 
order to achieve this, significant improvements in the technique, in the quality of the 
characterisation carried out thus far, and in the validation of the protocol are still required. 
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6. Future Plans
6.1 Review of previous work plan 
The scheme below summarises the planned work flow I established at the start of my PhD: 
It is clear from the work presented in this thesis, that this plan was over ambitious.  In order to 
fully address the questions inherent in this project and fully establish and validate the method 
being developed, considerably more work is required. 
The main reason for the failure to achieve these previously established goals was the lack of 
reliable techniques with which to validate results, foremost among these was detection of 
gadolinium without MRI.  Multiple methodologies were attempted in order to address this, the 
use of NMR and in vitro MRI are detailed in previous chapters.  However, in addition I also 
attempted to make a positive control cell line which could be infected and transplanted 
intracranially and would take up significant amounts of contrast agent in order to refine the in 
vivo imaging protocols.  No data is presented here as no useful data of any sort was generated 
from this attempt.  The strategy attempted was to use C6 glioma cells as I hoped that, as these 
secrete a large amount of VEGF (Plate et al. 1993), that they would grow relatively slowly, and 
cause a leaky blood brain barrier (BBB) (Shivers, Edmonds, and Del Maestro 1984) therefore 
facilitating the passage of contrast agent in to the extracellular space.  The hope being that cell 
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(EB-CCP) of adult rats [23]. This model, developed in the Franklin laboratory, creates
focal areas of demyelination that undergo spontaneous remyelination following
extensive OPC recruitment [24,25]. The Franklin laboratory has also shown that 
these cells are efficiently transfected by injected lentiviral-vectors [26]. Animal will be
imaged at 5, 10 (when differentiation of endogenous cells begins), 14 and 21 days.
Animals will then be examined histologically, including immunohistochemistry for
luciferase, NG2 (OPC marker) and CC1 (oligodendrocyte marker).
Transplantation of labeled OPCs. OPCs transfected in vitro will be transplanted
into EB-CCP lesions. Transplanted cells largely replace endogenous cells as the 
main mediators of remyelination [27]. Imaging and analysis will be as described
above. Some cells will also be labeled with SPIO and detected by T2-weighted MRI
[28].
All the techniques required for this project are established in the supervisors’
laboratories [e.g. 28-30].
c. Timetable and milestones
6 months 12 months 18 months 24 months 30 months 36 months 
Generation of viral 
vectors 
Validation of viral 
vectors 
Imaging 
endogenous OPCs 
Imaging 
transplanted OPCs
Thesis write up
Ta ble 10: Initial PhD work timeline 
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transplant numbers could be titrated down to establish the lowest detectable number of cells 
in vivo.  However no protocol was established by which the C6 cells could be infected with the 
lentivirus.  The challenge remains, and therefore, going forward, attempts at addressing this 
challenge, either with a new protocol, or with an alternative cell line will need to be considered. 
The use of ICP-MS proved to be a sensitive and reliable method by which to detect gadolinium 
in samples and as such can be used to refine the protocols established earlier in the project. 
In particular, ensuring that gadolinium is not adhering to the surface of cells or samples in in 
vitro experiments.  However, it does not offer a solution to the second challenge of establishing 
the cellular limits of resolution. 
Achieving high resolution is a combination of adequate tissue contrast, appropriate coils, and 
suitable imaging sequences.  These have been refined significantly since the commencement 
of the project.  However, without positive controls for the in vivo model it is not possible to 
assess if there are truly optimised yet. 
6.2 Future work plan 
It is clear that the original aims of the project are still far from fruition.  In order to progress 
this project, developments will be made on the foundations of the work detailed here, and 
additionally new innovations will be attempted in order to overcome some of the hurdles 
encountered.   
The main challenges remaining can broadly be split in to four categories: 
A) Refining answers to questions already addressed
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B) Developing validation techniques for the methodology
C) Developing the ex vivo model (cerebellar slice culture) to be a full recapitulation
of the Endogenous:Exogenous paradigm
D) Developing and refining the in vivo model to make it robust and suitable for
translation
Once this has been completed its hoped that the model system can be ultimately validated by 
perturbing remyelination using known enhancers and inhibitors of remyelination, thus 
demonstrating its utility as an outcome measure in the development of new therapies and in 
basic research. 
6.2i Refining answers to questions already addressed (A) 
Chapter 4.1 aimed to address the fundamental characterisation of progenitors expressing 
OATP under a constitutively active promoter; PGK.  This promoter was chosen by the Brindle 
group as they found that a weak promoter was optimal in the cell lines they used.  This principle 
was carried forward in to the work presented here.  The development of the overarching 
methodology may not require full or intimate characterisation, however, in the long term it 
would be beneficial. 
Initially a more complete characterisation would include comprehensive 
immunohistochemical analysis. Ki 67 is a nuclear antigen associated with the cell cycle and 
proliferation, it is present during all phase of the cell cycle apart from quiescence (G0), counts 
can be used to more accurately assess the rates of proliferation in cells (Scholzen and Gerdes 
2000).  Assessing Ki67 counts before and over a time course following infection will provide 
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insights into any lag in proliferation in infected vs control, and any over all effect on progenitor 
proliferation rates.  EdU and BrdU are synthetic DNA bases which incorporate in to S phase of 
the cell cycle.  Both incorporate instead of thymidine and is analysed using a click reaction 
whereas BrdU is usually analysed using an anti-BrdU antibody (Salic and Mitchison 2008), both 
elucidate the number of cells entering S phase and, when examined in conjunction with EdU 
(or BrdU) give a more comprehensive insight in to the mitotic behaviours of cells.   Propidium 
iodide (PI) by contrast is a viability stain which intercalates in to DNA when cell membranes are 
non viable.  PI was not used as a measure of viability in this study as it fluoresces in the red 
spectrum, and would therefore be indistinguishable from cells expressing the 
OATP:mStrawberry construct. Trypan blue exclusion was carrier out instead, however a new 
transfer vector could be constructed linking the mStrawberry:E2A: fluorophore to a different 
gene such as GFP.  PI can be used in flow cytometry and therefore larger and more reliable 
counts could be performed.  Use of TUNEL staining, which detects DNA fragmentation; a 
marker of apoptosis, will be required as part of the histological analysis of post mortem tissue 
following transplantation when assessing the viability of cells transplanted and the effect of 
viral infection. 
Migration assays, using transwells, may be of use in characterising the in vitro effects of OATP 
expression, however, they will be most important in assessing the functional capacity of cells 
following transplantation.  As in vivo imaging has thus far been unsuccessful, a full exploration 
of the functionality of transplanted or endogenously infected cells has not been carried out.  
In order to do this, a two pronged approach will be taken.  The first is to retain samples from 
the transplantation and assess them in vitro through migration, proliferation and 
differentiation assays.  The second is to assess the post transplant/infection tissue by 
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immunohistochemistry, and importantly electron microscopy.  In the first instance this will be 
done by TUNEL staining, mStrawberry, Olig2, and MBP or CNPase expression to assess cell 
survival in cryosectioned samples.  To fully characterise the anatomical extent of the infection, 
and the level of cellular migration tissue clearing and light sheet microscopy with 3D 
reconstruction (Tomer et al. 2014) will be used with staining against the mStrawberry 
fluorophore.  Functionality will also be expressed by looking at the MBP:Neurofilament ratios 
in CSC in infected vs controls as an intermediate step(La Fuente et al. 2015). 
Initially these should be carried out under the PGK promoter, however, other constitutively 
active promoters suck as Akt could also be attempted (Flores et al. 2008).  
Once a more comprehensive characterisation of cells expressing OATP under a constitutively 
active promoter has been carried out, the selective expression under the MBP promoter can 
be revisited. IHC staining in cells cultured in vitro, and in CSC show no premature expression, 
and no expression in GFAP positive astrocytes, although expression in microglia, though 
unlikely have not been ruled out, this can be carried out both in co culture and in CSCs. 
Chapter 4.3 has attempted to characterise EB-CCP lesion by ex vivo and in vivo MRI.  This has 
been largely with the intention of using the ex vivo MRI as an outcome or validation technique 
in the development of the in vivo protocol.  Ideally this would be refined by using co 
registration of histology to MRI, which has been shown to have up to 100% matching, using 3D 
printed cutting cradles made bespoke for each brain (Guy et al. 2016). 
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6.2ii Developing validation techniques (B) 
The mainstay of validation techniques, and positive controls developed so far have relied on 
the use of gadolinium standards measured by MRI, of the ex vivo high resolution MRI imaging 
of post mortem tissue, and the use of ICP-MS as a non magnetic method for measuring and 
detecting Gadolinium.  Validation techniques differ from other methods used in the 
development of the protocol in that they are intended to be used regularly as controls or 
outcome measures for steps within the protocol itself, rather than just as a means by which to 
improve and develop the methodology. 
There are three main points in the proposed protocol which I believe will require the 
development of specific validation methods.  The first is confirming the expression of OATP in 
cells following their transplantation, or following endogenous infection by delivery of virus.  
The second is the assessment of the functionality of cells which have been transplanted or 
infected endogenously, this is discussed briefly in the section above as it also ties in to 
confirming the effect of OATP on the physiology of the cells.  The third is the validation of 
contrast agent reaching the ECF following IV administration during in vivo imaging. 
The first of these is the confirmation of expression of OATP in transplanted or endogenously 
infected cells.  This is of paramount importance in the development of the in vivo protocol, 
particularly prior to successful in vivo MRI detection of contrast uptake by MBP:OATP 
expressing cells, as it will help identify points of failure in the protocol.  Even once established 
it will be a vital checkpoint in confirming the gadolinium detection can be correlated with OATP 
expression and has not accumulated in tissue for any other reasons.  I intend to use two 
approaches to tackle this, the first is to develop a qPCR to detect and quantify the level of OATP 
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expression in the brain following transplant or endogenous infection.  This can be used in 
conjunction with a time course to establish peak OATP expression in vivo, and confirm 
expression in post mortem tissue.  Tissue clearing techniques, as discussed above can also be 
applied during the development of the protocol to confirm expression, and importantly, to 
confirm location of cells.  This is significant, when combined with co registration of MRI imaging 
as incorrect slice selection may yield false negative results.  By developing a clearer 
understanding of where expressing cells migrate to (or not), better slice selection based on 
anatomical markers can be made, and if necessary sequences run where slice intervals overlap 
to ensure maximum information is gathered and positive signal not lost between slices. 
The second of these, confirming functionality of transplanted and endogenously infected cells 
in vivo will require some of the techniques discussed above with regard to assessment of 
proliferation, migration, and cell death.  Additionally it is important that their capacity for 
myelination is assessed, this will be carried out by EM.  Identification of transplanted cells will 
by co labelling them SPIO particles (Franklin et al. 1999), Schwann cells carrying SPIO have been 
shown to form compact myelin following transplantation (Dunning et al. 2006).  Confirmation 
of true function is challenging as conduction speeds would need to be assessed, however the 
EB-CCP lesion, does not show significant clinical impairment and conduction speeds can’t be 
calculated for white matter tracts in the cerebellum.  Full electrophysiological characterisation 
of OATP expressing oligodendrocytes may be beyond the scope of this project. 
Validation or confirmation that gadolinium has reached the ECF following intravenous infusion, 
is somewhat more challenging.  Opening of the blood brain barrier can be informally confirmed 
by increased urination (due to osmotic diuresis) in rats studied, and histologically by the 
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confirmation of the entry of dyes such as Evans blue in to the parenchyma.  Electron 
microscopy changes, including the loss of tight junctions and morphological changes to 
endothelia cells have been described but are variably correlated with Evans blue staining, 
perhaps as this technique is prone to processing artefacts associated with drying which may 
mimic the changes associated with BBB opening (Cosolo et al. 1989; Rapoport 2000).  A 
combination of histology and acute post mortem ICP-MS may be necessary if a clear 
confirmation of gadoxetate delivery is to be achieved. 
6.2iii Developing the cerebellar slice culture model (C) 
Additionally the model only recapitulates the infection of endogenous OPCs, not those 
transplanted in to a region of demyelination.  Attempts to seed nOPCs on to CSCs were made, 
however all the seeded cells died (data not shown).  Bin and colleagues have demonstrated 
that it is possible to seed cells on to organotypic slice cultures in shiverer mice (Bin et al. 2012), 
therefore work needs to be done in order to achieve this.  Alterations to the protocol might 
include: using younger tissue, Bin and colleagues used p0 pups, whereas, based on work by 
Guzman and colleagues and Birgbauer and colleagues p9-p10 were used (La Fuente et al. 2015; 
Birgbauer, Rao, and Webb 2004), equally, thinner sections of 200µm (cf. 300µm) may improve 
survival, and transitioning towards a serum free media may also be required following 7-9 days 
recovery in vitro. 
6.2iv Developing and refining the in vivo model (D) 
This has been discussed briefly in Chapter 4 where it is clearly shown that there remain a 
number of challenges still to be overcome in order for the in vivo imaging technique to work. 
166 
The general approach to developing this system will be to ensure that all component parts are 
fully functioning before then combining them in sequence to bring together the full protocol.  
Even with all the individual components in place, the timescales for the protocol, and between 
each step, are likely to have a big impact on the success, therefore an iterative approach will 
be used.  This iterative approach was attempted during the curse of the work presented here, 
but was, in hindsight, premature, as the component parts had not been fully validated.  A 
summary of steps that require optimisation is detailed in Chapter 4.4, but they will be discussed 
in detail below, some have been discussed previously in this Chapter. 
Cell Failure 
As discussed in Chapter 4.4 and to some extent above, failure of transplanted or endogenously 
infected OPCs by be a potential underlying cause for the failure of the in vivo imaging to detect 
contrast agent uptake.  Cell failure may result from a failure of engraftment and cell death, a 
failure of transplanted cells to express OATP under the constitutively active promoter, or a 
failure to differentiate and therefore to express OATP under the MBP promoter, or from 
significant levels of cell death following endogenous infection. Substantial characterisation of 
OATP expression in cell lines, and the data presented here has found no evidence of increased 
cell death or any effect on proliferation or differentiation.  As discussed above, more thorough 
characterisation will be part of the ongoing development of the model, at each transplantation 
cells will be retained and kept in culture to confirm their viability and expression.  By generating 
a qPCR against OATP a quantitative assessment of the level of expression can be made, this 
will allow the time point of peak expression following endogenous infection to be targeted, 
and will give an indication of the level of cell survival following transplantation.  This 
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information can be used in conjunction with tissue IHC straining for markers of proliferation to 
give a full understanding of the OATP expressing cells behaviour. 
Cell death may be influenced by a number of technical factors including transplantation 
medium, technique needle type, and rate and volume of transplant.  
Cells may appear to fail if they are injected off target of migrate significantly.  It has been shown 
in a number of models that transplanted progenitors and CG4 lines are able to migrate widely 
throughout the CNS (Franklin, Bayley, and Blakemore 1996; Franklin and Blakemore 1997; 
Vignais et al. 1993 ; Van Evercooren et al. 1996), therefore selecting time points at which cells 
are expressing, but also relatively focal around the lesion will maximise the signal available to 
be collected.  Alternatively increased numbers of cells could be transplanted to increase the 
number that remain in the lesion. In conjunction with staining for other cell lines such 
astrocytes and microglia, and for cell cycle and viability markers surgical techniques can be 
refined.  By using tissue clearing techniques such as CLARITY (Tomer et al. 2014), mStrawberry 
positive cells can be traced throughout the brain giving an indication of the specificity of 
transplantation, the degree of migration, and spread of focal infection away from the injection 
site. By combining antemortem MRI, with 3D printed cutting cradles it may even be possible 
co register the images to allow direct comparisons.  This has been carried out using 
conventional staining (Guy et al. 2016), but the principles should be possible to apply to the 
cutting of a hydrogel converted brain.  The MRI of a cleared brain, is however, unlikely to be of 
much use as the loss of fats will alter signals significantly, therefore comparisons will always 
have to be ante mortem MRI:post-mortem IHC. Ideally a system which allows antemortem 
MRI, post mortem MRI, and post mortem IHC could be developed, however this may be 
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beyond the scope of this project.  With respect to optimising the I vivo imaging protocol 
CLARTITY will also allow accurate determination of maximal MBP expression which will be vital 
for the determination of time points for imaging. 
Gadolinium and the BBB 
As has been discussed at length above achieving passage of gadolinium across the BBB such 
that it is available in the ECF as a substrate for the OATP channel requires a number of factors 
to work in synchrony: The BBB must be permeable; there must be enough contrast agent 
delivered at the correct time relative to imaging that it can be taken up in to the cytosol, this 
has to be long enough after injection that enough has been take up, but not so long that the 
reversible nature of the channel has not removed a majority of the contrast; and finally the 
sequence needs appropriate parameters to detect the shortening: too much gadolinium may 
result in such short T1 readings, a standard sampling time point may not detect it causing a 
shim artefact.  In order to optimise these systems a combination of Evans –Blue staining to 
characterise the BBB permeability, ICP-MS to quantify the amount of gadoxetate present, and 
time course analysis to calculate the peak signal post contrast injection, will be required. 
In addition, the generation of a positive control may be necessary.  As previously discussed an 
attempt at a C6 control cell line was made, but was abandoned early as it showed little promise, 
however, using a tumour model during development, in order to establish sequences, and 
timings may be very beneficial.  CG4 cells are an oligodenroglial immortalised cell line which 
can be transplanted in to lesions in the rodent CNS (Louis et al. 1992; Franklin, Bayley, and 
Blakemore 1996; Franklin and Blakemore 1997; Chari et al. 2006).  CG4 have the potential to 
form astrocytes, as well as oligodendrocytes in vivo (Franklin, Bayley, and Blakemore 1996), 
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however their expression of MBP can be enhanced by the administration of erythropoietin  in 
vitro (Cervellini et al. 2013; Gyetvai et al. 2017), which may be particularly useful is OATP 
expression needs to be upregulated. 
Time points 
Key to the development of the in vivo imaging protocol will be establishment of correct time 
points.  Work by S. Patrick and colleagues showed that peak signal could be collected from 
xenografts between 5 and 10 hours post contrast injection.  In the work shown here 5 hours 
was chosen, however as discussed above a time curve will be required to ensure maximal signal 
can be collected.  A time line based on the current understanding of the behaviour of OATP 
expressing cells and the EB-CCP lesion is laid out in Figure 42. 
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6.3 Maximising the potential for translation of the technique 
In the short term, the development of this technique is one of proof-of-principle.  The aim of 
detecting differentiating progenitor cells using a T1 weighted MRI technique has not been 
reported elsewhere and has the potential to be applied to many basic science questions, and 
in drug development.  However, in the long term it may also be refined for use in man as an 
outcome measure for personalised medicine; it may allow differentiation of the resolution of 
an active lesion, from that of a truly repairing lesion in a far more rapid fashion than current 
methodologies permit.  This may allow patients to be switched from a treatment that is not 
working for them, or see evidence of efficacy far more rapidly.  At this stage, this is a distant 
goal, however, by making small adjustments to the current techniques employed, the method 
can be made increasingly translatable.  The first of these is to alter virus delivery to use an 
adenoviral vector rather than a lentiviral vector, and the second is to look at the safety of the 
contrast agent. 
6.3i Developing an AAV for systemic viral delivery 
The direct injection of lentiviral vectors into lesions is valuable for establishing proof-of-
principle, however it clearly has limitations in terms of its translational value where there 
would 1) be a degree of morbidity associated with delivery, and 2) would mean that only a very 
limited number of the many lesions with the MS brain lesions could be assessed.  It is therefore 
necessary to explore ways in which OATP could be more widely distributed through the brain. 
Additionally intracranial injection, carries with it inherent risks such as bleeding, infection, and 
the risks associated with any anaesthesia, all of which are better avoided, particularly infection 
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which can lead to pyrexia which can cause Uhrthoff’s phenomena which is associated with a 
worsening of neurological symptoms (Frohman et al. 2013).  A minimally invasive alternative 
to the intralesional injection of virus would be the recently developed neurotropic adeno 
associated viral vector which can be delivered systemically.  As AAVs are single stranded DNA 
viruses that are non-integrating and non-replicating, they are an attractive vector for gene 
therapy (Bennett et al. 2016). There are multiple strains of AAV, each that have viral capsid 
proteins that can efficiently target specific cell-types with the recently developed AAV-PHPeB 
is able to readily infect the CNS (Chan et al. 2017). 
Systemic AAV administration would allow for large-scale gene transfer across the CNS. 
However, most systemically administered AAVs inefficiently cross the blood brain barrier and 
very high titres of AAVs are required. To overcome these limitations of AAV vectors, AAV 
particles have been generated with randomly modified capsid protein sequences that cross 
the blood brain barrier and target the cells of the CNS with high specificity (Chan et al. 2017). 
As the AAV is highly specific for the CNS, it is possible to efficiently target the CNS with viral 
titers one thousand times lower than previously reported.  In particular an AAV that express 
GFP under the MBP promoter, has been shown to be able to label up to 70% of 
oligodendrocytes across the CNS (Chan et al. 2017).   
Using this new vector I would be able to develop both a focal and systemic model in tandem, 
preliminary work by colleagues in the Franklin group has shown show that ≥70% of CNS 
progenitors in the rodent brain are infected with this AAV  21 days-post intravenous infusion. 
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6.3ii Improving safety of Gadolinium chelators 
Primovist is Gadolinium containing MRI contrast agent manafactored by Bayer for use in 
imaging of hepatic carcinomas.  Hepatic carcinomas show upregulation of OATP channels, but 
can appear relatively homogenous on standard imaging, contrast studies however, are more 
elucidatory as Primovist accumulates in the neoplasia making its assessment and response to 
treatment far easier to monitor.  However Gadolinium is an inherently toxic element, and its 
use in pharmaceutical agents is only made possible by its chelation.  Chelators can be unstable, 
and the central ion can drop out of the chemical encasement becoming free in the body. 
Accumulation of gadolinium has been seen in post mortem samples in the basal ganglia, and 
elsewhere in the brain (Kanda et al. 2015).  There are, therefore clear safety concerns around 
its use.  Although no adverse effects have been reported due to its accumulation in the CNS, 
and there is no evidence of acute neurotoxicity reported (Olchowy et al. 2017), however its 
use is known to be associated with nephrogenic systemic fibrosis (Rogosnitzky and Branch 
2016).  The propensity of Gd3+ to drop out of a chelator varied with the chelator chosen. 
Linear ionic chelators, such as are used in Primovist, are thought to be most prone to this, 
whereas the macrocyclic chelators, such as those found in ProHance (Bracco Diagnostics) have 
lower dissociation constants, and are therefore less likely to undergo transmetalation.  If, 
however, evidence does arise to suggest that accumulation is detrimental efforts may need to 
be made to alter the chemistry of the OATP channel such that macrocyclic chelators can be 
transported by it. 
The methodology being developed here, and the techniques used in its development, are 
applicable questions over the safety of long term accumulation of Gd3+ in glial cells, and may 
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therefore go some way to elucidating the safety profile of gadolinium as a long term imaging 
agent. 
6.4 Use of the final imaging protocol 
Once developed and fully functional, it’s is hoped that the methodology whose early 
development is detailed here will be capable of non invasively identifying the expression of 
MBP, that this will be correlated to remyelination, and that serial imaging will possible to 
monitor the repair process longitudinally.  In order to fully validate the technique as a tool for 
use in remyelination biology it will be used as outcome measure in the assessment of known 
modulators of remyelination whose effects are well characterized by histology.  Up regulators 
of remyelination including  Retinoid X-Receptor Gamma agonists such as 9-cis-retinoic acid and 
or Bexarotene (Huang et al. 2011; Huang et al. 2010), and antimuscarinics like Clemastine  
(Deshmukh et al. 2013; Mei et al. 2014), and down regulators of the remyelination response, 
such as using aged rodents in the model (Sim et al. 2002).  I would expect that the histologically 
demonstrated enhancement or retardation of remyelination should be mirrored by a post 
contrast onset of T1 shortening in the region of the lesion location.  By testing the method in 
treated vs control in the against the EB-CCP lesion we hope to demonstrate its utility in drug 
development and as a non invasive measure of remyelination. 
6.5 Future work flow 
This chapter hopes to lay out a plan of the experimental work and development that will be 
required in order to progress towards the final goal of generating an in vivo tool for imaging 
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remyelination.  Below is a proposed work flow which lays out the remaining work over a three 
year period.  It is hoped that by then end of this period the tool will be functional and validated. 
Based upon the challenges identified  in this chapter a hierarchy of priorities can be 
identified; the most pressing issue is to unequivocally confirm that gadolinium contrast agent 
is able to cross the blood brain barrier at an appropriate time point and in sufficient 
quantities , or that the blood brain barrier can be manipulated (for example with mannitol) 
such that it can be opened at an appropriate time point.  Once this has been established , 
ways of increasing the amount of signal captured can be worked on.  These might include 
increasing  the number of cells transplanted, increasing the amount of gadolinium 
administered, using a more dorsal lesion closer to surface coils to reduce signal loss, using a 
model with greater area for remyelination like the shiverer mouse, or changing technical 
aspects such as MRI coils or sequences.  Table 11 below  summarises potential remaining 
challenges and their solutions, and Table 12 lays these out in terms of their relative priority.
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6months 12months 18months 24months 30months 36months 
A: refinements of current work 
B: validation of OATP expression 
in vivo 
B: validation of transplanted 
cells / endogenously infected 
cells viability 
B: Validation of BBB opening, 
and Gd crossing in to the ECF 
C: Generating the cell transplant 
model in cerebellar slice cultures 
D: Refinement of In vivo imaging 
Generation of AAV 
Perturbation of CSC model and 
in vivo model using modifiers of 
remyelination 
Table 11: Proposed work flow diagram detailing the work remaining on the project in order to bring it to fruition. 
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A 
Refining answers to questions already 
 addressed 
B 
Developing validation techniques for steps in 
the protocol 
C 
Developing the organotypic slice culture 
model 
D 
Refining the in vivo imaging method and 
protocol 
Question Answer Question Answer Question Answer Question Answer 
1. Does OATP
expression affect
OPC/Oligodendrocyte
proliferation,
differentiation,
migration, or survival
Ki67 
EdU 
TuNEL 
Migration Assays 
Propidium Iodide 
1. Validation of
OATP expression
in vivo
qPCR for OATP 
gene- ‘genotype’ 
tissue following 
transplant/infection 
in vivo transplants 
and infection 
followed by tissue 
clearing + time 
course 
viral titration for in 
vivo infection 
followed by tissue 
clearing and 
conventional 
sectioning for 
markers of 
inflammation 
1. Can
oligodendrocyte
progenitors be
transplanted in
the CSC, engraft,
and remyelinate
Develop 
organotypic 
technique for 
transplant.  
IHC time course 
gadolinium 
incubation 
MRI of slices 
ICP-MS of slices 
1. Can cells
expressing OATP
be see by in vivo
imaging
Correct number 
of cells imaged at 
the right time 
point, with the 
right contrast 
agent protocol, 
with the optimal 
imaging protocol 
2. Does the MBP
promoter restrict
expression
Co cultures to 
rule out 
aberrant/off 
target expression 
Extended time 
course and 
quantification of 
OATP:MBP 
2. Validation of
transplanted cell
viability
Retain samples for 
immediate fixation 
and staining 
following 
transplantation 
Retain samples for 
culture – 
demonstrate they 
remain viable in 
2. Can the model
be perturbated
with modulators
of remyelination
in order to
demonstrate real
utility as a non
invasive outcome
measure
Once established 
and functional, 
manipulate the 
lesion using 
molecules like 
bexatrotene or 
clemastine. 
178 
expression and in 
vitro and CSC 
culture by staining 
a time course 
3. Can OATP:virus
infect OPCs
Improve virus 
manufacture and 
concentration to 
achieve high viral 
titres to refine all 
in vitro and in 
vivo protocols 
3. Validation of in
vivo contrast
administration
Develop a 
technique which 
can be carried out 
during each 
experiment to 
confirm that Gd has 
crossed the BBB – 
for example always 
have a sentinel 
animal with an 
intracranial 
xenograft. 
Always sacrifice one 
animal at the 
imaging time point 
and send for ICPMS 
for gadolinium 
detection 
4. Can the EB-CCP
lesion be
characterised by MRI
Develop co 
registration of 
histology and MRI 
using 3d printed 
cutting cradles 
Table 12: Summary table of major outstanding questions and their potential solutions 
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B3 
B1 B2 
C1 D1 D2 
A1 A2 A3 A4 
Validation of in 
vivo contrast 
administration  
Validation of 
OATP expression 
in vivo  
Validation of 
transplanted cell 
viability  
Can cells 
expressing OATP 
be see by in vivo 
imaging  
Can the model be 
perturbated with 
modulators of 
remyelination 
Can OPCs be 
transplanted in the 
CSC and be 
functional  
 REFINING: Can the 
EB-CCP lesion be 
characterised by 
MRI  
REFINING: Can 
OATP:virus 
infect OPCs  
REFINING: Does 
the MBP 
promoter restrict 
expression 
REFINING: Does OATP 
expression affect 
OPC/Oligodendrocyte 
biology 
Table 13: Hierarchy of Challenges to be Addressed.  Based upon the work in this thesis and on the assessment of chapter 6 in particular, it is apparent 
that establishing if gadolinium can cross the BBB is the most important next step in developing this work.  This is followed by developing the 
appropriate validation techniques.  Following this it is likely that full in vivo imaging experiments can be attempted, with tier 3 and 4 questions being 
addressed simultaneously to in vivo imaging. 
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7. Conclusions
This thesis forms the basis for the development of a completely new technique for the 
assessment and study of progenitor cells in vivo. However, the methodology has the potential 
to be applied to any system in biology. By using cell line specific promotor sequences Oatp 
expression can be restricted even where viral infection cannot be, and allows expression to be 
linked to functional states. Although modelled here in regenerative neurobiology, any cellular 
state which is sustained enough to be longitudinally imaged could be traced.  
There is significant work still to do in order to fully develop and most importantly, to validate 
this technique, however if progress continues to be made in this vein, it is hoped that this could 
represent direct, in vivo, evidence for differentiation of progenitors; specifically the formation 
of new myelin, and be a valuable tool for the drug development and clinical trials community 
alike.  
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1 Active Clinical Trials 
Title Status Intervention Location Clinical Trials Identifier 
Nanocrystalline Gold to Treat Remyelination 
Failure in Chronic Optic Neuropathy In Multiple 
Sclerosis  
Not yet recruiting Drug: CNM-Au8 (A gold 
nanocrystal suspension) 
University of Sydney NCT03536559 
Impact of Vitamin D Supplementation in Patients 
With Multiple Sclerosis  
Recruiting Drug: Vitamin D •University Medical
Centre Maribor, Maribor,
Slovenia
NCT03385356 
Allogenic Mesenchymal Stem Cells And Physical 
Therapy for MS Treatment  
Recruiting Biological: Umbilical cord 
derived Mesenchymal 
Stem Cells - intrathecally 
•Cell Therapy Center,
University of Jordan,
Amman, Jordan •Cell
Therapy Center, Amman,
Jordan
NCT03326505 
Safety Study of Human Neural Stem Cells 
Injections for Secondary Progressive Multiple 
Sclerosis Patients  
Active, not recruiting Biological: hNSC - 
intraventricular 
IRCCS, Italy 
Azienda OSMdT, Italy 
Neurocentro della 
Svizzera Italiana, 
Switzerland 
NCT03282760 
Neural Stem Cell Transplantation in Multiple 
Sclerosis Patients  
Enrolling by Invitation Biological: fetal derived 
hNSC -  intrathecally 
IRCCS Ospedale San 
Raffaele, Milan. Italy 
NCT03269071 
Effect of MD1003 in Progressive Multiple 
Sclerosis (SPI2)  
Active not recruiting Drug: MD1003 (high 
dose biotin) 
MedDay 
Pharmaceuticals, 
San Francisco 
Nct02936037 
218 
Thyroid Hormone for Remyelination in Multiple 
Sclerosis (MS): A Safety and Dose Finding Study  
Recruiting Liothyronine Sodium Oregon Health and 
Science University. 
Oregon. USA 
NCT 02760056 
Pilot Trial of Domperidone in Relapsing-
Remitting Multiple Sclerosis (RRMS)  
Enrolling by invitation Drug: Domperidone, D2 
anatagonist 
University of Calgary 
Canada 
NCT02493049 
Domperidone in Secondary Progressive Multiple 
Sclerosis (SPMS)  
recruiting Drug: Domperidone, D2 
anatagonist 
University of Calgary 
Canada 
NCT02308137 
Effect of MD1003 in Spinal Progressive Multiple 
Sclerosis  
Active not recruiting Drug: MD1003 100mg 
capsule 
Hopital Maison Blanche, 
Reims, France 
NCT02220933 
Effect of MD1003 in Chronic Visual Loss Related 
to Optic Neuritis in Multiple Sclerosis  
Active not recruiting Drug: MD1003 100mg 
capsule 
Hopital Maison Blanche NCT02220244 
Safety and Tolerability of Quetiapine in Multiple 
Sclerosis  
Recruiting Drug: Extended-release 
quetiapine fumarate 
University of Calgary NCT02087631 
Idebenone for Primary Progressive Multiple 
Sclerosis  
Enrolling by invitation Drug: Idebenone National Institutes of 
Health Clinical Center, 
NCT01854359 
Role of Vitamin D in Reducing the Relapse Rate 
in Patients With Multiple Sclerosis  
Unknown Supplemented VitD3 King Saud University. NCT01753375 
Mesenchymal Stem Cells for Multiple Sclerosis Unknown Bone marrow 
mesenchymal stem cells 
autologous 
Karolinska Insitute NCT01730547 
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Vitamin D Supplementation in Multiple Sclerosis Recruiting Drug: Vitamin D3 Johns Hopkins University NCT01490502 
Cytotron® Delivered Rotational Field Quantum 
Nuclear Magnetic Resonance Therapy for 
Multiple Sclerosis  
Unknown Cytotron The Centre for Advanced 
Research & 
Development, India. 
NCT01220830 
Double Blind Placebo-Controlled Phase I/II 
Clinical Trial of Idebenone in Patients With 
Primary Progressive Multiple Sclerosis (IPPoMS) 
Active not Recruiting Drug: Idebenone small 
molecule analogue of 
CoEnzyme Q10 - 
antioxidant 
National Institutes of 
Health Clinical Center 
NCT00950248 
Mesenchymal Stem Cells for the Treatment of 
MS  
unknown Biological: Autologous 
Bone Marrow 
Transplantation -
intrathecal 
Hadassah University 
Hospital, Ein Kerem, 
Jerusalem, Israel 
NCT00781872 
Stem Cell Therapy for Patients With Multiple 
Sclerosis Failing Alternate Approved Therapy- A 
Randomized Study  
Active, not recruiting Biological: Autologous 
Bone Marrow 
Transplantation 
Northwestern University, 
Feinberg School of 
Medicine 
Neurologic Stem Cell Treatment Study Recruiting Procedure: Intravenous 
BMSC •Procedure: 
Intranasal BMSC  
The Healing Institute, 
Margate, Florida, United 
States  
Al Zahra Hospital, Dubai, 
United Arab Emirates  
 NCT02795052 
Outpatient Hematopoietic Grafting in Multiple 
Sclerosis Employing Autologous Peripheral Blood 
Stem Cells  
Enrolling by invitation Procedure: 
Hematopoietic stem cell 
transplantation  
- NCT02674217 
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Multiple Sclerosis - Simvastatin Trial 2 Recruiting Drug: Simvastatin 
disease modifying anti 
cholesterol medication 
University College 
London 
ISRCTN82598726 
MINERAL (Magnetic-resonance Image of 
Nutraceutical Efficacy on Relapsing-ms 
Autoimmune Lesions) study: a novel 
nutraceutical formula NEUROASPIS PLP10® for 
the treatment of relapsing-remitting multiple 
sclerosis 
Active, not recruitign Drug:  NEUROASPIS 
PLP10: proposed disease 
modifying neutraceutical 
The Cyprus Institute of 
Neurology and Genetics 
Nicosia 
ISRCTN06166891 
Cell Based therapies delivered by Intravenous Infusion 
Autologous Bone Marrow Derived Stem Cells for 
the Treatment of Multiple Sclerosis.  
Active, not recruiting Biological: Stem Cell 
Transplantation  
Chicago, Illinois, United 
States, 60611 
NCT03069170 
Allogeneic Stem Cell Transplantation for the 
Treatment of Multiple Sclerosis  
Active, not recruiting Biological: Autologous 
Bone Marrow 
Transplantation 
University of Louisville NCT00497952 
Safety and Efficacy of Umbilical Cord 
Mesenchymal Stem Cell Therapy for Patients 
With Progressive Multiple Sclerosis and 
Neuromyelitis Optica  
Unknown Biological: human 
umbilical cord 
mesenchymal stem cells 
Nanjing University 
Medical College 
Affiliated Drum Tower 
Hospital 
NCT01364246 
 Mesenchymal Cells From Autologous Bone 
Marrow, Administered Intravenously in Patients 
Diagnosed With Multiple Sclerosis  
Recruiting Bone marrow 
mesenchymal stem cells 
autologous 
University Regional 
Hospital Carlos Haya 
NCT01745783 
Assessment of Bone Marrow-derived Cellular 
Therapy in Progressive Multiple Sclerosis 
(ACTiMuS)  
Recruiting Biological: Autologous 
Bone Marrow 
Transplantation 
North Bristol NHS Trust 
NCT01815632 
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Safety and Efficacy of an Immunoablative 
Nonmyeloablative Conditioning Protocol for 
Autologous Bone Marrow Transplantation (BMT) 
in Patients With Multiple Sclerosis (MS)  
Unknown Biological: Autologous 
Bone Marrow 
Transplantation 
Hadassah University 
Hospital, Ein Kerem, 
Jerusalem, Israel  
NCT02529839 
Autologous Mesenchymal Stromal Cells for 
Multiple Sclerosis  
Active not recruiting Biological: BM-MSC Hospital Vall Hebron 
Barcelona, Spain, 
NCT02495766 
MEsenchymal StEm Cells for Multiple Sclerosis Recruiting Mesenchymal stem cells Purpan Hospital 
Toulouse, France 
NCT02403947 
Reduced-intensity Immunoablation and 
Autologous Hematopoietic Stem Cell 
Transplantation (AHSCT) for Multiple Sclerosis 
Recruiting Autologous 
haematopeitic stem cells 
Makati Medical Centre, 
Phillipines 
NCT 03113162 
Repeat Infusion of Autologous Bone Marrow 
Cells in Multiple Sclerosis  
Active not recruiting Biological: Autologous 
Bone Marrow 
Transplantation 
University Bristol North 
Birstol NHS trust 
NCT01932593 
Safety and Efficacy of BMMNC in Multiple 
Sclerosis (MS)  
Unknown Biological: Autologous 
Bone Marrow 
Transplantation 
Chaitanya Hospital NCT01883661 
MEsenchymal StEm Cells for Multiple Sclerosis Unknown Biological: Autologous 
Bone Marrow 
Transplantation 
University of Genova NCT01854957 
Tolerogenic Dendritic Cells as a Therapeutic 
Strategy for the Treatment of Multiple Sclerosis 
Patients (TOLERVIT-MS)  
recruiting VitD3 tolerogenic 
monocyte derived 
dendritic cells loaded 
with myelin peptides 
Hospital Universitari 
Germans TRias, 
Barcelona, Spain. 
NCT 02903537 
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- Source: NIH www.ClinicalTrials.gov
Search Criteria : Multiple Sclerosis 
Inclusion Criteria : 
Status : Recruiting, Not Yet Recruiting, Active Not Recruiting, Enrolling by invitiaion, Unknown Status 
Study Type: Interventional (clinical Trial) 
Age: Adult 
Sex: All 
Therapy: Cell Transplants, Pro regenerative, remyelination therapies 
Exlusion Criteria: 
Status: Trial Suspended, Terminated, Completed, Withdrawn 
Study Type: Observational, Patient register 
Age: Under 17years old, Over 65 years old 
Therapy: Anti Inflammatory treatment, Immunomodulatory 
-Source: www.isrctn.com
Search Criteria: Multiple Sclerosis 
Inclusion Criteria: 
Status: Ongoing 
Study Type: Interventional (Clinical Trial) 
Age: Adult 
Sex: All 
Therapy: Cell Transplants, Pro-regenerative, remyelination therapies 
223 
Gene Reporter Substrate Form of Contrast Affect on Contrast Promoter Vector Limitations Source 
Creatinine Kinase 
Phospho-
Creatinine 
Endogenous or 
supplemented 
31Phosphorous 
NMR 
23 fold increase in 
Phosphocreatine/ATP peaks 
in comparison to in vivo 
control 
Transthyretin 
Liver specific 
promoter 
Plasmid 
Spectroscopy 
therefore low 
resolution and 
specificity 
(Koretsky et al. 1990) 
Tyrosinase Endogenous Iron T2 1.35 fold increase in vivo Cytomegalovirus Plasmid Low contrast levels 
(Weissleder et al 
1997) 
Transferrin 
Receptor 
Iron Oxide Nano 
Particles T2 
5.3 fold decrease in signal 
(AU) in vivo hTR Plasmid Negative Contrast 
(Weissleder et al. 
2000) 
LacZ EGadMe T1 57% enhancement in vivo - mRNA Intracellular injection (Louie et al. 2000) 
Arginine Kinase Endogenous Argenine 
31Phosphorous 
NMR 50% increase in vivo Cytomegalovirus Adenovirus 
Spectroscopy 
therefore low 
resolution and 
specificity. Takes 12-13 
days to achieve 
expression 
(Walter, Barton, and 
Sweeney 2000) 
Transferrin 
Receptor 
Iron Oxide Nano 
Particles T2 
2.4 fold decrease 
in T2 Tet-Off Plasmid Negative Contrast (Moore et al 2001) 
Creatinine Kinase 
Phospho-
Creatinine 
Endogenous or 
supplemented 
31Phosphorous 
NMR - Cytomegalovirus Adenovirus 
Spectroscopy 
therefore low 
resolution and 
specificity 
(Auricchio et al. 
2001) 
Tyrosinase Endogenous Iron T2/ T1 
36% decrease in T2, 26% 
increase in T1 in vivo Cytomegalovirus Plasmid Negative Contrast (Alfke et al 2003) 
Ferritin Endogenous Iron T2 12% increate in (T2)-1 Tet-Off Plasmid Negative Contrast (Cohen et al. 2005) 
2. MRI Reporter Genes
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Gene Reporter Substrate Form of Contrast Affect on Contrast Promoter Vector Limitations Source 
Ferritin Endogenous Iron T2 
2.5 fold increase in R2 in 
vitro Cytomegalovirus Adenovirus Negative Contrast (Genove et al. 2005) 
LacZ 
2-Fluoro-4-
nitrophenol-β-d-
galactopyranoside 
(OFPNPG) 
19Fluorine - Cytomegalovirus Plasmid Substrate directly injected in to tissue 
(Kodibagkar et al. 
2006) 
Ferritin & 
Transferrin 
Receptor 
Supplemented Iron T2 21% increate in (T2)-1 ex vivo SV-40 Plasmid 
Negative contrast, 
Requires 
electroporation 
(Deans et al. 2006) 
Biotinalated 
Acceptor 
Peptides for cell 
surface receptors 
bis-5-HT- DTPA(Gd) 
/ Streptavidin- 
MNP / 
streptavidin– Alexa 
680 
T2/ T1 
2 fold increase in R2, 3.3 
fold R1 Cytomegalovirus Lentivirus 
Study only reports an n 
of 1 (Tannous et al. 2006) 
Vacuolar 
Transporter 
Chaperone 
Inorganic 
polyphosphates 
31Phosphorous 
NMR - Gal 1 Plasmid 
Spectroscopy 
therefore low 
resolution and 
specificity.  Non 
mammalian cells used 
(Ki 2006) 
LacZ OFPNPG 19Fluorine 
SNR 20-30 (after 
direct injection 
into tumour) 
Cytomegalovirus Plasmid 
Spectroscopy 
therefore low 
resolution and 
specificity. 
(Liu et al. 2007) 
Lysine Rich 
Protein 
Endogenous 
contrast 
Chemical 
Exchange 
Saturation 
Transfer 
8.2% enhancement vs 3.5 % 
for control Cytomegalovirus Plasmid 
Low signal to noise 
ratio (Gilad et al. 2007) 
Mag A Supplemented Iron T2
3-4 fold increase in (T2)-1 in
vitro Cytomegalovirus Lentivirus Negative Contrast 
(Zurkiya, Chan, and 
Hu 2008) 
Carboxypeptidase 
G2 
Hyperpolarised 
3,5-DFBGlu 
13Carbon NMR - - - Experiments done in solution (Jamin et al. 2009) 
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Gene Reporter Substrate 
Form of 
Contrast Affect on Contrast Promoter Vector Limitations Source 
LacZ S-Gal T2 3.5 fold decrease in signal Cytomegalovirus Plasmid 
Negative Contrast. 
Substrate directly 
injected in to tissue 
(Cui et al. 2010) 
       Amino-Acylase 
hyper-polarised [1-
13C]N- Acetyl-L- 
methionine 
13Carbon NMR - Cytomegalovirus pcDNA 3.1 No evidence can work in vivo (Chen et al. 2010) 
LacZ S-Gal & 
19Fluorine
S-Gal
19Fluorine T2
36% increase in R2, 
(intratumoural injection) 
19F didn't work in vivo 
Cytomegalovirus Plasmid 
Uses direct 
intratumoural 
injection, and low 
contrast levels 
(Yu et al. 2012) 
Membrane 
bound 
Biotinylated 
G.luciferase
111Indium-DTPA- 
biotin, 
coelenterazine, 
magnetic 
nanoparticles  
T2, PET, bio- 
luminescence 
2 fold increase in (T2)-1 in 
vivo Cytomegalovirus Lentivirus 
Negative contrast 
T2 enhancement is 
seen in absence of 
contrast agent, 
suggesting necrosis. 
(Niers et al. 2012) 
DMT1 Manganese 
Chloride T1 1.6-1.8 fold increase in R1 CAG 
Plasmid and 
Lentivirus 
Systemic background 
MnCl potentially toxic (Bartelle et al. 2012) 
HSV-TK 5-methyl-5,6-
dihydrothymidine CEST 
Change of 2% in 
magnetization Transfer 
Ratio 
Cytomegalovirus Lentivirus 
Minimal change, MTR 
variable across 
machines etc. (Bar-Shir et al. 2013) 
OATP1a1 gadoxetate T1 6.8 fold increase in signal PGK Lentivirus 
Uses linear 
Gd3+chealtor 
associated with basal 
ganglia accumulation 
(Patrick et al. 2014) 
Timd2 Manganese 
Apoferrtin 
T1 and T2 
3 fold increase in R1 in vivo and doubling of 
R2
Phosphoglycerate 
Kinase Lentivirus 
Manganese loaded 
ferrtin is toxic (Patrick et al. 2016) 
Ferritin Supplemented iron T2 and r2 - Ubiquitin Lentivirus with Tet-on Negative contrast (He et al. 2016) 
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3. Media Recipes
8.3i HALF 
5L solution: 
150.1mg Glycine (Sigma; G6201),  
9.8MG L-ALANINE L-Arginine hydrochloride (Sigma; A92600),  
4.12mg L- Asparagine-H2O (Sigma; A0884),  
12.06mg L-Cysteine hydrochloride-H2O (Sigma; C7880),  
209.6mg L-Histidine hydrochloride-H2O (Sigma; H8125),  
526.1mg L- Isoleucine (Sigma; I2752),  
526.1mg L-Leucine (Sigma; L8000),  
583.3mg L-Lysine hydrochloride (Sigma; L5626),  
149.9mg L-Methionine (Sigma; M9625),  
330.4mg L- Phenylalanine (Sigma; P2126),  
38.569 L-Proline (Sigma; P0380),  
210mg L-Serine (Sigma; S4500),  
474.8mg L-Threonine (Sigma; T8625),  
79.6mg L-Tryptophan (Sigma; T0254),  
360.6mg L-Tyrosine disodium salt dihydrate (Sigma; T1145),  
470.6mg L-Valine (Sigma; V0500),  
19.55mg Choline Chloride (Sigma; 26980),  
9.53mg D-Calcium pantothenate (Sigma; C8731),  
18.3mg Niacinamide (Sigma; 1462006),  
20.6mg Pyridoxine hydrochloride (Sigma; P9755)  
420.7MG Pyridoxine hydrochloride (Sigma; P9755),  
16.9mg Thiamine hydrochloride (Sigma; T4625),  
36mg i-Inositol (Sigma; I5125),  
0.5mg Ferric Nitrate (Sigma; 254223),  
1997.9MG Potassium Chloride (Sigma; P3911),  
369.9 Sodium Bicarbonate (Sigma; S5761),  
25810mg Sodium Chloride (Sigma; S9888),  
543.6mg Sodium Phosphate dibasic anhydrous (Sigma; 71640), 
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0.9633mg Zinc Sulfate (Sigma; Z4750),  
22525mg D-Glucose (Sigma; g8270),  
124.9 Sodium Pyruvate (Sigma; P2256),  
13465mg MOPS (Sigma M1254).  
Media was pH adjusted to 7.30 and filtered sterilized (Millipore; SCVPU02RE). 
8.3ii SATO 
50mL of SATO Stock Solution: 
50mL DMEM/F12,  
33mg/mL BSA fraction V (Sigma; A4919), 
4μg/mL Selenite (Sigma; S5261),  
1.61 mg/mL Putrescine (Sigma; P7505),  
4μg/mL Progesterone (Sigma; P0130). 
8.3iii Miltenyi Washing Buffer (modified) 
500ml of modified MWB: 
PBS (Thermo Fisher; 70011-044),  
5ml (2mM final concentration) Na-Pyruvate (Life Technologies 11360-039) 
0.2ml (2mM final concentration) EDTA (Thermo Fisher; 15575-020),  
10μg/mL Insulin (Thermo Fisher 12585-014) 
0.5% BSA 
8.3iv nOPC media 
100mL solution: 
95.4mL of DMEM/F12 (Thermo Fisher; 11039-021),  
2mL (1.5mM final concentration) Na-Pyruvate (Thermo Fisher; 11360-070), 
5mg (50ug final concentration )Apo-Transferrin (Sigma; T2036),  
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1.35mL 10% D(+)Glucose (25mM final concentration) (Sigma; G8644), 
1mL SATO Stock Solution (see 8.3ii),  
10ug/ml Insulin (Thermo Fisher; 12585-014). 
8.3v Slice Culture Media 
250mL solution: 
120ml BME (Life Technologies 21010046) 
60ml HBSS (Life Technologies 24020-091) 
60ml Heat Inactivated Horse Serum 
2.5ml 100x Glutamax (Life Technologies 35050) 
7ml 10%D(+)Gluose (Sigma G8644) 
0.5ml Mycozap (Lonza V2A2021) 
8.3vi Mixed Glia Media 
(Per 500mL solution) 
50ml  Fetal Bovine Serum (Biosera 280010) 
5ml PenStrep (Sigma P4333) 
445ml DMEM (Life Technologies 41966029) 
8.3vii Selective LB Broth 
Per 500ml 
LB Broth (Thermo Fischer 10855021) 
100ug/ml Ampicillin 
8.3viii LB Selective Agar Plates 
For 1L of microbial culture media : 
35g LB Agar (Sigma: L2897) 
1L dH2O 
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Autoclave solution at 121°C for 15 minutes 
Cool 40°C then add 100ug/ml Ampicillin (Sigma A0166) 
8.3ix Dissociation solution (MACS) 
4ml/brain 
4mL HALF (see 8.3i) 
2mM Pyruvate (Life Technologies 11360-039) 
2%B27 (Thermo Fisher 17504-001) 
34units/mL filtered Papain (Worthington LS003126) 
20ug/ml DNAse 
8.3x Dissociation Solution (Mixed Glia) 
3ml per T75 flask 
1 :100 DNAase 
1 :500 Papain 
3ml HALF 
8.3xi Cryoprotectant Solution 
per 1L solution : 
300g Sucrose (Sigma S9378) 
10g Polyvinylpyrrolidone (Sigma PVP40) 
500ml of 0.1M Phosphate Buffer (Sigma P5244) 
300ml Ethylene Glycol (Merck 109621) 
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8.4 Antibodies Used 
8.4i In vitro staining: 
Primaries 
Antibody Concentration Source 
A2B5 (mouse) 1:500 Millipore (MAB312) 
Cd11b (mouse) 1:500 Serotec MCA275R) 
CNPase (mouse) 1:400 Abcam (6319) 
GFAP (rabbit) 1:2000 Dako (Z0334) 
NG2 1:200 Millipore MAB5384 
MBP (rat) 1:500 Serotec (MCA409S) 
O4 1:1000 Millipore 1326 
Olig2 1:500 Millipore (AB9610) 
RFP (rabbit) 1:1000 Abcam ab34771 
Sox10 (goat) 1:500 Santacruz SC17342 
Secondaries 
Antibody Concentration Source 
Alexa 488 donkey α goat 1:500 Life technologies (A1055) 
Alexa 488 donkey α mouse 1:500 Life technologies (A21202) 
Alexa 647 donkey α goat 1:500 Life technologies (A21147) 
Alexa 594 donkey α rabbit 1:500 Life technologies (A21207) 
Alexa 488 donkey α chicken 1:500 Life technologies (A11039) 
Alexa 488 donkey anti rat 1:500 Life technologies (A21208) 
Alexa 647 donkey α mouse 1:500 Life technologies (A31571) 
Alexa 594 (streptavidin) 1:500 Life technologies (S32356) 
8.4ii Organotypic Slice Culture Staining 
Primaries 
Antibody Concentration Source 
CC1 (rabbit) 1:200 Abcam (15270) 
CNPase (mouse) 1:400 Abcam (6319) 
GFAP (rabbit) 1:2000 Dako (Z0334) 
MBP (rat) 1:500 Serotec (MCA409S) 
Neurofilament (mouse) 1:1000 Sigma (N5389) 
Sox10 (goat) 1:200 Santacruz SC17342 
Secondaries 
Antibody Concentration Source 
Alexa 488 donkey α goat 1:500 Life technologies (A1055) 
Alexa 647 donkey α goat 1:500 Life technologies (A21147) 
Alexa 594 donkey α rabbit 1:500 Life technologies (A21207) 
Alexa 488 doneky anti rat 1:500 Life technologies (A21208) 
Alexa 647 donkey α mouse 1:500 Life technologies (A31571) 
Alexa 594 (streptavidin) 1:500 Life technologies (S32356) 
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5. Predicted digestion products from restriction digests of plasmids
EcoR1 BamH1 Hind3 Nde1 Nco1 Pvu2 PsT1 Bgl1 EcoR1/H
ind3 
BH1 Bspe1 
PGK:OATP:mSt 3.4/3/
3/1.7/
0.2 
8.8/1.5/
0.4/0.8 
7.2/4.3 
MBP:OATP:mSt * * * 
pMDL 4.4/4.3/
0.4 
8/0.8 3.8/3.
6/0.9/
0.6 
RSV-Rec 2.9/1.3 2.6/1.6 3.1/0.6/
0.3 
VSVG 4.1/1.7 3.6/1.5/
0.6 
3.8/1.
5/0.5 
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6. Promoter Sequences
6i PGK Promoter: 
233 
6ii MBP Promoter: 
